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Investigating the Roles of ΔNp63 as a Suppressor of Migration, Invasion and 
Metastasis 
By 
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Supervised by 
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Abstract 	  
Cancer is one of the leading causes of death and disease in the world. Considerable 
resources are spent to study and understand cancer, with the hope of developing new 
treatments and eventually cures that will help millions of people. Efforts to understand 
cancer are hindered by its inherent complexity and instability. Nonetheless, understanding 
the basics of tumor development and progression are the key to focused on studying the 
role of ΔNp63 in cancer, a p53 family member known to be involved in epithelial 
development, microRNA biogenesis, and stem cell maintenance. Using the strength of in 
vivo mouse models, we found that ΔNp63 is capable of modulating tumor development by 
regulating the epithelial mesenchymal transition. ΔNp63 does this through its role regulating 
microRNAs, in this case, miR-98 and miR-34a, which in turn regulate known EMT 
transcription factors Twist1 and Lef1. Alterations of ΔNp63 led to the development of various 
tumor types, among them mammary adenocarcinomas that were aggressive and highly 
metastatic. Focusing on this tumor type, we investigated ΔNp63’s role regulating mammary 
gland development. We found a striking phenotype where ΔNp63 loss led to increased 
proliferation in mammary epithelial cells but stunted gland growth and promoted structural 
disorganization. We complemented these findings with sequencing results; where we were 
able to identify several pathways such as EMT, cell polarity, ER signaling, and IGF signaling 
	   vi 
that are also altered upon ΔNp63 loss and could potentially explain both of the 
developmental and tumor phenotypes observed. In the end, shed light on the role of ΔNp63 
as a modulator of cancer progression and on the pathways through which it could be doing 
this function. This information could potentially be used to identify novel targets and develop 
novel targeted cancer therapies that would greatly improve the lives of patients. 
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Chapter 1: Introduction 	  
Cancer remains one of the leading causes of death and disability around the world. 
In the United States cancer is the second leading cause of death and it is estimated that 
there will be around 1,600,000 new cases and 600,000 deaths due to cancer in 2016 alone 
(1). Most of the burden of cancer is due to its spread throughout the body, a process called 
metastasis. In metastasis, cells from the original primary tumor invade through adjacent 
tissues, get into the circulation, and travel to seed distant organs (2, 3). Metastasis can 
cause a variety of problems in patients ranging from metabolic deficiencies and cognitive 
difficulties to organ failure depending on the sites where the tumors were seeded. It is 
because of this burden and the many deleterious effects of cancer in our society that 
considerable efforts have been done to understand it and to develop ways to manage, treat 
and eventually cure it. 
In the decades that have passed since cancer was first described, our understanding 
of the disease has come a long way. Cancer can present in many forms and be caused by 
environmental factors, familial susceptibility, or occur spontaneously but they all have one 
common element: genomic instability. It is the intrinsic instability of tumor cells that drives 
their continued mutation and provides tumors their characteristic properties of uncontrolled 
growth, immune system evasion, metabolic reprograming, invasion of adjacent tissues, and 
spread to distant organs (4, 5). It is this genomic instability as well that has made it difficult 
to discover the key to treating and curing cancer. Cancer research has been focused on 
understanding the mechanisms and ramifications of genomic instability, the physiologic 
mechanisms that our cells have to deal with it, and how these mechanisms become altered 
leading to tumorigenesis. 
The processes of cell division and DNA replication have many instances where 
mutations can occur. Normally there are proofreading mechanisms, cell cycle checkpoints, 
and DNA repair mechanisms that look for mistakes in DNA replication that could lead to 
	   3 
harmful mutations and either repair the damage or program cell death if the damage is to 
severe. One of the most important molecules in these repair pathways is p53. Often called 
the guardian of the genome, p53 is a transcription factor that plays an essential role as a 
tumor suppressor in many pathways such as senescence and apoptosis among others that 
protect cells from the harmful effects of mutations. It is no wonder that in many cancers, 
inactivation of p53 through mutations, silencing, or other methods is one of the initial insults 
that start the tumorigenic cascade. 
Research in the p53 field has shed light in its many functions as a protector from 
cancer although this has not translated into new therapeutic modalities due to the 
physiological importance of tight p53 regulation. Systemic activation of p53 can lead to 
unforeseen side effects that can potentially cause the patients more harm than good. This is 
why focus has shifted into studying other molecules such as p53 binding partners, 
downstream effectors, and other p53 family members in order to be able to develop more 
nuanced, targeted therapies that only alter the p53 functions that have lead to a specific 
tumor while leaving the p53 physiologic function in the remaining normal tissues untouched. 
Our lab focuses on studying the p53 family members p63 and p73 with the ultimate goal of 
developing novel therapies to treat cancer. 
p63 and p73 are transcription factors that share structural homology with p53 mainly 
in their DNA binding domain (6). Although similar, the differences in the structure allow p63 
and p73 to regulate expression of their own sets of genes, as well as share some targets 
with p53 (7). To complicate matters further, both p63 and p73 have two different isoform 
families that arise from separate promoters: The TA isoforms, which contain a 
transactivation domain and the ΔN isoforms, which have a truncated transactivation domain. 
Both sets of isoform families have distinct functions and targets. Our lab has been one of the 
pioneers characterizing the different roles of the TA and ΔN isoform subfamilies, and the 
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interactions and cross talk between TA and ΔN p63 and p73 isoforms and p53. My focus 
has been particularly in understanding the roles of the ΔNp63 subfamily. 
In normal tissues, p63 plays important roles in, stem cell maintenance, cell 
differentiation, and microRNA biogenesis, among others (6, 8-15). TAp63 is essential for the 
maintenance of the stem cell compartments in the skin and regulates cellular aging, cellular 
energetics, and the processing of precursor microRNAs into mature microRNAs through 
regulation of Dicer (9-12). ΔNp63 on the other hand, is expressed in the basal layer of the 
skin and regulates differentiation into more specialized cell types. It is also involved in 
microRNA processing by regulating DGCR8, which is part of the enzyme complex that 
processes the primary transcript into the characteristic stem loop structure of the precursor 
microRNAs. In most tissues, ΔNp63 is the dominant isoform and also functions as a 
dominant negative by suppressing TAp63 and even p53. 
Besides their physiological roles, both TAp63 and ΔNp63 have been found to be 
involved in the tumorigenesis process (9, 13-19). TAp63 is commonly thought of as a tumor 
suppressor similar to p53 and has been found to suppress metastasis through Dicer 
regulation, regulate adult stem cells and aging, and regulate cellular energetics and 
metabolism. The picture for ΔNp63 on the other hand is more complex. ΔNp63 is used as a 
marker for epithelial tumors such as mammary adenocarcinoma and lung adenocarcinoma. 
This is due to its expression in the putative cells of origin for these tumor types. Beyond its 
use as a biomarker, some studies have found that ΔNp63 can exhibit both oncogenic and 
tumor suppressive functions (6, 13, 15-19). It appears that its function is context and tissue 
dependent, and perhaps even varies throughout different stages of the tumorigenic and 
metastatic cascades. Recently, ΔNp63 has been found to regulate multipotency (8), which 
could have implications in its role in cancer stem cells. Loss of ΔNp63 has also been 
associated with increased invasion and migration and with stimulation of an epithelial 
mesenchymal transition (EMT) in vitro (16-18, 20). Other studies have found that ΔNp63 can 
	   5 
promote tumor growth by inactivating TAp63, TAp73, and p53, at least in some tissues (13). 
Some of the conflicting evidence regarding the role of ΔNp63 in cancer is due to lack of 
knowledge regarding its physiologic role in many tissues. Loss of ΔNp63 in the embryonic 
stage results in craniofacial abnormalities, limb agenesis, and problems with development of 
the epidermal skin layer, which ultimately results in newborn pups dying within a day after 
birth (8). Because of this, a conditional knockout mouse model is necessary to study the 
physiologic roles of ΔNp63 in its biological context beyond the first day of life. In our lab we 
generated this model and have used it to better understand both the physiologic and 
pathologic functions of ΔNp63. 
The purpose of this project was to use our available mouse models to better 
understand the role of ΔNp63 in tumorigenesis. My hypothesis was that ΔNp63 can function 
as a tumor and metastasis suppressor through microRNA mediated regulation of migration, 
invasion, and transition into a mesenchymal phenotype. We also wished to corroborate 
whether the functions and mechanisms found to be regulated by ΔNp63 in previously 
published and our own in vitro data held up with the added complexity of a complete 
biological organism. To test this hypothesis, we used ΔNp63 knockout (ΔNp63-/-) mice, 
ΔNp63 heterozygous (ΔNp63+/-) mice, and ΔNp63 conditional knockout mice generated in 
our lab. The project was divided into three parts. First, enhance our basic understanding of 
the role of ΔNp63 in tumor development and metastasis. For this part, we used ΔNp63+/- 
mice crossed to mice with various p53 status backgrounds and compared their tumor 
spectrum and characteristics. We discovered that ΔNp63+/- status shifted the tumor spectrum 
and promoted aggressive metastatic tumors in these mice, which suggested that it might 
function as a tumor suppressor in some tissues. Second, elucidate the molecular 
mechanisms through which ΔNp63 exerts is functions in tumorigenesis and metastasis 
within an in vivo system. To this end we used ΔNp63 conditional knockout mice and a 
wound-healing assay as a surrogate for some of the processes involved in cancer and 
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metastasis. Using this system we discovered that ΔNp63 loss promotes a mesenchymal 
phenotype and its absence seems to prevent a full transition back into an epithelial 
phenotype, which suggests that ΔNp63 is an essential regulator of the epithelial 
mesenchymal transition. We also found evidence that ΔNp63 exerts this role through its 
regulation of specific microRNAs. And finally, combine the first and second parts together to 
understand the role of ΔNp63 in a specific tumor type. For this part, we chose to focus on 
breast cancer since it is a cause of significant morbidity and death every year. To fully 
understand the role of ΔNp63 in breast cancer it was necessary to study its role in normal 
mammary gland development and function. We used ΔNp63 conditional mouse models 
combined with transplantation procedures for this final part of the project. We also 
sequenced RNA and microRNA from primary mammary epithelial cells to obtain a broad, 
unbiased picture of how ΔNp63 loss affects overall gene and microRNA expression in the 
mammary gland. Together, these techniques gave us an idea of the essential pathways 
regulated by ΔNp63 in the developing mammary gland and how their potential alterations 
can lead to cancer. 
In the end, this project managed to shed light on the physiologic and pathologic 
functions of p63 within the context of an in vivo system. The results of these studies will be 
detailed in the upcoming chapters.  
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Chapter 2 
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Chapter 2: Materials and Methods 
2.1 Mouse genotypes 	  
Table 1. Information for mice used in various experiments 
Genotype Description  Uses 
ΔNp63+/- ΔNp63 heterozygous mice Used to generate 
ΔNp63-/- primary mouse 
keratinocytes  
 
Used for tumor studies 
ΔNp63+/-, p53-/- ΔNp63 heterozygous, p53 
knockout mice 
Used for tumor studies 
ΔNp63+/-, p53+/- ΔNp63 and p53 double 
heterozygous mice 
Used for tumor studies 
p53-/- p53 knockout mice Used for tumor studies 
p53+/- p53 heterozygous mice Used for tumor studies 
TAp63-/- TAp63 knockout mice Used to generate  
TAp63-/- keratinocytes 
ΔNp63fl/fl, RosaM/M, K14Cre ER+ ΔNp63 conditional knockout, 
Rosa mTmG fluorescent 
reporter mice with Tamoxifen 
inducible Cre under the 
control of the K14 promoter 
Used for the in vivo 
wound healing 
experiment 
ΔNp63fl/fl, RosaM/M ΔNp63 conditional knockout, 
Rosa mTmG fluorescent 
reporter mice 
Used to isolate 
Mammary Epithelial 
Cells for mammary gland 
transplantations, RNA 
and miRNA sequencing, 
validation and 3D culture 
experiments 
 
Used for Adenoviral Cre 
Intraductal Injections 
ΔNp63fl/fl, BRCA1fl/fl RosaM/M ΔNp63 conditional knockout, 
BRCA1 conditional knockout, 
Rosa mTmG reporter mice 
Used for Adenoviral Cre 
Intraductal Injections 
TAp63fl/fl, RosaM/M TAp63 conditional knockout, 
Rosa mTmG fluorescent 
reporter mice 
Used for Adenoviral Cre 
Intraductal Injections 
TAp63fl/fl, BRCA1fl/fl, RosaM/M TAp63 conditional knockout, 
BRCA1 conditional knockout, 
Rosa mTmG fluorescent 
reporter mice 
Used for Adenoviral Cre 
Intraductal Injections 
BRCA1fl/fl, RosaM/M BRCA1 conditional knockout, 
Rosa mTmG fluorescent 
reporter mice 
Used for Adenoviral Cre 
Intraductal Injections 
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2.2 Mouse husbandry and tumor analysis 	  
Mice heterozygous for ΔNp63 isoforms (ΔNp63+/-) with intact TAp63 isoforms in a 
C57BL/6 background were generated as previously detailed (Chakravarti, et. al., 2014). A 
subset of these mice was crossed with p53-/- or p53+/- for the tumor study. Mice were aged 
until moribund for up to 24 months. Distressed or visibly sick mice were euthanized by 
asphyxiation using carbon dioxide and subsequent cervical dislocation following IACUC 
guidelines. Necropsies were performed and soft tissues were kept in 10% neutral buffered 
formalin overnight and then switched to 70% ethanol, while bones were placed in Bouin’s 
fixative solution for 3 weeks and then switched to ddH2O. Tissues were then submitted to 
the MD Anderson Cancer Center Research Histology Core Laboratory for processing and 
embeddeding in paraffin blocks. The blocks were then sectioned onto slides. Slides were 
stained with hematoxylin and eosin at the core and histopathological analysis was 
performed for each tissue. 
 
2.3 Primary mouse keratinocyte isolation 	  
To obtain primary mouse keratinocytes, we set up crosses using TAp63-/- mice, 
ΔNp63+/- mice and wild type mice. All the crosses were set up between the same genotypes. 
To time the gestation period, the females were monitored the morning after set up (no more 
than15 hours after setting up the cross) for the presence of plugs that suggested that 
copulation had taken place. Embryos were harvested at the 18.5-day of gestation. 
Epidermal cells were isolated from skin of embryos at day 18.5 by treatment with Dispase II 
(Roche) as previously detailed (Su et. al., 2009). Each pregnant female was euthanized 
using carbon dioxide asphyxiation and cervical dislocation. Their abdominal cavity was 
opened and the uterus taken out, placed on a 10 cm dish with PBS, and transferred to the 
sterile tissue culture hood. Then the uterus was opened and the individual embryos were 
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taken out. The head, tail and four limbs for each embryo were removed and the skin was 
peeled off from the remaining torso using sterile forceps. The skin was then placed in 
Dispase II in a culture tube and placed on the 4°C refrigerator for 16 hours. The cut tails of 
the pups were stored at -20°C for confirmatory genotyping. After the overnight incubation, 
the separated epidermis was minced using straight blades and incubated at 37°C in 0.25% 
trypsin/EDTA (Corning) for 20 minutes. Cells were plated on collagen-coated flasks (50 
µg/ml) collagen type I (BD Biosciences) in defined K-SFM medium (GIBCO). After the 
cultures reached 70% confluence in about 5 days, the cells were passaged into new flasks. 
Once the secondary passage cells reached 70% confluence, they were frozen down in 
media with 10% DMSO (Corning) and stored in liquid nitrogen until needed. Keratinocytes 
were isolated from wild type, ΔNp63-/-, and TAp63-/- mice. 
 
2.4 In vitro scratch assay 	  
Primary mouse keratinocytes were plated on 6 well plates on top of J2 3T3 feeder 
cells. Once the keratinocyte colonies were big enough any remaining feeders were removed 
using 0.02% EDTA before starting the assay. Using a 200µl sterile pipette tip, a scratch was 
made through the colony and the progress of the gap closure was monitored over a 24-hour 
period using time-lapse microscopy. Time-lapse images were taken every 10 min. For the 
analysis, individual cells were followed using the time-lapse images and their path lengths 
were quantified and compared. 
 
2.5 In vitro Boyden Chamber assay 	  
Primary murine keratinocytes harvested as previously detailed were resuspended in 500 μl 
of F media (8) with 2% FBS (3 × 104	  cells/insert) and added to the top of each chamber 
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containing BD BioCoat cell culture inserts (354578; BD Biosciences) or Matrigel Invasion 
Chamber (354480; BD Biosciences). 750 μl of media with 20% FBS was added to the 
bottom chamber. The cells were fixed and stained with Diff-Quik kit (Siemens). Non-invasive 
cells were removed from the upper chamber using a cotton swab. The remaining cells were 
counted with a Zeiss AxioObserver A1 inverted microscope. 
 
2.6 In vivo wound healing assay 	  
ΔNp63 conditional knockout mice (ΔNp63fl/fl) were crossed to RosaM/M mice, and 
K14CreER+ mice to generate the ΔNp63fl/fl, RosaM/M, K14CreER+ mice used for the in vivo wound 
healing studies. 15 mice per condition were used, for a total of 30 mice. Mice were 
anesthetized using inhaled isoflurane. The backs of the mice were shaved and treated with 
Nair for of 90 seconds the day before starting the experiment. Proper rinsing of the Nair 
under running water and application for no more than 90 seconds are essential to prevent 
burn wounds that would affect the experiment. On Day 1, a 1 cm wound constrained to the 
epidermis was made using DXB compound. DXB is a detergent compound that selectively 
dissolves the epidermis. To induce the wound, a vacuum seal was created in the shaved 
mouse back using a plastic seal chamber. The skin rises inside the chamber when a proper 
seal is established. A proper seal is required to prevent leakage of DXB solution beyond the 
intended wound site. Once a seal was established, 250 µl of DXB solution were added and 
the area was sheared using an electric drill file for 40 seconds. After 40 seconds, the 
solution with the sheared cells was removed and the area cleaned. 200 µl of Tamoxifen 
(100mg/mL in 100% Ethanol) was applied topically using a cotton swab for three 
consecutive days following wound induction to induce recombination in the experimental 
mice. For the control mice, an equivalent volume of 100% Ethanol was applied instead. Up 
to three mice were housed together, and subsets were euthanized at days 1, 4, and 8 after 
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induction, Three at day 1 for each group, and 6 at days 4 and 8 for each group. One half of 
the epithelium was fixed in 10% formalin and the other frozen in OCT medium (Tissue Tek). 
Frozen sections were used to assess recombination status. Formalin fixed sections were 
embedded in paraffin and sectioned onto slides by the MD Anderson Cancer Center 
Research Histology Core Laboratory. Slides were stained with hematoxylin and eosin and 
the wound sizes were measured and analyzed. To measure the wound size, the 
hematoxylin and eosin stained sections were measured using the Olympus IX83, 10x 
objective, and the CellSense software. Unstained slides were used for immunofluorescence 
and immunohistochemical analysis.  
 
2.7 Immunohistochemistry 	  
Paraffin embedded tissue sections were prepared as previously described (7). 
Sections were incubated with anti-ΔNp63 (619002, Biolegend, 1:1000), Twist1 (sc-81417, 
Santa Cruz, 1:100), or Lef1 (2230S, Cell Signaling, 1:200) antibodies overnight at 4°C in a 
humid chamber followed by incubation with horseradish peroxidase conjugated-secondary 
antibody in the ImmPRESS kit (Vector lab) for 45 minutes at room temperature, then 
followed by the DAB kit (Vector lab). Images were taken using the Olympus IX83 
microscope, using objectives 10x and 40x) 
 
2.8 Immunofluorescence 	  
Paraffin embedded tissue sections were prepared as previously described (7). 
Sections were incubated with anti-GFP (ab13970, Abcam, 1:1000), Ki67 (ab15580, Abcam, 
1:250), Cytokeratin 5 (ab53121, Abcam, 1:500), E-Cadherin (ab76319, Abcam, 1:200), 
Vimentin (ab92547, Abcam, 1:200) Aquaporin 5 (178615, Calbiochem, 1:100), , Cytokeratin 
14 (LS-C22637, LifeSpan Biosciences, 1:500), Sox9 (Ab5535, Millipore, 1:100), Slug (SC-
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10437, Santa Cruz, 1:100), Laminin (L9393, Sigma, 1:125), Cytokeratin 18 (Sigma, 
SAB4501665, 1:200), Smooth Muscle Actin (SMA) (A2547, Sigma, 1:250), and RFP (600-
401-379, Rockland, 1:200) primary antibodies. For secondary antibodies, Alexa Fluor 568 
goat anti-mouse (Life Technologies 1:500), Alexa Fluor 568 goat anti-rabbit (Life 
Technologies, 1:500), Alexa Fluor 633 goat anti-rabbit (Life Technologies, 1:500), FITC goat 
anti-guinea pig (Jackson ImmunoResearch, 1:500), or Alexa Fluor 488 donkey anti-chicken 
(Jackson ImmunoResearch, 1:500) antibodies were used. DAPI was used to stain the nuclei 
of all immunofluorescence samples when mounting the slides (Vector). An Olympus IX83 
fluorescent microscope or Olympus FV1000 confocal microscope was used to take images, 
using the 10x, 20x, and 40x objectives.  
 
2.9 SYBR Green qRT-PCR assays 	  
Total RNA was isolated from human and mouse keratinocytes by using TRIzol 
Reagent (Invitrogen) or from mouse primary mammary epithelial cells using TRIzol reagent 
(Invitrogen) with the PureLink RNA isolation kit (Ambion) modified to enrich for small RNAs. 
Complementary DNA was synthesized from total RNA using SuperScript First-Strand 
Synthesis System (Invitrogen) and followed by qRT-PCR with the 7500 Fast real-time PCR 
System using Power SYBR Green PCR Master Mix (Kapa Biosystems) in accordance with 
the manufacturers’ protocols. The following primers were used: human Twist1: 5’-
GGAGTCCGCAGTCTTACGAG-3’ (forward) and 5’-TCTGGAGGACCTGGTAGAGG-3’ 
(reverse), human Lef1: 5’-CGGGTACATAATGATGCCAA-3’ (forward) and 5’-
TCACTGTAAGTGATGAGGGGG-3’ (reverse), murine Twist1: 5’-
GCCGGAGACCTAGATGTCATTG-3’ (forward) and 5’-CACGCCCTGATTCTTGTGAA-3’ 
(reverse), murine Lef1: 5’-CCCACACGGACAGTGACCTA-3’ (forward) and 5’-
TGGGCTCCTGCTCCTTTCT-3’ (reverse), murine Igfp5 5’-
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AGATGGCTGAAGAGACCTACTCC-3’ (forward) and 5’-GCTTTCTCTTGTAGAATCCTTTG-
3’ (reverse), murine Tgfbr3: 5’-CCCTGCATCTGAACCCCATT-3’ (forward) and 5’-
ACCACAGAACCCTCCGAAAC-3’ (reverse), murine Cnp: 5’-
TACTTCGGCTGGTTCCTGAC-3’ (forward) and 5’- GCCTTCCCGTAGTCACA-3’ (reverse), 
murine Cdh2: 5’-AGGGTGGACGTCATTGTAGC-3’ (forward) and 5’-
CTGTTGGGGTCTGTCAGG-3’ (reverse), murine Hif1A: 5’-
TGGTGCTAACAGATGACGGCGA-3’ (forward) and 5’-CCCGTGCAGTGAAGCACCTTCC-3’ 
(reverse), murine Cald1: 5’-CGCCAGAAGATGCCAGAAGATG-3’ (forward) and 5’-
TTGGAGACTATTGCTGCTTG-3’ (reverse), murine Pten: 5’-
CATGACAGCCATCATCAAAGAGA-3’ (forward) and 5’-
TGCTTTGAATCCAAAAACCTTACT-3’ (reverse), and murine Cdkn1A: 5’-
TCAGAGTCTAGGGGAATTGGA-3’ (forward) and 5’-AATCACGGCGCAACTGCT-3’ 
(reverse). Human GAPDH: 5’-TCTCTGCTCCTCCTGTTC-3’ (forward) and 5’-
GCCCAATACGACCAAATCC-3’ (reverse), and murine GAPDH: 5’-
TCACCACCATGGAGAAGGC-3’ (forward) and 5’-GCTAAGCAGTTGGTGGTGCA-3’ 
(reverse) were used as internal controls. Each sample was run in triplicate. Ct values for 
each gene were calculated and normalized to Ct values for GAPDH. 
 
2.10 TaqMan RT-PCR assays 	  
TaqMan mRNA and TaqMan miRNA assays from Applied Biosystems were used to 
quantify mRNA and mature miRNAs, respectively using looped-primer real-time PCR. Total 
RNA were isolated from human and mouse keratinocytes using TRIzol Reagent (Invitrogen) 
or from mouse primary mammary epithelial cells using TRIzol reagent (Invitrogen) with the 
PureLink RNA isolation kit (Ambion) modified to enrich for small RNAs. Total RNA (500 ng) 
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was used to synthesize complementary DNA with the Two-Step TaqMan MicroRNA Assay 
kit (Applied Biosystems) in accordance with the protocol. qRT-PCR was performed with the 
7500 Fast real-time PCR System, TaqMan PCR master mix (Applied Biosystems), and 
TaqMan primers for murine Nrip1 (ID: Mm01343437_m1, Applied Biosystems), murine Itga7 
(ID: Mm00434400_m1, Applied Biosystems), hsa-miR-34a-5p (ID: 000426, Applied 
Biosystems), hsa-miR-98-3p (ID: 472125_mat, Applied Biosystems), mmu-miR-98* (ID: 
462189_mat, Applied Biosystems), mmu-miR-592 -5p (ID: 002017, Applied Biosystems), 
hsa/mmu-miR-150-5p (ID: 000473, Applied Biosystems), hsa/mmu-miR-33-3p (ID: 002136, 
Applied Biosystems), hsa/mmu-miR-146b-5p (ID: 001097, Applied Biosystems), hsa/mmu-
miR-10b-5p (ID: 002218, Applied Biosystems), mmu-miR-147-5p (ID: 463997_mat, Applied 
Biosystems), hsa/mmu-miR-193b-5p (ID: 002366, Applied Biosystems), mmu-miR-205-3p 
(ID: 464195_mat, Applied Biosystems), and hsa/mmu-miR-147-3p (ID: 002262, Applied 
Biosystems). Each sample was run in triplicate. Ct values for mRNAs and miRNAs were 
calculated and normalized to Ct values for either human RNU6B (ID: 001093, Applied 
Biosystems) or murine snoRNA234 (ID: 001234, Applied Biosystems). 
 
2.11 ChIP assay 	  
ChIP was performed with nuclear extracts from NHEK-WT and NHEK-shΔNp63 as 
previously described (12). Briefly, cells were grown to 90% confluence. Cellular proteins 
were crosslinked to DNA using 1% formaldehyde. Samples were sonicated on ice to obtain 
500-1000bp DNA fragments. 2µg of either ΔNp63-specific antibody (sc-8609, Santa Cruz) or 
control IgG (sc-2027, Santa Cruz) was added to each sample and incubated overnight at 
4°C. Then, protein-DNA complex was precipitated using protein A agarose beads/Salmon 
sperm DNA (Millipore). qRT-PCR was performed with the following primer sequences 
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specific for p63-binding sites: human Twist1: 5’-CGCTCTTCTCCTCTGCCC-3’ (forward) and 
5’- TCTTCCTCGCTGTTGCTCAG-3’ (reverse), human Lef1: 5’-
GCGTTGGTGACGGACTTTTT-3’ (forward) and 5’- TGGAACCCTAATCCCCGAGA-3’ 
(reverse). Primer sequences for non-specific binding sites were as follows: human Twist1 
promoter: 5’-AATTCTAGAGGCACCCAGGAG-3’ (forward) and 5’-
GCCCTCTGAATACCAAACTGGA-3’, human Lef1 promoter: 5’-
GCAGAGGCAACAAGGACTGA-3’ (forward) and 5’-TGGCTTCCTCTTGCTCACTG-3’ 
(reverse). 
 
2.12 Western blot analysis 	  
Total cell lysates were prepared from cell pellets of WT keratinocytes or ΔNp63-/- 
keratinocytes. 50µg of total protein were electrophoresed on 10% SDS-PAGE gel and 
transferred to PVDF membrane as previously described (12). Blots were probed with anti-
ΔNp63 (619002, Biolegend, 1:500), E-cadherin (3195, Cell Signaling, 1:1000), Vimentin 
(ab92547, Abcam, 1:1000), Twist1 (sc-81417, Santa Cruz, 1:250), Lef1 (2230S, Cell 
Signaling, 1:1000), Snail (3879S, Cell Signaling, 1:1000) and Zeb1 (sc-10572, Santa Cruz, 
1:500) overnight at 4oC. Horseradish peroxidase conjugated- secondary antibodies against 
murine, rabbit, or goat IgG (Jackson lab) were incubated with the blots for 1 hour at room 
temperature. Actin (A5060, Sigma) or Hsp90 (ab13495, Abcam) was used as loading 
control. Detection was performed using ECL Plus Kit (Amersham).  
 
 
	   17 
2.13 Lentiviral infection 	  
Lentivirus-based vectors (3 µg) overexpressing mmu-miR-34a (SBI), mmu-miR-98-
3p (Sigma) or an empty vector (as  a control) were transfected into 293T cells along with 3 
µg of each vector required for lentivirus packaging (pCMV-VSVG and pRSV-REV) using X-
tremeGENE HP (Roche) in accordance with the manufacturer’s protocol. After 48 hours 
post-transfection, supernatants containing the lentivirus were collected, filtered and added to 
ΔNp63-/- keratinocytes for 48 hours in the presence of 8 µg/ml Polybrene (Santa Cruz). 2 
µg/ml of purmocyin was added to the media 48 hours after infection for 2 days. Cells were 
then changed to fresh media for further analysis. Infected cells were analyzed by miRNA 
TaqMan assay to determine the level of miRNA overepxression. These cells were further 
analyzed for migration and invasion capacity using the Boyden chamber assay described 
above.  
 
2.14 siRNA transfection 	  
1×106 ΔNp63-/- keratinocytes were plated in 10-cm dishes. siTwist1 
(SASI_Mm01_00043025, Sigma) or siLef1 (SASI_Mm01_00158789, Sigma) was 
transfected into the cells at 40 nM using Lipofectamine RNAi Max (Invitrogen) according to 
manufacturer’s protocol. The cells were collected 48 hours post-transfection for further 
analysis. Infected cells were analyzed by western blot to determine knockdown efficiency. 
These cells were further analyzed for migration and invasion capacity using a Boyden 
chamber assay as described above.  
 
2.15 Generation of a single cell suspension of primary mammary epithelial cells 	  
To generate a single cell suspension of primary mammary epithelial cells, the #4 pair of 
mammary glands from the donor mice was isolated. The donor mice were females between 
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the ages of 8 and 12 weeks. The glands were placed on a previously weighed 50 ml conical 
tube containing 30 ml of Hank’s Buffered Saline Solution (HBSS) (Corning). The tube 
containing the glands was then weighed again and the weight subtracted from the original 
weight. For every 1 g of tissue, 10 ml volume of digestion media was used. The digestion 
medica consisted of 1mg/ml Type 1 Collagenase (GIBCO) in HBSS with calcium and 
magnesium. 10% Pen/Strep was added. After weighing the glands, they were placed on a 
glass Petri dish and the tissue was minced using two feather scalpels (size #21 until it 
resembled a paste. Individual pieces of the minced tissue should be ~1mm in diameter. This 
step is imperative and will determine the efficiency of the digestion. After mincing, the tissue 
was digested Digest tissue in the calculated volume of digestion media in a clean, 
autoclaved 125 ml Erlenmayer flask with beveled bottom and covered with a foil lid. 
Digestion occurs for 2 hours in a 37°C incubator set to rotate at 125rpm. Every 30 minutes, 
the mixture was pipetted up and down to break any aggregated clumps. After 2 hours, the 
digest should not have any undigested pieces remaining. After the digestion was completed, 
the digested sample was transferred to a 15 ml conical tube (or multiple tubes if the 
digestion volume was more than 15 ml) and centrifuged at 450g for 5 minutes. After the 
initial centrifugation, the supernatant was aspirated and the remaining pellet resuspended in 
10 ml 1x HBSS. If there were multiple tubes, the pellets were combined and resuspended in 
10 ml total. 3 short centrifugation steps were then performed on this suspension to enrich for 
mammary organoids. These steps were done in PBS. Each of this steps was done by 
centrifuging the suspension at 450g for 7 seconds, removing the supernatant, resuspending 
in fresh PBS, and repeating the steps, two more times until a clear supernatant was 
observed. Upon completion of these steps, the pellet would be enriched for mammary 
organoids. At this stage you should have enriched for mammary epithelial organoids in the 
pellet. After enriching for mammary organoids, the pellet was washed once with PBS (5 
minutes at 450g), resuspended in 2 ml pre-warmed 0.25% Trypsin EDTA (Corning), and 
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transferred to a single well of a 6 well tissue culture dish. This step is to dissociate mammary 
organoids into a single cell suspension. The suspension was then placed in a 37°C 
incubator for 5 minutes, pipetting up and down every 2 minutes using a 1 ml pipette. The 
disassociation of the organoids was monitored under a microscope. Once complete 
dissociation was observed, the trypsin was neurtralized using mammary epithelial cell 
growth media (DMEM/F-12 50:50, 10% FBS, 5ug/ml Insulin, 1ug/ml Hydrocortisone, 10 
ng/ml EGF, and 10% Pen/Strep) and filtered through a 40 µm cell strainer into a 50 ml 
conical tube. After transferring the filtered cell suspension into a 15 ml conical tube, it was 
centrifuged at 300g for 5 minutes and the resulting pellet was washed two times with growth 
media. The final pellet was then resuspended in 4 ml of growth media and the cells were 
counted using a hemocytometer or Cellometer before proceeding to the desired application. 
The final yield was approximately 2 million cells per mouse. 
 
2.16 Adenovirus Transduction of Primary Mammary Epithelial Cells 	  
For adenovirus transduction of primary mammary epithelial cells in suspension, adenovirus 
Cre (Ad-Cre) and adenovirus Empty (Ad-Empty) were purchased from the Baylor Vector 
Development Laboaratory. Cre virus stock concentration: 5 x1012 particles per ml, Cre virus 
particle functional units (pfu): 2 x 1011 pfu/ml. Empty virus stock concentration: 5 x 1012 
particles per ml, Empty virus pfu: 1.3 x 1011pfu/ml. To transduce the mammary epithelial 
cells, Ad-Cre or Ad-Empty virus was added to 2 ml of growth media with cells in 50 ml 
conical tubes at Multiplicity of Infection (MOI) of 50. 50 ml tubes were used because they 
provide a larger surface area. The tubes with the cell suspensions with the virus were paced 
at 45° angle in a 37° C and incubated for 1 hour. Every 15 minutes, the tubes were taken 
out and mixed, at the 15 and 45 minute time points the tubes were gently agitated to mix, 
while at the 30 minute time point the suspensions were my by gently pipetting up and down. 
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Once the incubation period was completed, the cell and virus suspensions were transferred 
to 15 ml conical tubes and the volume brought up to 15 ml using HBSS. The suspensions 
were centrifuged at 300g for 5 minutes to remove any unbound virus and. The resulting cell 
pellets were washed once more with HBSS at 300g for 5 minutes and then resuspended in 
the appropriate media for the downstream applications. 
 
 
2.17 Mammary Gland Transplantation 	  
In this procedure Adenovirus treated primary mammary epithelial cells or pieces of 
mammary outgrowths were transplanted into the cleared fat pads of 3 week old female 
SCID mice. The primary mammary epithelial cells were obtained as detailed above. Mice 
were harvested 5 or 10 weeks after injection to check growth of the transplanted cells into 
mammary ductal trees. The recipients were 3-week-old virgin female SCID mice. For 
primary transplantations, cell suspensions were prepared fresh before each injection: 
100,000 cell suspension in 20 µl 50:50 Growth Factor Reduced (GFR) matrigel (BD 
Biosciences 354230)/HBSS solution per injection. The matrigel needed to be placed 
overnight on ice in the 4°C refrigerator to liquefy. Thawing at higher temperatures caused 
the matrigel to polymerize prematurely. A glass syringe with 50 µl capacity and a fixed 12° 
beveled-ended, 22 gage, ½ inch long needle was used to deliver the cells (Hamilton). For 
secondary transplantations, the 4th mammary fat pads of mice previously transplanted 10 
weeks before were harvested and kept on PBS. The pads were then imaged using a 
fluorescent stereomicroscope to assess the percent of the fat pad covered mammary gland. 
Once the glands were visualized, fine forceps, scissors, and scalpels were used to dissect 
the mammary gland out. 1 mm diameter pieces of mammary gland were then placed on 1.5 
ml microcentrifuge tubes with PBS and kept on ice until transplantation. The mice were 
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anesthetized using a Ketamine/Xylazine mixture (10 mg ketamine and 1 mg xylazine per kg 
of body weight) administered intraperitoneally. Buprenorphine (0.1 mg per kg of body 
weight) was used for analgesia, administered intraperitoneally as well. The anesthetized 
mice were then shaved and tagged and placed on an impervious board for the surgery. 
Sterile strips were used to immobilize the mouse limbs. The surgical area in the mouse was 
then cleaned using 70% ethanol and betadyne, after which a Y-incision was made on the 
abdomen to allow the skin covering the inguinal mammary fat pads to be peeled back to 
expose the inguinal (4th) gland. The connection between the 4th and 5th mammary glands 
was then carefully severed. The vessels in the area were cauterized to prevent bleeding. To 
clear the fat pad, a cautery pen was used to cut at the level of the visible lymph node, at a Y 
shaped intersection of three vessels. Each vessel was cauterized to prevent blood loss. The 
connection of the fat pad to the nipple area was also cauterized off. For primary 
transplantations, 20 µl of the cell suspension was injected into each mammary fat pad. The 
injections were done parallel to the mammary fat pad while being careful to avoid piercing 
the skin. Ad-Cre infected cells were injected into the left 4th mammary fat pad while Ad-
Empty infected cells were injected into the right 4th mammary fat pad of the same mouse. 
For the secondary transplantations, a small pocket was cut into the cleared fat pad and the 
piece of donor tissue was placed in it. Pieces coming from knockout donor tissue were 
transplanted into the left mammary fad pad while pieces coming from control donor tissue 
were transplanted into the right mammary fat pad of the same mouse. The skin flaps were 
re-positioned normally and held together with wound clips. Wound clips were removed 2 
weeks after the procedure. The mice were housed together, up to 5 mice per cage. They 
were closely monitored for 72 hours after the surgery for sings of distress and additional 
analgesia was administered as needed. They were monitored every other day throughout 
the remainder of the experiment. After the conclusion of the experiment the 4th mammary 
glands were harvested and fixed using 4% PFA. Fixed tissues were then submitted to the 
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MD Anderson Cancer Center Research Histology Core Laboratory for processing and 
embedding in paraffin blocks. The blocks were then sectioned onto slides. Slides were 
stained with hematoxylin and eosin at the core and histopathological analysis was 
performed for each gland. Unstained slides were used for immunofluorescence analysis. 
 
2.18 Characterization of Transplanted Mammary Glands 
 
The outgrowths arising from transplanted mammary epithelial cells were characterized as 
follows. To determine the fat pad coverage, the glands were dissected and placed between 
two glass slides to flatten the gland and imaged using a fluorescence stereomiscroscope. 
Pictures were taken for the red and green fluorescence channels and imported into 
Photoshop, where using the measurement tool, the area covered by the gland outgrowth 
was divided by the total area of the fat pad. The average percentage of the fat pad covered 
for the knockout condition was compared to the average percentage of the fat pad covered 
for the control condition at both 5 weeks and 10 weeks after transplantation.  
To assess the number of terminal end buds for each sample analyzed, the number of 
terminations per gland was counted directly from the whole mount fluorescent images. The 
average number of terminal end buds for the knockout condition was compared to the 
average number of terminal end buds for the control condition at both 5 weeks and 10 
weeks.   
To assess the organization of the luminal and a basal layers, paraffin embedded slides were 
cut and stained with cytokeratin 18, to stain the luminal layer, SMA, to stain the basal layer, 
GFP to stain recombined cells that had lost ΔNp63 expression, and RFP to stain 
unrecombined cells. The stained slides were then imaged using an Olympus FV1000 
confocal microscope with a 20x objective. A high-low filter was used to optimize the image. 
20 1 µm stacked images were used to create the composite image used for quantification. 
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The number of ducts per sample with SMA staining, the number of ducts with 2 or more 
clearly visible luminal layers, and the number of ducts with stacked basal layers were 
quantified.  
To assess proliferation, slides were stained for Ki67 and GFP and the number of Ki67 
positive nuclei and the number of total nuclei per duct were counted. The slides were 
imaged using the Olympus IX83 fluorescent microscope with a 40x objective. The average 
percentage of Ki67 positive nuclei in the knockout condition was compared to the average 
percentage of Ki67 positive nuclei in the control condition at both 5 weeks and 10 weeks.  
Prism software, version 6 was used to plot graphs for all of these counts. 
 
2.19 Primary Mammary Epithelial Cell 3D Cultures 	  
For the primary mammary epithelial cell 3D cultures, a previously published method for the 
3D culture of normal and malignant mammary epithelial cells (21) was modified. ΔNp63fl/fl, 
RosaM/M mammary epithelial cells were isolated and infected them to induce recombination 
as previously detailed. During the final steps of the infection procedure, chamber slides were 
coated with 40 µl of GFR matrigel (BD Biosciences) and set to dry in a 37° C incubator for 
15 to 30 minutes, being careful not to over dry the slides. Once the infection was complete, 
the cells were counted and resuspended directly in matrigel at a concentration of 667 cells 
per µl. 150 µl of the cell mix was added to each well, so that there would be 100,000 cells 
per well. The slides were then placed for another 15 to 30 minutes in the 37° C incubator to 
polymerize the matrigel after which 200 µl of mammoshpere growth media (DMEM/F12 
50:50, 5% Horse Serum, 5µg/ml Insulin, 1µg/ml Hydrocortisone, 20 ng/ml EGF, 100 ng/ml 
cholera toxin, 1% Pen/Strep) were added. Media was replaced every other day for the two-
week duration of the culture. Once the culture period was complete, the spheres were fixed 
in 4% PFA as detailed in the published protocol for whole culture fixation. The number of 
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spheres per condition and the size of those spheres was assessed. The size of the spheres 
was measured using an Olympus IX83 fluorescent microscope, 10x objective, and the 
CellSense software. Finally, the spheres were stained for GFP(abcam, 1:1000) and SMA 
(Sigma, 1:250) following the published protocol as well. 
 
2.20 Intraductal Adenovirus Injections 	  
In this procedure Adenovirus-Cre was injected intraductally through the nipple into 6-week-
old conditional knockout female mice to induce recombination and knockout expression of 
desired genes in the mammary ducts. The mice were aged for up to 18 months to assess for 
the development of tumors. Recipients were 6-week-old virgin female mice. Virus 
suspensions were prepared fresh before injection of adenovirus. A 30-gauge glass syringe 
with 50µl capacity and a blunt-ended ½ inch needle (Hamilton) was used to deliver the virus. 
The mice were anesthetized using a Ketamine/Xylazine mixture (10 mg ketamine and 1 mg 
xylazine per kg of body weight) administered intraperitoneally. Buprenorphine (0.1 mg per 
kg of body weight) was used for analgesia, administered intraperitoneally as well. The 
anesthetized mice were then shaved and tagged and placed on an impervious board for the 
surgery. Sterile strips were used to immobilize the mouse limbs. The surgical area in the 
mouse was then cleaned using 70% ethanol and betadyne, after which a Y-incision was 
made on the abdomen to allow the skin covering the inguinal mammary fat pads to be 
peeled back to expose the inguinal (4th) gland. Using a stereomicroscope to visualize the 
nipple, the nipple of the inguinal gland was held using angled fine forceps (FST, 9cm, cat# 
11063-07) and snipped using Wecker spring scissors (FST, 11cm, 7mm blades, cat# 15010-
11) so that the needle could be directly inserted through the nipple into the primary duct. 
Two thirds of the nipple was snipped in this step. 20 µl of virus PBS solution (with 0.1% 
trypan blue) containing virus at 1.3 x 105 pfu/µl is injected. The injected liquid was visually 
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detected in the duct to confirm successful injection. Ad-Cre virus was injected into the left 4th 
mammary gland while Ad-Empty virus was injected into the right 4th mammary gland. The 
skin flaps were re-positioned normally and held together with wound clips. Wound clips were 
removed 2 weeks after the procedure. The mice were housed together, up to 5 mice per 
cage. They were closely monitored for 72 hours after the surgery for sings of distress and 
additional analgesia was administered as needed. They were monitored once a week 
throughout the remainder of the experiment, up to 2 years. After the conclusion of the 
experiment the 4th mammary glands were harvested and fixed using 4% PFA. Fixed tissues 
were then submitted to the MD Anderson Cancer Center Research Histology Core 
Laboratory for processing and embedding in paraffin blocks. The blocks were then 
sectioned onto slides. Slides were stained with hematoxylin and eosin at the core and 
histopathological analysis was performed for each gland. 
 
2.21 Statistical Analysis 	  
Unpaired t-test with equal variances was used to test for statistical significance. The 
Prism software, version 6 was used to perform all statistical tests. 	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Chapter 3: Using Mouse Models to further understand the role of ΔNp63 in 
tumorigenesis. 	  
Mouse models have helped to significantly increase our knowledge of genetics. 
Although, cell culture and other in vitro experiments can provide useful information regarding 
the functions and pathways regulated by specific genes, they lack the complexity and 
biological context of a full organism, which limits the information we can obtain. Using 
knockout mouse models, we can specifically address this, and paint a picture of all the 
essential functions of a specific gene within the context of a whole organism. 
 
As previously mentioned, ΔNp63 knockout (ΔNp63-/-) mice have a striking phenotype 
of craniofacial abnormalities, limb deformities and, impaired epidermal development (8). 
ΔNp63-/- pups have a discontinuous and disorganized epidermis due to problems in terminal 
differentiation of epidermal cells that impairs the skin’s barrier function and regulation of 
water transport ultimately resulting in their death within the first day after birth. Because 
ΔNp63-/- pups die so soon, we need alternative approaches to study adult biological 
processes such as cancer in the absence of ΔNp63 in vivo. One such approach is to use 
ΔNp63+/- mice instead of the full knockout. ΔNp63+/- mice have a grossly normal phenotype 
and can grow into adulthood. They have reduced levels of ΔNp63, which do not seem to 
affect development but could lead to a tumor phenotype later on. To this end, we used mice 
heterozygous for ΔNp63 isoforms with intact TAp63 isoforms in a C57BL/6 background 
generated as previously detailed (8). 
To understand the roles of ΔNp63 in tumor development, we crossed ΔNp63+/- mice 
to of various p53 backgrounds p53 wild type (p53WT), p53 heterozygous (p53+/-), or p53 
knockout (p53-/-) mice and followed them for a period of up to two and a half years looking 
for the development of tumors. Crossing the ΔNp63+/- mice to others with various p53 
backgrounds that have been fully characterized previously (9, 13) allowed us to compare 
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any differences in tumor characteristics. Distressed or visibly sick mice were euthanized by 
asphyxiation using carbon dioxide and subsequent cervical dislocation following IACUC 
guidelines. We performed necropsies and fixed soft tissues with 10% neutral buffered 
formalin, while bones were fixed in Bouin’s fixative solution for 3 weeks, after which soft 
tissues were switched to 70% ethanol and bony tissues to deionized distilled water (ddH20) 
before processing, embedding in paraffin and sectioning onto slides. Finally, slides were 
stained with hematoxylin and eosin (H&E) to perform histopathological analysis of each 
tissue.  
Our first significant finding was that crossing ΔNp63+/- mice into various p53-/- or 
p53+/- backgrounds shifted the tumor spectrum towards increased carcinomas. On a p53-/- 
background, ΔNp63+/- increased the percentage of carcinomas from 0% to 8%, while at the 
same time reducing lymphomas from 90% to 57%. The percentages of sarcomas increased 
as well, from 10% to 29%. There were 6% of ΔNp63+/-, p53-/- mice that did not present any 
tumors (Figure 1). Similarly, in a p53+/- background, the percentage of carcinomas also 
increased from 0% to 32%, while both lymphomas and sarcomas decreased from 80% to 
29% and from 20% to 18%, respectively. There were 21% of ΔNp63+/-, p53+/- mice that did 
not present any tumors (Figure 1). Moreover, 67% of ΔNp63+/- mice in a wild-type p53 
background developed tumors, which were exclusively carcinomas.  
 
 
Figure 1. Pie charts representing the mouse tumor spectrums. For p53-/- (N = 100), 
ΔNp63+/- p53-/- (N = 49), p53+/- (N = 100), ΔNp63+/- p53+/- (N = 28), or ΔNp63+/- (N = 
	   29 
24) genotype mice. Red represents lymphomas, blue represents sarcomas, 
yellow represents carcinomas, and green represents no tumor. 
 
The types of tumors identified among the different genotypes were varied and 
included thymic lymphomas, osteosarcomas, squamous cell carcinomas, lung 
adenocarcinomas, mammary adenocarcinomas, pancreatic adenocarcinomas, and ovarian 
adenocarcinomas among others (Table 2).  
Table 2. Tumor spectrum for mice mutant for p53 and ΔNp63 
 
Genotype Tumor Type % mice 
p53 -/- thymic lymphoma 65% 
  lymphoma NOS 25% 
  angiosarcoma 0% 
  histiocytic sarcoma 0% 
  osteosarcoma 0% 
  rhabdomyosarcoma 0% 

























  carcinoma NOS 0% 
  hemangioma 0% 	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Genotype Tumor Type % mice 
p53 +/- thymic lymphoma 0% 
  lymphoma NOS 20% 
  angiosarcoma 0% 
  histiocytic sarcoma 0% 
  osteosarcoma 0% 
  rhabdomyosarcoma 0% 

























  carcinoma NOS 0% 
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Genotype Tumor Type % mice 
ΔNp63 +/-; 
p53 -/- thymic lymphoma 44% 
  lymphoma NOS 5% 
  angiosarcoma 10% 
  histiocytic sarcoma 7% 
  osteosarcoma 5% 
  rhabdomyosarcoma 5% 

























  carcinoma NOS 0% 
  hemangioma 2% 	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Genotype Tumor Type % mice 
ΔNp63 +/-; 
p53 +/- thymic lymphoma 14% 
  lymphoma NOS 9% 
  angiosarcoma 0% 
  histiocytic sarcoma 0% 
  osteosarcoma 14% 
  rhabdomyosarcoma 0% 

























  carcinoma NOS 5% 
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Genotype Tumor Type 
%  
mice 
ΔNp63 +/- thymic lymphoma 0% 
  other lymphoma 0% 
  angiosarcoma 0% 
  histiocytic sarcoma 0% 
  osteosarcoma 0% 
  rhabdomyosarcoma 0% 

























  Carcinoma NOS 31% 
  hemangioma 0% 
 
Besides shifting the tumor spectrum, ΔNp63+/- status also resulted in more metastatic 
tumors, independent of the p53 background: 22.9% of ΔNp63+/-, p53-/- metastasized while 
none of the p53-/- tumors did while the percentage of metastatic tumors increased from 5% 
for p53+/- mice to 10% for ΔNp63+/-, p53+/- mice. In the case of ΔNp63+/- mice with a p53 wild-
type p53 background, 88% of the observed tumors metastasized (Figure 2).  
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Figure 2. Percentage of metastatic tumors for p53-/-, ΔNp63+/- p53-/-, p53+/-, ΔNp63+/- 
p53+/-, or ΔNp63+/- mice. 
 
The most common observed metastatic site for tumors that arose in ΔNp63+/- mice 
irrespective of their p53 status was the liver upon analysis of hematoxylin and eosin (H&E) 
stained formalin fixed paraffin embedded (FFPE) sections (Figure 3A-F). Mammary 
adenocarcinoma was the most common tumor in ΔNp63+/- mice, and H&E analysis showed 
all the tumors observed in this background were highly metastatic (Figure 4), not only to the 
liver but the lung as well (Figure 3G-I). Some of these tumors were poorly differentiated, but 
the specific subtypes of mammary adenocarcinomas observed still need to be determined. 
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Figure 3. H&E stained cross sections of mouse primary tumors and metastases. H&E 
stained cross sections of primary tumors (A-C) and liver metastases (D-F) from 
ΔNp63+/- p53-/-, ΔNp63+/- p53+/-, or ΔNp63+/- mice. MA: Mammary Adenocarcinoma, 
OS: Osteosarcoma, Li: Liver. G-I. H&E stained cross sections of ΔNp63+/- mice 
tumor lung metastases. Lu: Lung 
 
 
Figure 4. Number of metastatic mammary adenocarcinomas for ΔNp63+/- p53-/-, 
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Finally, we compared the tumor free survival of these cohorts. ΔNp63+/- status did not 
affect tumor free survival in the cases p53+/-, or p53-/-, only the tumor spectrum. However, 
ΔNp63+/- status alone significantly reduced survival when compared to wild type (WT) 
(Figure 5).  
 
 
Figure 5. Tumor free survival curve for Wild type (WT), p53-/-, ΔNp63+/- p53-/-, p53+/-, 
ΔNp63+/- p53+/-, or ΔNp63+/- mice. 
 
Taken together, these data provide evidence that alterations in ΔNp63 could lead to 
the formation of tumors, specifically carcinomas. There is some evidence for ΔNp63’s 
putative role as a tumor and metastasis suppressor, at least in certain tissues. This function 
could be due to loss of heterozygosity or alterations ΔNp63 dependent pathways. 
Nonetheless, questions remained regarding the mechanism through which ΔNp63 exerts its 
tumor and metastasis suppressive functions, which were sought to address in other sections 
of this work.  
  




















ΔNp63 +/-, p53 -/-
ΔNp63 +/-, p53 +/-
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Chapter 4: Using a conditional knockout mouse model to understand the 
mechanism for ΔNp63 mediated tumor suppression 	  
The ΔNp63+/- tumor cohort study gave us in vivo evidence that ΔNp63 plays a role in 
the processes of tumor development and metastasis. Our next step was to push forward to 
understand the mechanisms through which ΔNp63 plays such a role. Previous studies have 
shed some light on what are some of the functions of ΔNp63 in the context of cancer. 
Venkatanarayan et al. (2015) showed that ΔNp63 promotes lymphoma growth in vivo by 
affecting glucose metabolism, cellular energetics and suppressing p53, TAp63, and TAp73 
and their tumor suppressive functions (13). This effect was also observed in several cancer 
cell lines. Chakravarti et al. (2014) found that loss of ΔNp63 in keratinocytes causes 
dysregulation of the microRNA transcriptome, interferes with terminal differentiation, and 
confers properties of stem cells such as self renewal and the capacity to contribute to 
multiple tissues in chimeras and to form teratomas when transplanted in immune 
compromised mice (8). These properties are similar to those present in cancer stem cells. 
Other studies such as Tran et al. (2013) also showed that ΔNp63 can regulate the epithelial 
mesenchymal transition (EMT) (17). EMT is a process through which epithelial cells lose 
cell-cell contacts and acquire mesenchymal properties (22-27). This morphological change 
is usually accompanied by decreased expression of epithelial markers such as E-Cadherin 
and increased expression of mesenchymal factors such as Vimentin. EMT is an important 
process in development, wound healing, and metastasis (22-26, 28-32). Taking these data 
as a starting point, we proceeded to develop new methods and models to understand the 
role of ΔNp63 in cancer development and metastasis. 
One of the issues with our current understanding of the role of ΔNp63 in cancer is 
that it is mostly based on in vitro assays using cancer cell lines. Cancer cell lines have many 
additional mutations that may confound any results obtained. With this in mind, our aim was 
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to reassess these findings using primary cell lines obtained from the ΔNp63-/- mice and to 
develop an in vivo system to study the mechanisms through which ΔNp63 regulates cancer.  
 
4.1 Loss of ΔNp63 promotes a mesenchymal phenotype in cultured primary mouse 
keratinocytes 	  
To generate primary keratinocytes, epidermal cells were isolated from skin of 
embryos at day 18.5 by treatment with Dispase II (Roche) as previously detailed (Su et. al., 
2009). The separated epidermis was minced and incubated in 0.25% trypsin/EDTA 
(Corning) for 20 minutes. Cells were plated on collagen-coated flasks (50 µg/ml) collagen 
type I (BD Bioscience) in defined K-SFM medium (GIBCO). Cells were fed every other day 
and grown until 60% - 80% confluent and passaged into a secondary culture. The 
secondary culture was grown until 60% to 80% confluence as well under the same 
condition. Once the desired confluence was achieved, the keratinocytes were trypsinized 
and frozen culture freezing media with 10% DMSO. Keratinocytes were isolated from wild 
type, ΔNp63-/-, and TAp63-/- mice. For the experiments, the cells were grown on top of J2-
3T3 feeder cells using F-media (8). 
We first analyzed the morphology of the primary keratinocytes in culture. ΔNp63-/- 
knockout keratinocytes no longer grew in colonies or required feeder cells to grow in culture 
and exhibited an elongated mesenchymal-like phenotype when compared to wild type 
(Figure 6).  
 
 
WT KC ∆Np63-/- KC 
A B 
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Figure 6. ΔNp63-/- mouse keratinocytes exhibit mesenchymal morphology. Cell 
morphology of Wild-type (WT) (A) and ΔNp63-/- mouse keratinocytes (KC) (B).  
 
These morphological changes were accompanied by changes in protein expression 
consistent with a transition towards a mesenchymal phenotype: decreased E-cadherin and 
increased Vimentin. Protein levels of the transcription factors associated with EMT Lef1, 
Snail, Twist1, Zeb1 were also increased (Figure 7). 
 
 
 Figure 7. Comparison of protein expression in WT and ΔNp63-/- KCs. Western blot 
analysis for expression of EMT-related factors in WT and ΔNp63-/- KCs derived 
from three independent embryos using the indicated antibodies. Actin was used 
as loading control.  
 
Next we tested whether ΔNp63 knockout keratinocytes had changes in their 
functional properties to accompany their mesenchymal-like appearance and protein 
expression profile. Increased migratory and invasive capabilities are essential aspects of the 
mesenchymal phenotype and we used an in vitro scratch assay and an in vitro Boyden 
Chamber assay to test for changes in migration an invasion.  For the scratch assay, primary 
mouse keratinocytes were plated on 6 well plates on top of J2 3T3 feeder cells. Once the 
keratinocyte colonies were big enough, any remaining feeders were removed using 0.02% 
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EDTA before starting the assay. Using a 200 µl pipette, we made a scratch was across the 
center the colony and the progress of the gap closure was monitored over a 24-hour period 
using time-lapse microscopy. Time-lapse images were taken every 10 min. For the analysis, 
individual cells were followed using the time-lapse images and their path lengths were 
quantified and compared. For the Boyden Chamber assay we used a BioCoat Matrigel 
Invasion Chamber (Corning). Matrigel invasion inserts were used together with 24 well 
plates. The inserts had two chambers separated either by a Matrigel coated porous 
membrane, to assess invasion or just a membrane, to assess migration. Primary mouse 
keratinocytes were plated on the upper compartment. F-media was used in both chambers. 
No nutrient gradient was established in order to determine so that we could observe the 
base migratory and invasive potential of the cells. After a 24-hour period, the membranes 
were removed, fixed, and stained and the numbers of cells that migrated through the 
membrane or invaded through the Matrigel were counted using bright field microscopy and a 
10x objective. Migrating cells per field and invading cells per field were quantified and 
compared. We found that knocking out ΔNp63 significantly increased migration in both 
assays (Figure 8, Figure 9, Figure 10A) as well as invasion in the Boyden Chamber assay 
(Figure 10B). For comparison, TAp63-/- keratinocytes were also used in these assays as 
TAp63 had been previously implicated as a regulator of tumor migration and invasion 
(reference). 
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Figure 8. Images from in vitro scratch assay using WT, ΔNp63-/-, and TAp63-/- KCs. 
Time points for 0 hours, 8 hours, and 24 hours are shown. 
 
 
Figure 9. In vitro scratch assay quantification. Measurements of distance traveled by 
WT, ΔNp63-/-, and TAp63-/- KCs in the in vitro scratch assay shown in figure 8. 
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Figure 10. Boyden Chamber Assay Migration and Invasion Results. Migration (A) and 
invasion (B) assay of WT, ΔNp63-/-, and TAp63-/- KCs. Asterisks, p < 0.0001. 
 
Moreover, when we analyzed the behavior of individual ΔNp63-/- cells in the scratch 
assay, we saw that their cell contacts had been lost, and they migrated individually and 
more erratically (Figure 8). In contrast, TAp63-/- cells, they still retain their cell contacts and 
migrate as a unit even though overall migration is increased. We followed the paths that 
individual cells and quantified their traveled distance and saw that ΔNp63-/- cells also 
traveled a significantly longer distance than WT or TAp63-/- cells (Figure 9). These results 
further evidence that loss of ΔNp63 promotes a mesenchymal phenotype, as their migration 
patterns closely mirror those of mesenchymal cells. 
Taken together, these data provide evidence that ΔNp63 loss in keratinocytes 
promotes a transition from an epithelial to a mesenchymal phenotype. ΔNp63-/- 
keratinocytes lose expression of E-cadherin and cell-cell contacts typical of epithelial cells 
while at the same time acquire expression of Vimentin and other EMT related transcription 
factor typical of mesenchymal cells. Besides expression changes, the transition into a 
mesenchymal phenotype affected the functional properties of ΔNp63-/- making them more 
migratory and invasive, as observed in the in vitro assays. ΔNp63-/- keratinocytes also 
appear to migrate individually and in an erratic manner, suggesting that they have little 
communication with surrounding cells. With this in mind, we sought to address the question 
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as to whether ΔNp63 loss leads to EMT and increased migration and invasion with the 
added complexity of an in vivo system. 
 
4.2 Loss of ΔNp63 promotes an epithelial to mesenchymal transition in vivo. 	  
To investigate how ΔNp63 regulates the epithelial to mesenchymal transition in vivo, 
we developed an in vivo cutaneous wound-healing assay. p63 has been previously shown 
to play a role in normal cutaneous wound healing through mostly through its function as a 
regulator of skin stem cell compartments (12, 33). The process of cutaneous wound healing 
shares many similarities and molecular pathways with tumor development and metastasis 
(34-40). Many of the pathways that are involved in cutaneous wound healing are also 
present in an unregulated way during cancer and metastatic progression. For example, cell 
proliferation and migration are important to repopulate the wound site and heal it while in 
cancer, uncontrolled proliferation leads to tumor growth and migration and invasion through 
tumor adjacent stroma are essential parts of metastasis. EMT is another important process 
common between cutaneous wound healing and cancer progression. In cutaneous wound 
healing, epidermal cells at the wound edge partially lose cell-cell adhesions, alter their cell 
morphology, and acquire mesenchymal properties that allow them to migrate and close the 
wound gap (29, 32, 41-44). A similar process takes place during metastasis. The cutaneous 
wound healing mouse model allows us to study proliferation, migration, invasion and EMT in 
a shorter and more controlled time frame and also using the power of genetically engineered 
conditional knockout mice.  
For the cutaneous wound healing mouse model, ΔNp63 conditional knockout mice 
(ΔNp63fl/fl) were crossed to reporter RosaM/M mice (45) and to mice expressing a tamoxifen 
inducible Cre under the K14 promoter (K14CreER+) mice (46) to generate ΔNp63fl/fl, RosaM/M, 
K14CreER+ mice. The mice were anesthetized using inhaled isoflurane and a 1 cm wound 
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constrained to the epidermis was made using DXB compound. DXB is a proprietary 
detergent solution provided by one of our collaborators that selectively dissolves the 
epidermis to generate the wound. This allows us to solely focus on the processes involved 
in epidermal repair. Tamoxifen (100 mg/mL 100% Ethanol) was applied topically to the mice 
backs for three consecutive days following wounding to activate Cre and induce 
recombination. Mice were housed together, and subsets were euthanized at days 1, 4, and 
8 after induction (Figure 11).  
 
 
Figure 11. Experimental design for in vivo wound healing experiment. ΔNp63fl/fl, 
RosaM/M, K14CreER+ mice in a C57Bl/6, 129 background were treated topically with 
DXB compound to create 10 mm epidermal wounds and with Tamoxifen for 3 
consecutive days to induce recombination constrained to the epidermis. Wounds 
were assessed on days 1, 4, and 8 after wound induction 
 
One half of the epithelium was fixed in 10% formalin and the other frozen in OCT 
medium (Tissue Tek). Frozen sections were used to assess recombination status. Due to 
the RosaM/M reporter, the recombined tissues would express GFP and fluoresce green  as 
shown in this representative image (Figure 12). 
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Figure 12. Assessment of recombination efficiency. In vivo recombination efficiency 
of unrecombined (ΔNp63fl/fl) and recombined (ΔNp63Δ/Δ) wound sites was 
assessed after three days of Tamoxifen by imaging frozen sections using 
fluorescence microscopy. R, Rosa mutant. Red, TdTomato. Green, GFP. Blue, 
DAPI.  
 
Formalin fixed sections were embedded in paraffin and sectioned onto slides. These 
slides were stained with hematoxylin and eosin and the wound sizes were measured and 
analyzed. Unstained paraffin embedded tissue sections were dewaxed in xylene and 
rehydrated in a graded series of ethanol following standard protocols (7). Slides were 
incubated with primary antibodies for ΔNp63 (rabbit, BioLegend 1:100), Twist1 (rabbit, 
1:100) from Santa Cruz, Lef1 (rabbit, 1:200) from Cell Signaling, GFP (chicken 1:1000), 
Ki67 (rabbit 1:100), Cytokeratin 5 (rabbit 1:500), E-Cadherin (rabbit 1:300), and Vimentin 
(rabbit 1:200) from Abcam, and cytokeratin 14 (guinea pig 1:500) from LifeSpan 
Biosciences. For immunohistochemical detection, Vectastain ABC Kit (Vector Lab) was 
used. For immunofluorescence detection, Alexa Fluor 568 goat anti-rabbit (Life 
Technologies, 1:500), FITC goat anti-guinea pig (Jackson ImmunoResearch 1:500), or 
Alexa Fluor 488 donkey anti-chicken (Jackson ImmunoResearch 1:500) secondary 
antibodies were used. 
We confirmed that for all ΔNp63fl/fl, RosaM/M, K14CreER+ samples treated with 
tamoxifen, the recombination efficiency was 100% after the third day and was constrained to 
the epidermis (Figure 12). At day 1, only about 20% of the epidermis showed recombination 
in the tamoxifen treated samples. We then analyzed H&E stained formalin fixed paraffin 
ΔNp63Δ/Δ ; RΔ/Δ ; K14Cre+ 
TdT/GFP/DAPI TdT/GFP/DAPI 
ΔNp63fl/fl ; RM/M ; K14Cre+ 
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embedded (FFPE) sections of the wound site and found that while the control wounds were 
completely reepithelialized by the fourth day, the ΔNp63 knockout wounds remained open 
even after the eighth day (Figure 13).  
 
 
Figure 13. H&E-stained cross sections of ΔNp63fl/fl and ΔNp63Δ/Δ skin. Samples were 
collected on days 1, 4, and 8 after wounding. The dotted line marks the epidermal 
border and the box marks the wound site. 
 
Staining for cytokeratin 5 (K5), which is only present in the epidermis, to ddeliniate 
the epidermal layer confirmed that control wounds had completely healed after 4 days while 
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Figure 14. Staining of wound sites for cytokeratin 5 to delineate the epidermis. Double 
immunofluorescence staining of ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 4, 
and 8 after wounding for cytokeratin 5 (red) and GFP (green).  
 
To quantify this, we measured the wound gap sizes at the different time points of the 
experiment and found the size of ΔNp63 knockout wounds to be significantly bigger across 
the eight-day duration of the experiment (Table 3, Figure 15).  
 
Table 3. Wound Gap Measurements for Various Time Points 
Sample Experiment Group Time Point Wound Size (mm) 
G992 Control Day 1 7.8 
G1013 Control Day 1 6.9 
G1014 Control Day 1 6.7 
G1000 Knockout Day 1 10.4 
G1001 Knockout Day 1 9.9 
G669 Control Day 4 0 
G696 Control Day 4 0 
G668 Knockout Day 4 4.7 
G695 Knockout Day 4 2.6 
G700 Knockout Day 4 4 
G671 Control Day 8 0 
G698 Control Day 8 0 
G666 Knockout Day 8 2.6 
G667 Knockout Day 8 3.1 
G701 Knockout Day 8 4 
 
 
Figure 15. Wound size quantification. Quantification of the size of the wound site on 
days 1, 4, and 8 after wounding. n = 3, p < 0.05 
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Although, the wound gap in the ΔNp63 knockout condition decreased throughout the 
duration of the experiment, the wound never fully healed. Our intention was to continue the 
experiment beyond eight days to observe if the wound eventually healed but we had to stop 
at the eighth day time point due to health concerns brought up by our animal facility 
veterinarians.  
To test whether ΔNp63 knockout wounds failed to re-epithelialize due to a defect in 
proliferation, we performed immunofluorescence staining on FFPE sections of the wound 
site with Ki67. We observed comparable Ki67 staining in both ΔNp63 knockout wounds 1 
day after induction and significantly increased Ki67 staining on days four and eight for 
ΔNp63 knockout wounds when compared to control (Figures 16, 17).  
 
 
Figure 16. Ki67 staining at the wound sites to assess proliferation. Double 
immunofluorescence staining of ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 4, 
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Figure 17. Quantification of proliferation in wound healing samples. Quantification of 
Ki67-positive cells on days 1, 4, and 8 post-wounding. n = 3, p < 0.0002. 
 
This suggests that epidermal cells in the wound edges continue to proliferate in the 
absence of ΔNp63 while the wound remains open. Taken together these data show that 
ΔNp63 knockout in the epidermis delays wound healing but it is not due to a defect in 
proliferation. 
Since ΔNp63 knockout epithelial cells continued to proliferate as expected, we 
decided to look at other processes that could explain the impaired re-epithelialization 
observed in ΔNp63 knockout wounds. Based on our in vitro experiments and its importance 
in normal epithelial wound healing, we set our sights on the EMT process and how changes 
due to loss of ΔNp63 could explain the observed wound-healing defect. We performed E-
cadherin and Vimentin staining and saw E-cadherin loss (Figure 18A) upon ΔNp63 deletion 
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Figure 18. E-cadherin and Vimentin expression at the wound sites. Double 
immunofluorescence staining of ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 4, 
and 8 post-wounding for E-cadherin (red) and GFP (green) (A), or Vimentin (red) 
and GFP (green) (B).  
 
These changes were present throughout the duration of the experiment during which 
the ΔNp63 knockout wounds failed to heal. In contrast, E-cadherin expression persisted 
even as Vimentin increased during wound healing in the control condition, as observed in 
the day one staining. This suggested that epidermal cells that lose ΔNp63 undergo a 
different kind of EMT and go further into a mesenchymal phenotype. To test this we 
performed immunohistochemistry for known EMT related transcription factors and found that 
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Figure 19. Twist1 and Lef1 immunohistochemistry staining at the wound sites. 
Immunohistochemical staining of ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 
4, and 8 after wounding for Twist1 (C) and Lef1 (D).  
 
This persisted throughout the eight-day duration of the experiment during which the 
wounds did not heal. In contrast, Twist1 and Lef1 expression never increased in the control 
condition, even during the first day when the wound was still in the process of healing. This 
suggests that the EMT program activated in the absence of ΔNp63 could be different than 
the one observed in conventional wound healing: The transcription factors Twist1 and Lef1 
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To tie the results from the in vivo model to the tumor phenotype observed on the 
ΔNp63+/- mice we performed immunohistochemistry on the tumors collected from ΔNp63+/- 
mice and the same reciprocal relationship between ΔNp63 and Twist1 and Lef1 levels at 
both the primary tumors and liver metastases. In well-differentiated primary tumors, ΔNp63 
continued to be expressed while Twist1 and Lef1 expression was low. In poorly 
differentiated primary tumors, ΔNp63 expression was decreased while Twist1 and Lef1 
expression was increased, pushing the tumors towards a more migratory and invasive 
phenotype. In the metastases, the inverse was true: ΔNp63 expression was restored and 
Twist1 and Lef1 expression was decreased, suggesting a reversion to the epithelial 
phenotype essential to seed the target metastatic organ (Figure 20). These stains also 
suggest that at least some of the tumors observed in the ΔNp63+/- mice are not due to loss 
of heterozygosity since ΔNp63 continues to be expressed in well differentiated tumors and 
in the metastases.  
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Figure 20. ΔNp63, Twist1 and Lef1 expression in tumors from ΔNp63+/- mice. ΔNp63 
expression inversely correlates with Twist1 and Lef1 expression in primary 
mammary tumors and metastases from ΔNp63+/- mice. Immunohistochemical 
staining for ΔNp63, Twist1, and Lef1 in well-differentiated or poorly differentiated 
primary mammary tumors and liver metastases.  
 
Taken together these data show that ΔNp63 loss appeared to promote a different 
EMT program and mesenchymal phenotype in vivo from the EMT program observed with 
wild type ΔNp63. In this program, E-cadherin loss was observed as Vimentin expression 
increased rather than what is observed in the typical wound healing process where E-
cadherin expression persists even as Vimentin increases. Furthermore, Twist1 and Lef1 are 
two EMT associated transcription factors that are typically not activated in the partial EMT 
found in wound healing, yet they were activated in the EMT program observed in the 
absence of ΔNp63, which further differentiates it. Finally, the tumors and metastases from 
Well-differentiated 
primary mammary tumors 
Poorly differentiated 
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the ΔNp63+/- cohort presented the same reciprocal relationship between ΔNp63 and Twist1 
and Lef1, which suggested that the same EMT program could be activated in these tumors.  
 
4.3 ΔNp63 modulates invasion, migration, and EMT through regulation of microRNAs 	  
To build on our in vivo findings we designed in vitro experiments using ΔNp63-/- 
primary keratinocytes to understand mechanism through which ΔNp63 could modulate 
migration. The first step was to address whether the relationship between ΔNp63, Twist1, 
and Lef1 observed in vivo could be recapitulated in an in vitro system. To this end, we used 
siRNA to knockdown expression of Twist1 and Lef1 (Figure 21) and performed a Boyden 
Chamber assay to test for reversion of the migration and invasion phenotypes observed in 
the absence of ΔNp63.  
 
Figure 21. Western blot analysis for knockdown efficiency of either Twist1 or Lef1 in 
ΔNp63-/- KCs. 
 
We saw that knockdown of either Twist1 or Lef1 in ΔNp63-/- primary keratinocytes 
decreased migration and invasion when compared to the non-targeting control (Figure 22A-
B) confirming that the migration and invasion phenotype observed upon loss of ΔNp63 is 
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Figure 22. Migration (A) and invasion (B) assay of WT KCs and ΔNp63-/- KCs 
transfected with either siTwist1 or siLef1. Asterisks, p ≤ 0.0006.  
 
We also performed qRT-PCR to determine if the mRNA levels of Twist1 or Lef1 were 
affected upon loss of ΔNp63. We found that ΔNp63-/- keratinocytes had increased levels of 
Twist1 (Figure 22A) and Lef1 (Figure 22B). We also confirmed that this phenomenon can be 
recapitulated when deleting ΔNp63 in normal human epidermal keratinocytes (NHEKs) 
(Figure 22A-B).  
 
   
Figure 22. Relative Twist1 and Lef1 expression in keratinocytes upon loss of ΔNp63. 
qRT-PCR of human and mouse Twist1 mRNA (A) and Lef1 mRNA (B) in NHEK-
WT, NHEK-shΔNp63, WT KCs and ΔNp63-/- KCs. Asterisks, p < 0.0005.  
 
Finally we performed a CHIP assay to determine if ΔNp63 directly bound to the 
Twist1 or Lef1 promoters and regulated their transcription but found no significant evidence 
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Figure 23. ChIP assay for human Twist1 (A) and Lef1 (B) in NHEK-WT and NHEK-
shΔNp63. NSBS, non-specific binding sites. 
 
Overall these data show that the mesenchymal phenotype observed in ΔNp63-/- 
keratinocytes and ΔNp63 knockdown NHEKs is partly due to its repression of Twist1 and 
Lef1. However, ΔNp63 does not directly bind to either the Twist1 or Lef1 promoters, which 
suggests that it regulates their expression through indirect pathways.  
Since ΔNp63 did not directly regulate Twist1 or Lef1 transcription, we decided to 
focus on ΔNp63’s role in microRNA biogenesis as an indirect pathway through which ΔNp63 
could regulate their expression. Using mRNA and microRNA sequencing data previously 
published by our lab (8), we did a functional pair analysis looking at candidate microRNAs 
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Figure 24. Functional pair analysis using ΔNp63-/- mRNA and microRNA sequencing. 
MicroRNA-RNA functional pair analysis for genes associated with EMT upon the 
depletion of ΔNp63 in KCs. Expression down (blue), expression up (red)  
 
We found two candidates: miR-98 and miR-34a. Both of these microRNAs are 
DGCR8 dependent (8). Using Taqman qRT-PCR, we confirmed that there was significantly 
reduced expression of both miR-98 (Figure 25A) and miR-34a (Figure 25B) upon loss of 
ΔNp63 in both keratinocytes and NHEK. 
 
     
Figure 25. miR-98 and miR-34a expression upon loss of ΔNp63. Taqman qRT-PCR of 
miR-98-3p (miR-98) (A) and miR-34a-5p (miR-34a) (B) in NHEK-WT, NHEK-
shΔNp63, WT KCs and ΔNp63-/- KCs. Asterisks, p ≤ 0.0001.  
 
 We then proceeded to re-introduce and overexpress these microRNAs to ΔNp63-/- 
keratinocytes (Figure 26A-B) and assess whether they were enough to reverse the effects of 
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Figure 26. Confirmation of reintroduction and expression of miR-98 or miR-34a into 
ΔNp63-/- KCs. Taqman qRT-PCR of miR-98 (A) and miR-34a (B) in ΔNp63-/- KCs 
overexpressing either miR-98 (A) or miR-34a (B). Asterisks, p < 0.0001.  
 
We saw that upon overexpression of miR-98, Twist1 protein levels were significantly 
reduced (Figure 27A) and upon overexpression of miR-34a, Lef1 protein levels were 
significantly reduced (Figure 27B).  
 
 
Figure 27. Change in Twist1 and Lef1 protein levels upon reintroduction of miR-98 or 
miR-34a. Western blot analysis of Twist1 (A) and Lef1 (B) expression levels in 
ΔNp63-/- KCs overexpressing either miR-98 (A) or miR-34a (B).  
 
Finally, using a Boyden Chamber assay, we observed that overexpression of miR-98 
or miR- 34a in ΔNp63-/- primary keratinocytes decreased migration and invasion thus 
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Figure 28. Migration (A) and invasion (B) assay of WT KCs and ΔNp63-/- KCs infected 
with either miR-98, miR-34a, or an empty vector. Asterisks, p < 0.0006.  
 
Taken together, these data give evidence that ΔNp63 can modulate migration, 
invasion, and EMT by indirectly regulating Twist1 and Lef1 through miR-98 and miR-34a 
regulation, respectively. 
In summary, we used in vivo mouse models and primary cells to explore 
mechanisms through which ΔNp63 could suppress tumor development and metastasis. We 
found that ΔNp63 loss leads to loss of epithelial characteristics and cell-cell contacts, and 
increased migration and invasion in vitro. This migration is erratic, as it appears that the 
cells are not coordinating well with each other. Using mouse models, we found evidence 
that an EMT program happens in the absence of ΔNp63 where levels of Twist1 and Lef1 are 
increased and cells could their cell-cell contacts and ability to coordinate, which could lead 
to the observed inability to close a wound gap. ΔNp63 appears to regulate Twist1 and Lef1 
indirectly, in part through its role as a regulator of microRNA biogenesis. These findings 
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Chapter 5: Role of ΔNp63 in mammary gland development and tumorigenesis 	  
The most common tumors present in ΔNp63+/- mice were mammary 
adenocarcinomas. Breast cancer is the second cause of cancer related death among 
women, only behind lung cancer. In 2016 alone, approximately 250,000 cases of breast 
cancer will be diagnosed in the United States alone. Some of these tumors will respond to 
surgery, hormone therapy or other targeted therapies such as anti Her2 receptor therapy. 
However, significant subsets of tumors termed triple negative breast cancers have limited 
response to chemotherapy but no effective targeted therapies. These tumors tend to be 
poorly differentiated, aggressive, and metastatic, characteristics they share with the 
mammary tumors observed in ΔNp63+/- mice. Because of these similarities, we sought to 
understand better what is the role of ΔNp63 in the mammary gland in the context of 
development as well as in breast cancer. 
 In the clinic, p63 is used in conjunction with a panel of cytokeratins as a biomarker 
to stage breast tumors. In this immunohistochemical stain, p63 is expressed in normal basal 
cells and gives information of whether a tumor has progressed beyond carcinoma in situ and 
is invading into the stroma (47, 48). Even though a total p63 antibody is used for this test, 
the main p63 isoform expressed in the basal cells is ΔNp63. Studies have confirmed that 
replacing the total p63 antibody with a ΔNp63 specific antibody produces comparable 
results (49). Beyond its use as a clinical biomarker, the role of ΔNp63 in breast cancer is not 
very clear. There are a number of contradicting reports that argue that ΔNp63 can function 
as an oncogene or as a tumor suppressor: some studies report that ΔNp63 functions 
oncogene by regulating stem cell properties, differentiation, and proliferation in basal type 
breast cancer (50-52), while others show that ΔNp63 can function as a tumor suppressor by 
working together with Brca1 and by modulating sensitivity to chemotherapy (53, 54). Even 
ΔNp63’s role in mammary gland development is not well understood. Recent studies have 
shown that ΔNp63 is can promote mammary stem cells through the Wnt pathway (50) and 
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that it can control the process of lactogenesis (55). Still many questions remain. We sought 
to use our ΔNp63 conditional knockout mouse model to further understand the role of 
ΔNp63 in normal mammary gland development and answer some of these questions. This 
would enable us to learn about the role ΔNp63 plays in breast cancer by understanding 
better its physiological role. Our approach consisted of three main parts. First, we 
characterized mammary transplants of primary recombined ΔNp63 knockout mammary 
epithelial cells. Second, we sequenced RNA and microRNA isolated from the primary 
recombined ΔNp63 knockout mammary epithelial cells to obtain a global and unbiased 
picture of expression changes due to loss of ΔNp63 in this tissue. And finally, we sought to 
develop a new mouse model that would more closely represent the evolution and metastatic 
profile of human tumors. 
 
5.1 Lack of ΔNp63 impairs ductal growth and branching in the developing mammary 
gland 	  
Mammary gland development mostly occurs after birth and can be divided into four 
distinct phases. First, pubertal development starts once an organism reaches puberty, which 
is around 3 weeks in mice, and includes ductal elongation, tunneling of the terminal end 
buds through the mammary fat pad, and branching to form the final mammary ductal tree. 
Second, during pregnancy, the ducts undergo rapid proliferation to form terminal alveoli that 
are used in milk production. Third, after delivery, the luminal cells in the alveoli begin milk 
production, which will continue until nursing stops. And fourth, once the infants have been 
weaned off milk, the glands undergo a process called involution in which they revert to a 
pubertal state. Since ΔNp63-/- mice die shortly after birth, we need to use alternative 
approaches to study the role of ΔNp63 in postnatal mammary development. To this end, we 
chose to take advantage of the ΔNp63 conditional knockout mouse. 
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To study the role of ΔNp63 in early pubertal mammary gland development, our 
approach was to transplant harvested mammary epithelial cells into the cleared fat pads of 
Severe Combined Immune Deficiency (SCID) mice and then study the resulting outgrowths 
(Figure 29).  
 
 
Figure 29. Mammary Transplantation Procedure Diagram. 
 
The mammary epithelial cells were harvested from ΔNp63fl/fl, RosaM/M mice, which 
contain a reporter that turns the cells fluorescent green once recombination has happened. 
The protocol to obtain single mammary epithelial cells was as follows. We harvested the 
number 4 mammary glands from 8 week old ΔNp63fl/fl, RosaM/M mice, recorded their total 
weight, and minced the glands into 1 mm3 portions for subsequent digestion. The digestion 
was done using a 1mg/ml collagenase solution for 2 hours, pipetting every 30 minutes to 
properly mix. A minimum of 10 ml of solution was used per 1 g of gland. Once the digestion 
was done, we washed the suspension with Hank’s Buffered Saline Solution (HBSS) and 
performed 3 short 7-second centrifugation steps at 450g to enrich for mammary organoids. 
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pipetting every 2 minutes until a single cell suspension was observed under the microscope. 
Finally, the suspension was run through a 40 µm cell strainer to remove debris and 
resuspended on fresh mammary epithelial cell growth media (DMEM/F12 50:50, 10% FBS, 
5µg/ml Insulin, 1µg/ml Hydrocortisone, 10 ng/ml EGF, 1% Pen/Strep) and counted to set up 
the recombination step. To induce recombination, we infected the harvested mammary 
epithelial cells in suspension with Adenovirus-Cre or Adenovirus-Empty as a control at a 
multiplicity of infection (MOI) of 50 for a total of 1 hour at 37°C, mixing the suspension every 
15 minutes. The recombination efficiency after infection was consistently 95-100%. After 
infection, the cells were resuspended in a 50:50 HBSS:Growth Factor Reduced (GFR) 
Matrigel (Corning) mix, with 0.1% Trypan Blue. The Trypan Blue helped visualize the cells 
when transplanted. For the transplantation surgeries, 3 week-old SCID mice were 
anesthetized using intraperitoneal ketamine/xylazine (10mg/1mg per 10 g weight). We then 
proceeded to clear their 4th mammary fat pads of native gland and transplanted 100,000 
cells in a 20 µl suspension. We transplanted the Adenovirus Cre treated cells (ΔNp63Δ/Δ) in 
the right side and the control Adenovirus Empty treated cells (ΔNp63fl/fl) on the left side of 
each mouse. The mice were monitored for a period of 5 or 10 weeks at which point the 
transplants were harvested and characterized.  
The first step to characterize the transplants was to image the whole mounts upon 
harvest. Since the transplanted cells had the Rosa reporter, we used a fluorescent 
stereomicroscope to image the glands and record their fat pad coverage. There was a lot of 
variability from mouse to mouse. For the knockout (ΔNp63Δ/Δ) outgrowths, the maximum fat 
pad coverage was 13%, the minimum was 0% and the average was 1.9% at 5 weeks, while 
the maximum fat pad coverage was 29%, the minimum 0% and the average 7.6% at 10 
weeks. For the control (ΔNp63fl/fl) outgrowths, the maximum fat pad coverage was 93%, the 
minimum was 1% and the average was 36.8% at 5 weeks, while the maximum fat pad 
coverage was 100%, the minimum 5% and the average 58.9% at 10 weeks. Overall, the 
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knockout outgrowths covered a significantly smaller percentage of the mammary fat pad 
when compared to the control outgrowths at both 5 and 10 weeks (Figures 30-31, Table 4).  
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Figure 30. Fluorescent whole mounts for 5 weeks and 10 weeks ΔNp63 mammary 
epithelial cell transplantations. The pie charts represent the percentage of the fat 
pad covered for each sample. ΔNp63fl/fl, RosaM/M outgrowths (Red), ΔNp63Δ/Δ, 
RosaΔ/Δ outgrowths (Green) 
 
 
Figure 31. Percentage of fat pad coverage. Asterisks, for 5 weeks time point: p = 
0.003, ΔNp63fl/fl, RosaM/M n = 10, ΔNp63Δ/Δ, RosaΔ/Δ n = 10. For 10 weeks time point: 
p < 0.0001 ΔNp63fl/fl, RosaM/M n = 13, ΔNp63Δ/Δ, RosaΔ/Δ n = 15. 
 
Table 4. Percentage of mammary fat coverage for each knockout and control sample 
analyzed at the 5 week and 10 week time points. 
5 week - ΔNp63 fl/fl, Rosa M/M 
Sample Percent Coverage 
G848-RE 0% GFP 30% TdT 
G920-LE 0% GFP 55% TdT 
G921-LE 0% GFP 81% TdT 
G922-LE 0% GFP 33% TdT 
G924-LE 0% GFP 93% TdT 
G1275-LE 0% GFP 1% TdT 
G1277-LE 0% GFP 5% TdT 
G1279-LE 0% GFP 10% TdT 
G1310-LE 0% GFP 10% TdT 
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5 week - ΔNp63 Δ/Δ, Rosa Δ/Δ 
Sample Percent Coverage 
G848-LC 13% GFP 0% TdT 
G920-RC 0% GFP 0% TdT 
G921-RC 0% GFP 0% TdT 
G922-RC 5% GFP 0% TdT 
G924-RC 0% GFP 0% TdT 
G1275-RC 1% GFP 1% TdT 
G1277-RC 0% GFP 10% TdT 
G1279-RC 0% GFP 0% TdT 
G1310-RC 0% GFP 0% TdT 
G1312-RC 0% GFP 0% TdT 
 
10 week - ΔNp63 fl/fl, Rosa M/M 
Sample Percent Coverage 
G591-RE 0% GFP 55% TdT 
G847-RE 0% GFP 37% TdT 
G976-LE 0% GFP 77% TdT 
G977-LE 0% GFP 61% TdT 
G980-LE 0% GFP 31% TdT 
G1264-LE 0% GFP 50% TdT 
G1265-LE 0% GFP 5% TdT 
G1266-LE 0% GFP 50% TdT 
G1267-LE 0% GFP 50% TdT 
G1269-LE 0% GFP 100% TdT 
G1270-LE 0% GFP 100% TdT 
G1271-LE 0% GFP 100% TdT 
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10 week - ΔNp63 Δ/Δ, Rosa Δ/Δ 
Sample Percent Coverage 
G591-LC 19% GFP 32% TdT 
G594-RC 29% GFP 0% TdT 
G847-LC 6% GFP 0% TdT 
G976-RC 6% GFP 6% TdT 
G977-RC 5% GFP 5% TdT 
G979-RC 7% GFP 7% TdT 
G980-RC 7% GFP 7% TdT 
G1264-RC 0% GFP 0% TdT 
G1265-RC 25% GFP 25% TdT 
G1266-RC 10% GFP 10% TdT 
G1267-RC 0% GFP 0% TdT 
G1269-RC 0% GFP 0% TdT 
G1270-RC 0% GFP 0% TdT 
G1271-RC 0% GFP 0% TdT 
G1273-RC 0% GFP 0% TdT 
 
The number of terminal end buds was significantly lower in the knockout outgrowths 
as well (Figure 32, Table 5).  
 
 
Figure 32. Number of terminal end buds per outgrowth. Asterisks, for 5 weeks time 
point: p = 0.015, ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ n = 5. For 10 weeks 

























ΔNp63 fl/fl; RosaM/M ΔNp63 Δ/Δ; Rosa Δ/Δ
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Table 5. Number of Terminal End Buds (TEBs) for each knockout and control sample at the 
5 week and 10 week time points 
 
5 week - ΔNp63 fl/fl, Rosa M/M 







5 week - ΔNp63 Δ/Δ, Rosa Δ/Δ 







10 week - ΔNp63 fl/fl, Rosa M/M 







10 week - ΔNp63 Δ/Δ, Rosa Δ/Δ 
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Next we compared the histology of knockout and control outgrowth using 
hematoxylin and eosin (H & E) stained slides. We noticed that some of the knockout ducts 
were more disorganized and had an increased number of layers (Figure 33).  
 
 
Figure 33. H&E staining of 5 week and 10 week post transplantation mammary 
outgrowths. 
 
The normal mammary structure has two layers: a myoepithelial or basal layer 
adjacent to the stroma and a luminal layer that faces the lumen. To assess this further, we 
did immunofluorescence staining using anti - cytokeratin 18 antibody (rabbit 1:200) from 
Sigma to stain the luminal layer, anti- smooth muscle actin (SMA) antibody (mouse 1:250) 
from Sigma to stain the basal myoepithelial layer, and anti-GFP antibody (chicken 1:1000) to 
stain recombined cells to check for structural differences (Figures 34-35). We observed that 
there were in fact multiple luminal layers in the ΔNp63 knockout outgrowths at both the 5 
week (Figure 34) and 10 week (Figure 35) time points and that the basal layer was 
disorganized in some of the 10-week ΔNp63 knockout samples (Figure 35). 
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Figure 34. SMA and K18 expression in transplant outgrowths at 5 weeks. SMA (red), 
GFP (green), K18 (white), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ 
n = 3 
 
 
Figure 35. SMA and K18 expression in transplant outgrowths at 10 weeks. SMA (red), 
GFP (green), K18 (white), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 6, ΔNp63Δ/Δ, RosaΔ/Δ 
n = 8 
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We quantified the disorganization and found that 5 weeks after surgery 69% of the 
observed knockout ducts had multiple luminal layers while none of the control ducts did. 10 
weeks after surgery 72% of the observed knockout ducts had multiple luminal layers 
compared to only 8% of the observed control ducts (Figure 36, Table 6).  
 
 
Figure 36. Percentage of ducts with multiple luminal layers. For 5 weeks time point: 
ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ n = 5. For 10 weeks time point: 
ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ n = 7. 
 
56% of the knockout ducts appeared to have a discontinuous basal layer at the 5-
week post surgery time point evidenced by lack of SMA signal around the ducts (Figure 37, 
Table 6).  
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Figure 37. Percentage of ducts with a discontinuous basal layer evidenced by lack of 
SMA staining. For 5 weeks time point: ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ 
n = 5. For 10 weeks time point: ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ n = 7. 
 
44% of the knockout ducts appeared to have a disorganized basal layer as well at 
the 10-week post surgery time point (Figure 38, Table 6).  
 
 
Figure 38. Percentage of ducts with a disorganized basal layer. For 5 weeks time 
point: ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ n = 5. For 10 weeks time point: 
ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ n = 7. 	  
Table 6. Number of ducts with structural abnormalities per sample analyzed for the 5 week 
and 10 week time points 
 








G848-RE 0 0 0 
G920-LE 0 0 0 
G921-LE 0 0 0 
G922-LE 0 0 0 
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G848-LC 5 0 3 
G920-RC 0 0 0 
G921-RC 0 0 0 
G922-RC 6 0 6 
G924-RC 0 0 0 
 








G591-RE 0 0 0 
G847-RE 1 0 0 
G976-LE 0 0 0 
G977-LE 0 0 0 
G980-LE 0 0 0 
 








G591-LC 0 0 0 
G594-RC 3 0 0 
G847-LC 0 0 0 
G976-RC 0 0 0 
G977-RC 10 7 0 
G979-RC 0 0 0 
G980-RC 0 1 0 
 
To get to the root of this phenotype, we planned a set of immunofluorescence 
experiments to look at changes in EMT, polarity, or stem cell properties as potential 
explanations.  
One of the theories we had regarding the ductal disorganization was that, similarly to 
what we previously observed in culture and in the wound-healing model, ΔNp63 loss could 
le leading to unregulated EMT and affecting ductal development. We proceeded to stain the 
transplants for E-cadherin, but we were not able to detect any gross differences between E-
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cadherin expression and localization between knockout and control glands at either 5 weeks 
(Figure 39) or 10 weeks (Figure 40).  
 
 
Figure 39. E-cadherin expression in transplant outgrowths at 5 weeks. E-cadherin 
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Figure 40. E-cadherin expression in transplant outgrowths at 10 weeks. E-cadherin 
(red), GFP (green), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 5, ΔNp63Δ/Δ, RosaΔ/Δ n = 7. 
 
This lead us to believe that the ΔNp63-regulated pathways leading to the observed 
phenotype could be different than those observed in the skin.  
The next possibility we tested was whether a defect in polarity might be the cause for 
the observed disorganization. To test this, we performed immunofluorescence stains with 
Laminin (Rabbit 1:125, Sigma) antibody to look at the integrity of the basal membrane 
(Figure 41) and with Aquaporin 5 (AQP5) (Rabbit 1:100, Calbiochem) antibody to look at the 
orientation of the luminal cells regarding the lumen (Figures 42- 43).  
 
 
Figure 41. Laminin expression in transplant outgrowths at 10 weeks. Laminin (red), 
GFP (green), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 2, ΔNp63Δ/Δ, RosaΔ/Δ n = 3. 
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Figure 42. AQP5 expression in transplant outgrowths at 5 weeks. AQP5 (red), GFP 
(green), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 2, ΔNp63Δ/Δ, RosaΔ/Δ n = 2. 
 
 
Figure 43. AQP5 expression in transplant outgrowths at 10 weeks. AQP5 (red), GFP 
(green), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 4, ΔNp63Δ/Δ, RosaΔ/Δ n = 5. 
 
We did not notice any differences in laminin expression, however we noticed that in 
30% of the knockout ducts observed at 5 weeks and 10% of the knockout ducts observed at 
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10 weeks, AQP5 appeared to be mislocalized and not clearly delineating a lumen (Figure 
44, Table 7).  
 
Figure 44. Percentage of ducts with AQP5 mislocalization. For 5 weeks time point: 
ΔNp63fl/fl, RosaM/M n = 2, ΔNp63Δ/Δ, RosaΔ/Δ n = 2. For 10 weeks time point: 
ΔNp63fl/fl, RosaM/M n = 4, ΔNp63Δ/Δ, RosaΔ/Δ n = 5 	  
Table 7. Number of ducts with AQP5 mislocalization per sample analyzed for the 5 week 
and 10 week time points 
5 week - ΔNp63 fl/fl, Rosa M/M - Total Ducts: 8 
Mouse ID Normal AQP5 Distribution Mislocalized AQP5 
G848-RE 2 0 
G922-LE 6 0 
 
5 week - ΔNp63 Δ/Δ, Rosa Δ/Δ - Total Ducts: 13 
Mouse ID Normal AQP5 Distribution Mislocalized AQP5 
G848-LC 1 2 
G922-RC 8 2 
 
10 week - ΔNp63 fl/fl, Rosa M/M - Total Ducts: 16 
Mouse ID Normal AQP5 Distribution Mislocalized AQP5 
G847-RE 6 0 
G976-LE 2 0 
G977-LE 7 0 
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10 week - ΔNp63 Δ/Δ, Rosa Δ/Δ - Total Ducts: 20 
Mouse ID Normal AQP5 Distribution Mislocalized AQP5 
G594-RC 4 1 
G847-LC 3 0 
G977-RC 10 0 
G979-RC 0 1 
G1266-RC 1 0 	  	  
This suggested that apical basal polarity may be affected in the knockout outgrowths, 
however the small number of 5  and 10 week knockout samples we had to analyze did not 
allow us to reach a definitive conclusion. More samples need to be collected to properly 
assess this potential phenotype. 
The final possibility we tested for was whether the phenotype observed was due to a 
stem cell or differentiation defect. Previous studies in keratinocytes demonstrated that 
ΔNp63 regulates differentiation and its loss causes cells to acquire stem cell properties such 
as self-renewal (8). We performed two stains to test for stem cells: a Slug (goat 1:100, Santa 
Cruz) and Sox9 (Rabbit 1:100, Millipore) co-stain to identify mammary stem cells (reference) 
and a Ki67 (Rabbit 1:250, abcam) stain for active proliferation, one of the properties of cells 
with capacity for self-renewal. We did not find any Slug and Sox9 double stained cells 
(Figure 45).  
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Figure 45. Slug and Sox9 co-expression in transplant outgrowths at 10 weeks. Slug 
(red), GFP (green), Sox9 (white), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 2, ΔNp63Δ/Δ, 
RosaΔ/Δ n = 3. 
 
The low total number of ducts we observed in our transplants together with the fact 
that stem cells marked by Slug and Sox9 double staining are only present in a small fraction 
of normal mammary ducts could explain why we failed to see any double positive nuclei in 
our samples. The results from the Slug and Sox9 staining were inconclusive so we could not 
draw any conclusions regarding ΔNp63’s role in mammary stem cells. On the other hand, 
Ki67 staining demonstrated that cells in knockout ducts proliferate (Figure 46). 
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Figure 46. Assessment of proliferation in the ducts using Ki67 staining. Ki67 (Red), 
GFP (Green), DAPI (Blue). For 5 weeks time point: ΔNp63fl/fl, RosaM/M n = 15, 
ΔNp63Δ/Δ, RosaΔ/Δ n = 8. For 10 weeks time point: ΔNp63fl/fl, RosaM/M n = 15, 
ΔNp63Δ/Δ, RosaΔ/Δ n = 13 
 
We proceeded to quantify the proliferation in the knockout and control ducts by 
counting the Ki67 positive nuclei and dividing by the total number of nuclei. Table 8 shows 
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Table 8. Quantification of total nuclei (DAPI stain) and proliferating nuclei (Ki67 stain) in 
knockout and control ducts 5 and 10 weeks after transplantation. 
5 week - ΔNp63 fl/fl, Rosa M/M 
Sample DAPI Ki67+ Percent Positive 
G922-LE-1 300 109 36.33 
G922-LE-2 130 67 51.54 
G922-LE-3 100 60 60.00 
G922-LE-4 76 1 1.32 
G922-LE-5 214 99 46.26 
G922-LE-6 255 35 13.73 
G848-RE-1 99 6 6.06 
G848-RE-2 116 0 0.00 
G848-RE-3 150 14 9.33 
G848-RE-4 42 4 9.52 
G848-RE-5 226 51 22.57 
G848-RE-6 179 31 17.32 
G848-RE-7 120 23 19.17 
G848-RE-8 86 34 39.53 
G848-RE-9 45 17 37.78 
Total     24.70 
St dev     19.16 
 
5 week - ΔNp63 Δ/Δ, Rosa Δ/Δ 
Sample DAPI Ki67+ Percent Positive 
G922-RC-1 194 95 48.97 
G922-RC-2 237 149 62.87 
G922-RC-3 80 50 62.50 
G848-LC-1 360 186 51.67 
G848-LC-2 310 130 41.94 
G848-LC-3 128 62 48.44 
G848-LC-4 133 73 54.89 
G848-LC-5 91 51 56.04 
Total     53.41 
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10 week - ΔNp63 fl/fl, Rosa M/M 
Sample DAPI Ki67+ Percent Positive 
G847-RE-1 85 15 17.65 
G847-RE-2 156 18 11.54 
G847-RE-3 184 24 13.04 
G847-RE-4 97 6 6.19 
G847-RE-5 168 4 2.38 
G847-RE-6 132 17 12.88 
G847-RE-7 124 27 21.77 
G847-RE-8 123 24 19.51 
G976-LE-1 52 4 7.69 
G976-LE-2 72 8 11.11 
G977-LE-1 218 5 2.29 
G977-LE-2 143 4 2.80 
G977-LE-3 118 5 4.24 
G977-LE-4 45 5 11.11 
G977-LE-5 112 3 2.68 
Total     9.79 
St dev     6.47 
 
10 week - ΔNp63 Δ/Δ, Rosa Δ/Δ 
Sample DAPI Ki67+ Percent Positive 
G847-LC-1 49 20 40.82 
G847-LC-2 42 20 47.62 
G847-LC-3 110 48 43.64 
G591-LC-1 47 19 40.43 
G591-LC-2 150 14 9.33 
G591-LC-3 70 13 18.57 
G591-LC-4 46 10 21.74 
G977-RC-1 100 25 25.00 
G977-RC-2 198 18 9.09 
G977-RC-3 126 10 7.94 
G594-RC-1 224 95 42.41 
G594-RC-2 190 49 25.79 
G594-RC-3 195 122 62.56 
Total     30.38 
St dev     17.14 
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In fact, it appeared that proliferation may be significantly increased upon ΔNp63 loss 
in the mammary gland (Figure 47). This appeared to contradict earlier findings where we 
saw that the knockout mammary ductal trees grew to cover significantly smaller portions of 
the mammary fat pad than the control glands, although it offers a potential explanation for 
the observed expansion of the luminal layer and disorganization of the basal layer. One 
possibility was that increased cell death or apoptosis accompanied the increased 
proliferation, but we were unable to perform a suitable apoptosis assay in our samples to 
test this theory. This is something that should be tested in the future. 
 
 
Figure 47. Quantification of proliferation cells per duct. Percentage of Ki67 positive 
cells per duct. For 5 weeks time point: p = 0.0006, ΔNp63fl/fl, RosaM/M n = 15, 
ΔNp63Δ/Δ, RosaΔ/Δ n = 8. For 10 weeks time point:  p = 0.0002, ΔNp63fl/fl, RosaM/M n 
= 15, ΔNp63Δ/Δ, RosaΔ/Δ n = 13. 
 
To expand on this, we designed a secondary transplantation experiment to more 
directly test the self-renewal capacity of ΔNp63 knockout mammary epithelial cells. We 
harvested mammary gland tissue from SCID mice transplanted with ΔNp63Δ/Δ and ΔNp63fl/fl 
mammary epithelial cells following the same protocol detailed previously and transplanted 
them into 3-week-old SCID mice. To obtain the donor tissue, we imaged the fat pads 
harvested from the primary transplants under a fluorescent stereomicroscope and used a 
#11 blade scalpel and fine forceps to isolate 1 mm3 pieces of the glands for transplant. The 
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pieces were placed on HBSS and stored on ice until transplantation. We transplanted the 
mammary gland pieces by first clearing the fat pad and then placing the piece of donor 
mammary gland into a pocket within the remaining fat pad. ΔNp63Δ/Δ donor glands were 
transplanted into the right side and control ΔNp63fl/fl donor glands onto the left side of each 
mouse. 10 weeks after the surgeries, we harvested the secondary transplants and prepared 
fluorescent whole mounts. All of the ΔNp63fl/fl secondary transplantations grew out to varying 
degrees. In contrast, none of the ΔNp63Δ/Δ secondary transplantations grew out. The only 
visible signal under the fluorescent microscope corresponded to the transplanted donor 
piece (Figure 48, Table 9).  
 
 
Figure 48. Fluorescent whole mounts for 10 weeks ΔNp63 secondary mammary 
transplantations. The pie charts represent the percentage of the fat pad covered 
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Table 9. Percentage of mammary fat coverage for each knockout and control sample 
analyzed for the secondary Mammary Transplantations. 
2ry Transplant - ΔNp63 fl/fl, Rosa M/M 
Mouse ID Percent Coverage 
G1349-LE 0% GFP 100% TdT 
G1350-LE 0% GFP 100% TdT 
G1351-LE 0% GFP 50% TdT 
G1352-LE 0% GFP 50% TdT 
G1353-LE 0% GFP 50% TdT 
G1354-LE 0% GFP 25% TdT 
G1355-LE 0% GFP 5% TdT 
G1356-LE 0% GFP 5% TdT 
 
2ry Transplant - ΔNp63 Δ/Δ, Rosa Δ/Δ 
Mouse ID Percent Coverage 
G1349-RC 2.5% GFP 2.5% TdT 
G1350-RC 2.5% GFP 2.5% TdT 
G1351-RC 2.5% GFP 2.5% TdT 
G1352-RC 2.5% GFP 2.5% TdT 
G1353-RC 2.5% GFP 2.5% TdT 
G1354-RC 2.5% GFP 2.5% TdT 
G1355-RC 2.5% GFP 2.5% TdT 
G1356-RC 2.5% GFP 2.5% TdT 
 
This suggests that ΔNp63 loss adversely affects the mammary stem cell population’s 
capacity to self renew.  
In summary, although we observed that transplanted ΔNp63 knockout mammary 
epithelial cells are able to grow into mammary ducts, the ducts that grow out have aberrant 
morphology. ΔNp63 knockout ducts have reduced fat pad coverage, reduced number of 
terminal end buds, and expanded luminal and basal layers. Further staining did not show 
any changes in E-cadherin, Laminin, or AQP5 expression or localization, which suggests 
that in the context of mammary gland development, ΔNp63 does not appear to regulate 
EMT or polarity. The ΔNp63 knockout ducts did not co express Slug and Sox9 which could 
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mean that ΔNp63 loss does not affect the stem cell population in the ducts, although it is not 
conclusive. On the other hand, secondary transplantation experiments demonstrated that 
ΔNp63 loss appears to impair the self-renewal capacity of the mammary epithelial cells, 
which could mean that the stem cell population is decreased or affected in some other way. 
Finally, proliferation was significantly increased in the ΔNp63 knockout ducts, even though 
this additional proliferation did not translate into ductal growth. This initial characterization 
presented a clear phenotype upon los of ΔNp63, but questions still remained regarding the 
pathways involved. We explored next whether the presence of ΔNp63 expressing cells 
could account for the phenotype involved and give us an idea of what might be happening. 
5.2 ΔNp63 epithelial mammary epithelial cells have a competitive growth advantage 
when transplanted together with ΔNp63 knockout cells. 	  
Previous publications had suggested that ΔNp63 was essential for mammary gland 
development. However, no definitive in vivo studies had been done to confirm this. Our data 
seems to suggest that ΔNp63 is essential for normal mammary gland development, but 
disorganized mammary ducts can grow in its absence. As detailed before, even in the 
apparent absence of ΔNp63, there were some ducts that retained the expected normal 
structure. We speculated this might be due to the presence of cells that had not undergone 
recombination and thus continued to express ΔNp63. To test this, we performed an 
immunofluorescence stain using RFP antibody (Rabbit 1:200, Rockland) to stain 
unrecombined cells in conjunction with GFP antibody to stain recombined cells and SMA 
antibody to stain the myoepithelial basal cells, which delineate the mammary ducts. We 
found out that at 5 weeks, all the observed ducts from knockout cell transplants appear to 
solely contain unrecombined basal cells (Figures 49, 51, Table 10). 
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Figure 49. RFP, GFP and SMA co-expression in transplant duct outgrowths at 5 
weeks. RFP (red), GFP (green), SMA (white), DAPI (blue). ΔNp63fl/fl, RosaM/M n = 2, 
ΔNp63Δ/Δ, RosaΔ/Δ n = 2 (17 ducts analyzed). 
 
 However, at 10 weeks, 41.66% of the observed ducts from knockout cell transplants 
contained only recombined basal cells (Figures 50, 51, Table 10).  
 
 
Figure 50. RFP, GFP and SMA co-expression in transplant duct outgrowths at 10 
weeks. RFP (red), GFP (green), SMA (white), DAPI (blue). ΔNp63Δ/Δ, RosaΔ/Δ n = 2 
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Figure 51. Quantification of the composition of the basal layer for 5 week and 10 week 
ΔNp63 transplantations. For 5 week old transplantations, 76.47% of ducts had 
basal layers composed solely of unrecombined cells, while for 10 week old 
transplantations, 41.66% of the ducts had basal layers composed solely of 
recombined basal cells, while 33.33% of the ducts had basal layers composed 
solely of unrecombined basal cells. 	  	  
Table 10. Quantification of the composition of the basal layers per sample analyzed for the 5 
week and 10 week time points.  	  




Only GFP+  
basal layer 
No Basal Layer 
Staining 
G848-LC 3 0 0 
G922-RC 10 0 4 
 




Only GFP+  
basal layer 
No Basal Layer 
Staining 
G594-RC 1 4 0 
G847-LC 3 1 3 	  	  
This suggests that although cells that express ΔNp63 have a growth advantage, 
transplanted ΔNp63 knockout cells are still capable to grow into ducts although it might take 
longer for the ducts to grow out.  
ΔNp63 Δ/Δ; Rosa Δ/Δ 
 5 weeks
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To further assess the apparent growth advantage of ΔNp63 expressing cells, we 
designed a transplantation experiment where known ratios of recombined and 
unrecombined cells would be transplanted to evaluate competition between ΔNp63 
knockout and control mammary epithelial cells in a controlled in vivo environment. We 
transplanted 4 different combinations: 50% knockout cells with 50% control cells (50:50 
ΔNp63Δ/Δ:ΔNp63fl/fl), 90% knockout cells with 10% control cells (90:10 ΔNp63Δ/Δ:ΔNp63fl/fl), 
10% knockout cells with 90% control cells (10:90 ΔNp63Δ/Δ:ΔNp63fl/fl), and 100% knockout 
cells (100% ΔNp63Δ/Δ). These combinations would allow us to assess whether the knockout 
or the control cells have a competitive advantage and whether the disadvantaged cell group 
can overcome the disadvantage with increased cell numbers. The cells were transplanted in 
the same manner as detailed above: 100,000 cells in 20 µl 50:50 HBSS:GFR Matrigel mix, 
with the known ratios of cells transplanted on the right side, 100% control cells transplanted 
of the left. Glands were harvested 10 weeks after surgery. Unfortunately, only a few of the 
glands grew out so we could only draw some preliminary conclusions. For the 50:50 
ΔNp63Δ/Δ:ΔNp63fl/fl group, three of the transplants grew out: one of them had a  50% fat pad 
coverage with mixed growth (ducts were double positive for GFP (recombined cells) and 
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Figure 52. Fluorescent whole mounts for 10 weeks 50:50 ΔNp63Δ/Δ:ΔNp63fl/fl mammary 
transplantations. ΔNp63fl/fl, RosaM/M outgrowths (Red), ΔNp63Δ/Δ, RosaΔ/Δ 
outgrowths (Green) 
 
For the 90:10 ΔNp63Δ/Δ:ΔNp63fl/fl group, three transplants grew out as well: one had 
95% unrecombined cells and 5% recombined cells while the other two had only 
unrecombined cells (Figure 53).  
 
 
Figure 53. Fluorescent whole mounts for 10 weeks 90:10 ΔNp63Δ/Δ:ΔNp63fl/fl mammary 
transplantations. ΔNp63fl/fl, RosaM/M outgrowths (Red), ΔNp63Δ/Δ, RosaΔ/Δ 
outgrowths (Green) 
 
For the 10:90 ΔNp63Δ/Δ:ΔNp63fl/fl group, only two transplants grew out and both had 
only unrecombined cells. Taken together, these data suggest that control mammary 
epithelial cells that express ΔNp63 have a growth advantage that is not handily overcome by 
ΔNp63 knockout cells.  
In summary, we demonstrated that mammary epithelial cells that express ΔNp63 
have a competitive growth advantage and the presence of ΔNp63 expressing myoepithelial 
basal cells could promote the organization of ΔNp63 into ducts. A small percentage of 
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reason we saw the ΔNp63Δ/Δ outgrowths stall. Still, this does not fully explain the observed 
phenotype, particularly because we did observe ducts that only had recombined basal cells.  
Because we were not able to account for a mechanism to explain the mammary 
gland development phenotype observed in the absence of ΔNp63, we decided to sequence 
the mRNA and microRNA of ΔNp63 knockout and wild type mammary epithelial cells, to 
obtain a more complete, unbiased picture of expression changes due to loss of ΔNp63 in 
the mammary gland.  
 
5.3 mRNA and microRNA sequencing of ΔNp63 knockout and wild type mammary 
epithelial cells presents a complex network of pathways affected upon ΔNp63 loss. 	  
Biological systems are very complex and interconnected. Advances in sequencing 
and bioinformatics have helped us make considerable inroads understanding complex 
biological interactions. RNA and microRNA sequencing allows us to obtain a comprehensive 
picture of the gene and microRNA expression profile of a specific cell type. It also allows us 
to establish correlations with sequencing data from human tumors and determine common 
elements that could give an idea of how a gene is involved in cancer. In our case, 
sequencing coupled with bioinformatic analysis allowed us to compare the expression 
profiles of knockout mammary epithelial cells with wild type mammary epithelial cells 
profiles, determine which pathways and mechanisms are altered, and how they relate to the 
observed phenotype.  
To obtain mammary epithelial cells for sequencing, we harvested the 4th mammary 
gland pair from wild type mice and from ΔNp63fl/fl, RosaM/M mice and isolated the mammary 
epithelial cells following the protocol outlined before. To generate ΔNp63 knockout 
(ΔNp63Δ/Δ) cells, we infected ΔNp63fl/fl, RosaM/M with adenovirus Cre following the same 
infection protocol as the transplants as and plated them in monolayer culture without feeders 
for 3 days. We used EpiCult B-Basal Medium (Stem Cell Technologies) for these cultures. 
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After 3 days, the recombination was complete, evidenced by GFP signal under the 
microscope. The cells were then harvested and we performed RNA extraction. In order to 
obtain enough material to extract the RNA, pools of 3-4 mice were plated together. At least 
five 10 cm dishes per sample were required in order to be able to harvest enough RNA for 
sequencing. The RNA extraction was done using Trizol and the PureLink RNA extraction kit 
(Ambion), modified to collect small RNAs, which gave us the best combination of yield and 
quality. We checked the yield and purity with a Nanodrop spectrophotometer and did an RT-
PCR for ΔNp63 to confirm knockout (Figure 54). Although there was variability in the ΔNp63 
mRNA expression among the three different ΔNp63Δ/Δ samples, their levels were reduced 
when compared to the wild type samples so they were all sent for sequencing. We were 




Figure 54. Relative expression of ΔNp63 in the sequencing samples. qRT PCR to 
verify knockout of ΔNp63 in the mammary epithelial cell sequencing samples 
after infection. WT, wild type. 
 
 Once we handed the samples to the sequencing core, they tested the quality and 
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sequencing was completed, the data was analyzed. Three independent pools of ΔNp63Δ/Δ 
samples and two wild-type samples were used for the analysis.  
We set the criteria for significance at a fold change of 1.5 with a p value equal or less 
than 0.05 between ΔNp63Δ/Δ and wild type samples. Based on these criteria we identified 
1247 genes that were differentially expressed when comparing ΔNp63Δ/Δ to wild type, 691 
whose expression was decreased and 556 whose expression was increased (Appendix 
Table 1).  
For microRNAs, we identified 34 microRNAs that were differentially expressed when 
comparing ΔNp63Δ/Δ to wild type, 12 that were down regulated and 22 that were up 
regulated (Appendix Table 2).  
 
We performed unsupervised hierarchical clustering of the results and for both the 
mRNA and microRNA sequencing, the three ΔNp63Δ/Δ samples clustered together and were 
different from the two wild type samples that clustered together as well (Figures 55-56).  
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Figure 55. Unsupervised hierarchical clustering of mRNA sequencing results from 
ΔNp63 knockout and wild type mammary epithelial cells. DNp63D.DMECs = 
ΔNp63Δ/Δ mammary epithelial cells,  DNp63WTMECs = wild type mammary 
epithelial cells. 
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Figure 56. Unsupervised hierarchical clustering of microRNA sequencing results from 
ΔNp63 knockout and wild type mammary epithelial cells. A.DNp63DD = ΔNp63Δ/Δ 
mammary epithelial cells, miRNAWT = wild type mammary epithelial cells. 
 
To understand the role of these differentially expressed genes, we did pathway 
analysis and identified 553 pathways that were significantly altered upon loss of ΔNp63.  
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Finally, we did functional pair analysis using the mRNA and microRNA sequencing 
data to understand the relationship between the identified microRNAs and genes, and found 
6 microRNAs whose targets were decreased while they were increased and 3 microRNAs 
whose targets were increased while they were decreased (Appendix Table 3).  
This preliminary analysis gave us the big picture regarding the expression changes 
that occur in mammary epithelial cells upon loss of ΔNp63. Our next step was to validate 
these sequencing results. To this end, we developed an algorithm to narrow down the list of 
genes and microRNAs and select a relevant subset to begin the validation. 
To select genes and microRNAs for validation, we developed an algorithm that takes 
into account, the sequencing results, the phenotype we observed with our in vivo 
transplantation experiments, and the current published literature regarding genes of interest 
(Figure 57).  
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We first focused pathways that came up on the pathway analysis could potentially 
explain the phenotype observed in our previous in vivo experiments. The pathways we 
identified were apical junction, cell adhesion, cell fate commitment, cell junction 
organization, cell migration, cell proliferation, EMT, estrogen response, focal adhesion, gap 
junctions, actin cytoskeleton regulation, small GTPase signal transduction, TGF-β signaling, 
and pathways in cancer. There were a total of 114 genes in these pathways, which we then 
ran through our algorithm to narrow them further down (Table 11).  
 
Table 11. Differentially expressed genes in selected pathways. 
Gene Pathway fold change p value 
ldlrap1 Apical Junction 1.67 0.024 
mapk11 Apical Junction 1.81 0.001 
nrtn Apical Junction 1.63 0.029 
adam10 Cell Adhesion 0.53 0.023 
lgals7 Cell Adhesion 0.17 0.007 
rasa1 Cell Adhesion 0.49 0.024 
esam Cell Adhesion 3.31 0.045 
l1cam Cell Adhesion 1.81 0.002 
ifrd1 Cell Fate Commitment 0.55 0.041 
notch4 Cell Fate Commitment 1.69 0.016 
cldn5 Cell Junction Organization 5.64 0.017 
col17a1 Cell Junction Organization 0.27 0.005 
pvrl2 Cell Junction Organization 1.65 0.005 
tesk1 Cell Junction Organization 1.82 0.003 
clic4 Cell Migration 0.6 0.011 
trip6 Cell Migration 1.56 0.016 
abi1 Cell Proliferation 0.58 0.018 
bmpr2 Cell Proliferation 0.55 0.011 
cdh13 Cell Proliferation 2.62 0.017 
cdkn2d Cell Proliferation 1.6 0.042 
cul5 Cell Proliferation 0.49 0.036 
cxcr2 Cell Proliferation 2.14 0.02 
jag2 Cell Proliferation 2.9 0.032 
krt4 Cell Proliferation 1.75 0.025 
mxd4 Cell Proliferation 1.98 0.008 
nap1l1 Cell Proliferation 0.62 0.037 
	   102 
Gene Pathway fold change p value 
prkrir Cell Proliferation 0.54 0 
sertad1 Cell Proliferation 1.85 0.048 
tbx3 Cell Proliferation 0.48 0.006 
tnfrsf11a Cell Proliferation 0.45 0.035 
tnfsf15 Cell Proliferation 0.55 0.044 
aplp1 EMT 2.23 0.033 
cald1 EMT 0.58 0.038 
calu EMT 0.64 0.003 
cdh2 EMT 0.66 0.042 
cdh6 EMT 0.44 0.041 
col11a1 EMT 0.51 0.001 
eln EMT 2.42 0.001 
igfbp2 EMT 0.58 0.038 
il6 EMT 0.31 0.044 
inhba EMT 0.60 0.031 
itgav EMT 0.57 0.006 
nt5e EMT 0.62 0.027 
pmp22 EMT 0.59 0.03 
pvr EMT 0.66 0.022 
tgfbr3 EMT 2.45 0.034 
thbs1 EMT 0.51 0.012 
vcam1 EMT 0.58 0.047 
vegfa EMT 0.32 0.030 
add3 Estrogen Response 0.59 0.037 
aldh3b1 Estrogen Response 1.75 0.004 
dcxr Estrogen Response 2.61 0.003 
dhrs3 Estrogen Response 0.42 0.007 
faim3 Estrogen Response 2.90 0.045 
fasn Estrogen Response 1.56 0.020 
gale Estrogen Response 1.65 0.015 
hr Estrogen Response 1.67 0.045 
isg20 Estrogen Response 1.84 0.028 
kdm4b Estrogen Response 1.55 0.035 
ltf Estrogen Response 3.14 0.035 
nrip1 Estrogen Response 0.44 0.043 
pkp3 Estrogen Response 1.56 0.038 
sult2b1 Estrogen Response 0.33 0.031 
tpd52l1 Estrogen Response 1.85 0.000 
tsta3 Estrogen Response 1.66 0.037 
ugcg Estrogen Response 0.66 0.025 
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Gene Pathway fold change p value 
bcl2 Focal Adhesion 0.6 0.048 
birc3 Focal Adhesion 0.46 0.045 
crk Focal Adhesion 0.66 0.011 
flnc Focal Adhesion 1.51 0.047 
fyn Focal Adhesion 0.64 0.019 
itga7 Focal Adhesion 1.78 0.025 
itgb8 Focal Adhesion 0.36 0.042 
pdgfb Focal Adhesion 0.41 0.034 
pdgfd Focal Adhesion 0.41 0.044 
pik3ca Focal Adhesion 0.56 0.047 
ppp1cb Focal Adhesion 0.53 0.007 
pten Focal Adhesion 0.6 0.048 
rap1b Focal Adhesion 0.6 0.044 
sos1 Focal Adhesion 0.56 0.047 
htr2a Gap Junction 0.3 0.027 
map3k2 Gap Junction 0.46 0.024 
tuba1b Gap Junction 1.59 0.008 
cltc Gap Junction 0.66 0.009 
gjb2 Gap Junction 0.56 0.026 
gjb5 Gap Junction 1.91 0.035 
bax Pathways in Cancer 1.56 0.009 
ccdc6 Pathways in Cancer 0.55 0.027 
cdkn1a Pathways in Cancer 1.85 0.001 
cdkn2b Pathways in Cancer 1.74 0.045 
chuk Pathways in Cancer 0.57 0.003 
egln2 Pathways in Cancer 1.52 0.028 
hif1a Pathways in Cancer 0.59 0.029 
pml Pathways in Cancer 1.73 0.042 
ptgs2 Pathways in Cancer 0.55 0.017 
rb1 Pathways in Cancer 0.53 0.045 
runx1 Pathways in Cancer 0.65 0.036 
smad2 Pathways in Cancer 0.66 0.043 
tgfbr1 Pathways in Cancer 0.5 0.015 
tpm3 Pathways in Cancer 0.45 0.003 
bdkrb2 Regulation of Actin Cytoskeleton 0.59 0.045 
nckap1 Regulation of Actin Cytoskeleton 0.41 0.013 
mapre1 Regulation of Actin Cytoskeleton 0.65 0.027 
nebl Regulation of Actin Cytoskeleton 0.23 0.040 
apoe Small GTPase Mediated Signaling 0.38 0.010 
cdc42bpa Small GTPase Mediated Signaling 0.57 0.010 
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Gene Pathway fold change p value 
fgd4 Small GTPase Mediated Signaling 0.53 0.031 
grap Small GTPase Mediated Signaling 0.52 0.028 
cdk8 TGF_beta signaling 0.62 0.034 
rbl1 TGF_beta signaling 0.63 0.025 
skil TGF_beta signaling 0.56 0.02 
usp9x TGF_beta signaling 0.53 0.019 
xpo1 TGF_beta signaling 0.54 0.035 
id3 TGF_beta signaling 1.92 0.045 
 
In the end we selected 10 genes whose expression change seemed to agree with 
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(Δ/Δ vs. WT) p value 
Information from 
Literature 
Itga7   
Cell 
Adhesion 1.78 0.025 
Mediates migration and 
invasion on laminin 
isoforms (56) 
Pten   
Cell 
Adhesion 0.6 0.048 
PTEN deletion promotes 
Breast Cancer Progression 
and Poor Prognosis (57) 
Cdh2   EMT 0.66 0.042 
DNp63 promotes N-
Cadherin, N-Cadherin could 
be a marker of metastasis 




193b-5p EMT 2.45 0.034 
Increased levels in TNBC, 
regulates polarity in luminal 
cells, mislocalization 
promotes EMT, migration, 






Response 0.44 0.043 
regulator of Estrogen 
signaling and oncogenic 
pathways, role in breast 
cancer cell growth, inhibits 
Wnt/Beta Catenin pathway, 
increased in tumors (60, 61) 
Cdkn1A   
Pathways 
in Cancer 1.85 0.001 
Increased in breast cancer 
tissues, correlates with 
tumor size, 
dedifferentiation, lymph 
node mets, and shorter 
disease free survival, 
cytoplasmic expression in 
hyperplastic foci (62) 
Hif1A   
Pathways 
in Cancer 0.59 0.029 
Expression associated with 
metastatic high grade 
breast cancers, expressed 
during early mammary 
gland development prior to 
polarization, promotes 
angiogenesis through 






signaling 2.45 0.002 
Can inhibit IGF activity, 
regulates proliferation and 
cell death in mammary 
gland development (64) 
Cald1   EMT 0.58 0.038 
Down in human Mammary 
Stem Cell signature (65) 
Cnp   
Cell-Cell 
Signaling 1.70 0.043 
Up in human Mammary 
Stem Cell signature (65) 
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Two particularly interesting genes that came up were Nuclear receptor binding 
protein 1 (Nrip1) and Insulin Growth Factor Binding Protein 5 (Igfbp5). These genes are 
involved in estrogen receptor (ER) signaling and insulin growth factor (IGF) signaling, 
respectively, two pathways that closely intertwine and are essential in mammary gland 
development (60, 61, 64). Moreover, these pathways are also involved in processes such as 
cell proliferation and apoptosis, which could have potential implications in the context of 
cancer. Some genes also came up in the functional pair analysis and their microRNA 
partner was noted. We designed SYBR Green RT-PCR primers for 8 of these genes and 
Taqman RT-PCR probes for the remaining two that we could not find working SYBR green 
primers for and proceeded to validate the genes.  
We used fresh ΔNp63Δ/Δ RNA obtained from a pool of 3 mice for the validation. The 
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Figure 58. qRT PCR results for validation of selected genes. We were able to validate 
the expression of all the 10 selected genes. ΔNp63 FL/FL MEC =  ΔNp63fl/fl 
mammary epithelial cell RNA ΔNp63 Δ/Δ MEC =  ΔNp63Δ/Δ mammary epithelial 
cell RNA. 
 
In the case of microRNAs, we ran all the 34 differentially expressed microRNAs 
through our algorithm, focusing first on the ones that came up in the functional pair analysis. 
In the end we selected 9 microRNAs whose expression change seemed to agree with our 
phenotype and the published literature for validation (Table 13).  
 







vs. TS Literature 
mmu-mir-
592-5p 5.13 0.005 Oncogene 
Overexpressed in metastases vs. 
primary lung adenocarcinomas 
(66); increase correlates with poor 
prognosis in colorectal cancer (67) 
mmu-mir-
150-5p 2.94 0.006 Oncogene 
Overexpressed in breast cancer 
patients of all subtypes (68); promotes 
Breast Cancer growth (69);  
promotes prostate CSCs (70) 
mmu-mir-
33-3p 2.20 0.034 
Oncogene 
& TS 
targets p53 (71); targets HIF1a (72); 
knockouts are obese due to higher 
SREBP1 (73) 
mmu-mir-
146b-5p 1.63 0.050 
Oncogene 
& TS 
targets BRCA1 (74) and inhibits 
migration and invasion in vitro (75) 
mmu-mir-
10b-5p 1.60 0.030 Oncogene 
Promotes migration and invasion (Ma, 
Nature, 2007) (76) 
mmu-mir-
147-5p 0.35 0.001 
Tumor 
suppressor 
induces Mesenchymal to Epithelial 
Transition (MET) (77) 
mmu-mir-
193b-5p 0.34 0.043 
Tumor 
suppressor 
Promotes Breast Cancer progression 
(78)  
mmu-mir-
205-3p 0.29 0.003   ΔNp63 target inhibiting EMT (17) 
mmu-mir-
147-3p 0.05 0.002 
Tumor 
suppressor induces MET (77) 
 
We designed Taqman RT-PCR probes for all the microRNAs proceeded to validate 
their expression. We used the same fresh ΔNp63Δ/Δ RNA used for the gene validation. The 
RT-PCR validated the sequencing results for all 9 selected microRNAs (Figure 59).  
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Figure 59. qRT PCR results for validation of selected microRNAs. We were able to 
validate the expression of all the 9 selected microRNAs. ΔNp63 FL/FL MEC =  
ΔNp63fl/fl mammary epithelial cell RNA ΔNp63 Δ/Δ MEC =  ΔNp63Δ/Δ mammary 
epithelial cell RNA. 
 
Currently, we have identified a second set of genes for validation, this time focusing 
on the ER signaling and IGF signaling pathways since they are among the most important in 
mammary gland development and breast cancer. 
After validation of these genes and microRNAs with RT-PCR, our next step was to 
develop a system to test whether alterations in these validated genes can rescue the 
phenotypes observed in the in vivo experiments. Although it would be ideal to test these 
genes and microRNAs in vivo, we chose to start with an in vitro embedded 3D culture. An 
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cultures would be grown for 2 weeks while at the same time giving us information regarding 
the relationship and organization of mammary epithelial cells structures.  
To set up the 3D cultures, we modified the protocol for 3D culture of normal and 
malignant mammary epithelial cells previously published (21). We isolated ΔNp63fl/fl, 
RosaM/M mammary epithelial cells and infected them to induce recombination as previously 
mentioned. During the final steps of the infection procedure, we coated chamber slides with 
40 µl of GFR matrigel and set to dry in a 37° C incubator for 15 to 30 minutes, being careful 
not to over dry the slides. Once the infection was complete, the cells were counted and 
resuspended directly in matrigel at a concentration of 667 cells per µl. 150 µl of the cell mix 
was added to each well, so that there would be 100,000 cells per well. The slides were then 
placed for another 15 to 30 minutes in the 37° C incubator to polymerize the matrigel after 
which 200 µl of mammoshpere growth media were added. Media was replaced every other 
day for the two-week duration of the culture. After two weeks, the cultures were imaged 
using a fluorescent microscope (Figure 60) to assess for differences in size and number.  
 
 
Figure 60. Representative fluorescent images from the 13th day of 3D culture. 
 
We found that there were a significantly lower number of ΔNp63 knockout spheres 
when compared to wild type (Figure 61). 
 
ΔNp63 fl/fl, Rosa M/M ΔNp63 Δ/Δ, Rosa Δ/Δ 
TdTomato GFP  TdTomato GFP  
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Figure 61. Number of spheres per slide at the 13th day of 3D Culture.  Mixed glands 
had contributions from both recombined and unrecombined cells. There was 
significantly less number of spheres for the ΔNp63Δ/Δ, RosaΔ/Δ condition, p = 0.05, 
n = 2 
 
 However, the ΔNp63 knockout spheres were also significantly larger, which could be 
a sign that knocking out ΔNp63 results in increased proliferation (Figure 62). We attempted 
to stain the spheres with Ki67 to assess proliferation directly but unfortunately the spheres 
were lost while performing the washes in the immunofluorescence protocol. 
 
 
Figure 62. Average sphere diameter for each condition at the 13th day of 3D Culture.  
Mixed glands had contributions from both recombined and unrecombined cells. 
The diameter of the ΔNp63Δ/Δ, RosaΔ/Δ condition spheres was significantly larger, 
p = 0.03, n = 2 
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Finally, we performed immunofluorescence staining on these spheres to determine 
whether there were other phenotypic characteristics that correlated with what we observed 
in vivo. We stained the spheres with SMA to evaluate the basal layer and saw that, similarly 
to what we observed in vivo, the ΔNp63 knockout spheres had reduced expression when 
compared to the wild type: Some of the spheres did not have any SMA expression 
whatsoever while others had discontinuous expression only in a small population (Figure 
63). We were not able to determine whether these changes were significant because only 
three spheres survived the staining protocol. 
 
 
Figure 63. SMA staining to evaluate the basal layer of 3D cultures. Spheres were fixed 
and stained after 13 days in culture. GFP stains for cells that underwent 
recombination and lost ΔNp63 expression. SMA (red), GFP (green), confocal 
image, 10x. 	  	  
This in vitro phenotype was similar to what we observed in the in vivo 
transplantations where there were less ΔNp63 ducts but the resulting ducts had increased 
number of layers and increased proliferation. We believe that the phenotype observed in 
vitro and the similarities to the in vivo observations are evidence that the 3D culture system 
could a viable alternative to examine whether altering any of the validated genes rescues 
the ΔNp63 knockout mammary development defects. This was only a pilot experiment and 
more tests need to be done to determine if the expression changes observed are significant, 
SMA GFP  SMA GFP  SMA GFP  
ΔNp63Δ/Δ, RosaΔ/Δ ΔNp63Δ/Δ, RosaΔ/Δ ΔNp63fl/fl, RosaM/M 
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but it is a promising start. Our next step would also include optimizing the fixation and 
staining protocol so that we can recover more spheres. 
 
5.4. Attempted development of a new breast cancer tumor model. 	  
As mentioned before, our goal with this part of the project was to understand the role 
of ΔNp63 in mammary tumors since ΔNp63 has been previously connected to breast cancer 
and since mammary tumors were the most common tumor type in our own, ΔNp63+/- mice. 
We fist sought to understand its role in mammary gland development to have a base to build 
upon its role in tumor development but eventually our goal was to study ΔNp63 in a tumor 
context. To this end, we attempted to develop a mammary gland tumor model using 
conditional knockout mice and selectively knocking out in the mammary gland ΔNp63, 
TAp63, BRCA1, a known tumor suppressor in breast cancer that has previously been tied 
with ΔNp63 (53, 74, 79-81), or a combination of these genes using intraductal injection of 
adenoviral Cre. We were able to successfully inject the mice, 15 per condition, and confirm 
that the injections were successful and that recombination had taken place at both the 
luminal an basal layers of the mammary ducts (Figure 64, Appendix Table 4). We aged 
these mice for up to 2 years while monitoring for the development of tumors. 
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Figure 64. Confocal microscopy image and immunofluorescence staining showing 
successful intraductal injection and recombination to knockout ΔNp63. Left: 10x 
Confocal image of whole mammary gland RFP (red), GFP (green). Right: 40x 
Immunofluorescence staining for SMA (red) K18 (white), and GFP (green). 	  	  
Unfortunately, none of the mice developed tumors throughout the duration of the 
experiment. Upon harvesting the glands and analyzing the hematoxylin and eosin sections, 
no changes such as hyperplasia or ductal disorganization that could be suggestive of 
potential tumor development were observed. We collected and processed the tissues for all 
the injected mice and continue to analyze them looking for minor changes that might not 
have been evident at first glance. In the future, this experiment could be modified and 
repeated by crossing our conditional knockout mice with a known breast cancer tumor 
model with high penetrance to evaluate how lack of ΔNp63 modulates the development and 
progression of tumors. 
In summary, using the strength of in vivo models, primary cell culture methods, 
sequencing, and bioinformatics, we have increased our understanding of the pathways 
regulated by ΔNp63 in the mammary gland. Our main finding was that loss of ΔNp63 in 
mammary epithelial cells led to impaired mammary gland growth and disorganization of the 
ductal structure in spite of increased proliferation. Sequencing analysis gave us a broader 
picture of the mechanism for the observed phenotype, and we were able to confirm 
ΔNp63 Δ/Δ, Rosa Δ/Δ  ΔNp63 Δ/Δ, Rosa Δ/Δ  
SMA K18 GFP RFP GFP 
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alterations in EMT, ER signaling, IGF signaling, and cytoskeleton organization pathways 
among others. The next step will be to tie the sequencing findings to the observed 
phenotype and to this end we developed a 3D Culture system that appears in part to 
recapitulate what was observed in vivo. The 3D culture system still needs to be 
characterized further and optimized but it is a good start. All the pathways validated from the 
sequencing can also be linked to cancer, which would bridge our findings to the tumor 
phenotype observed in ΔNp63+/- mice. We are currently following up on these leads. 
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Chapter 6: Discussion 	  
6.1 Discussion and Future Directions 	  
Treatment of cancer remains one of our generations most pressing health issues. 
Our aim with this project was to address this by focusing on the basics and improving our 
understanding of the mechanisms of cancer development and progression. Understanding 
the basics is the key to developing new, more effective ways to treat this horrible disease. 
We focused on ΔNp63, a member of the p53 family of transcription factors that had been 
previously linked to various tumor types. Many of the previous research done on ΔNp63 was 
done on cancer cell lines, which provide valuable information but come with inherent 
limitations. The relationships and mechanisms discovered in vitro are done so in isolation, 
and there is no guarantee that these relationships will hold up in more complex systems. Is it 
to this end that we sought to use the various ΔNp63 mouse models we developed in house 
to address questions regarding its functions in both physiological and pathological contexts. 
We began with a tumor cohort study using ΔNp63+/- mice to obtain a broad idea 
regarding the role of ΔNp63 in cancer. In this study we found indisputable evidence that 
differences in ΔNp63 expression affect tumor development. ΔNp63 expression changes can 
both modulate the tumor spectrum in known genetic background such as p53-/-, as well as 
tumor initiation in the case where ΔNp63 heterozygosity was the sole genetic alteration. 
More work needs to be done to determine if the increased propensity for tumors in the 
ΔNp63+/- mice. Loss of heterozygosity is an option, although immunohistochemistry showed 
that at least some of the tumors retain ΔNp63 expression. Another option could be that 
ΔNp63 heterozygosity leads to genetic instability. To test this we could do karyotyping or 
comparative genomic hybridization to check if ΔNp63+/- mice exhibit any abnormalities. Our 
analysis also demonstrated that ΔNp63 potentially modulates tumor progression as well, 
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evidenced by the increased aggressiveness and metastases observed in tumors developed 
on a ΔNp63+/- background.  
With this evidence in hand, our next step was to try to understand the mechanisms 
through which ΔNp63 was modulating cancer. We began by characterizing the ΔNp63 
knockout phenotype using primary keratinocytes directly harvested from ΔNp63-/- embryos. 
Previous research had shown that ΔNp63 loss leads to multipotency (8), but we 
demonstrated that it also jumpstarts an EMT program that results in increased invasion and 
migration. After establishing the EMT in vitro, we developed an in vivo wound healing mouse 
model that allowed us to study EMT and migration within the complex biological context of a 
living organism. With this model we found that ΔNp63 also regulates EMT in vivo and its 
loss promotes a transition into a mesenchymal phenotype that is potentially different from 
the typical EMT that occurs during wound healing and is unable to fully reepithelialize the 
wound site. Delving further into the mechanism of this phenotype, we found that ΔNp63 
suppression of Twist1 and Lef1 through regulation of miR-98 and miR-34a, respectively, 
leads to the EMT observed. These transcription factors are not commonly involved in the 
EMT observed in traditional wound healing and we saw evidence of this as well in our 
system. We think that what is happening is that when ΔNp63 is lost, epithelial cells transition 
fully into a mesenchymal phenotype and become more invasive and migratory but they have 
poor directionality and little communication with their surrounding cells making the collective 
migration that is required for proper wound reepithelialization impossible to do. We also 
theorize that the cells could also be unable to revert back to an epithelial phenotype unless 
ΔNp63 expression was restored. The experiments to test this were beyond the scope of this 
project and were currently underway at the time of this writing. This contrasts with what 
happens in the control wounds, where the epidermal cells undergo a partial EMT program 
that is both transient and reversible, which allows them to migrate collectively to close the 
wound gap and restore the epidermal layer. We believe that a similar phenomenon could be 
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what causes ΔNp63+/- mouse tumors to be more aggressive and metastatic and saw 
immunohistochemical evidence that this could be the case: both Twist1 and Lef1 have 
reciprocal relationships to ΔNp63 expression in tumors and their corresponding mets. 
However, we still need to check for levels of miR-98 and miR-34a in the tumor samples, 
which could be done using fluorescence in situ hybridization. An alternative approach, could 
be to design a new tumor cohort experiment and collect pieces of the developing tumors 
and normal tissues could be flash frozen to extract RNA and protein. The RNA extracted 
could be sequenced to determine how ΔNp63 heterozygosity affects gene expression in the 
tumors and how it compares to normal tissues.  The protein extracted could be used to 
study ΔNp63 induced changes at the protein level and how these could modulate tumor 
development, one area we were unable to test with our project. Finally, based on our data 
there is potential for miR-98 and miR-34a to be used as drug targets to attempt to stop 
metastatic progression, something that will be explored further. 
The final part of this project concerned focusing on a specific tumor type to 
understand the role of ΔNp63 in its development and progression. We chose breast cancer 
since mammary adenocarcinoma was the most common tumor type observed in the 
ΔNp63+/- mouse model. We also theorized that the similarities between keratinocytes and 
mammary epithelial cells could mean that some of the same pathways could be regulated 
by ΔNp63 in both tissue types. Combing through the literature we found that ΔNp63 can be 
used as a biomarker for breast cancer in the clinic but when it comes to its function in breast 
cancer, there conflicting information detailing its role as both a tumor suppressor and an 
oncogene. Our own mouse data suggests that ΔNp63 could be functioning as a tumor 
suppressor, at least in some cases, but a lot of questions remained. We determined that 
part of the controversy regarding ΔNp63’s role in breast cancer is due to gaps in knowledge 
about the roles of ΔNp63 in mammary development. Therefore, we decided to tackle the 
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subject of mammary development and how the role that ΔNp63 plays in it could clue us into 
its role in breast cancer. 
Our data show that ΔNp63 loss impairs mammary ductal growth in spite of increased 
proliferation. The ducts that do grow out have an aberrant structure with multiple luminal 
layers and a disorganized basal layer. However, we were unable to fully explain the 
observed phenotype by staining the collected tissue samples, which led us to take a step 
back and try a different approach: sequencing the ΔNp63 knockout mammary epithelial cells 
to obtain a broader picture of expression changes due to ΔNp63 loss. We sequenced both 
ΔNp63 knockout mRNA and microRNA and saw that ΔNp63 loss significantly affected a 
complex network of pathways. Combining bioinformatics tools and our experimental data 
with information already available in the literature, we narrowed down the list of pathways, 
genes, and microRNAs to a more manageable number, and were able to validate the 
expression of all the candidates we tested. These candidates are involved in pathways such 
as EMT, ER signaling, cell polarity, and IGF signaling among others that could help explain 
our in vivo phenotype. Moreover, all of these pathways can potentially contribute to cancer 
as well, giving us an idea of ΔNp63’s role in tumorigenesis. When comparing the these 
sequencing results with the previously published keratinocyte sequencing (8), we saw very 
little overlap. This shows that even though keratinocytes and mammary epithelial cells are 
related, ΔNp63 appears to regulate different sets of genes although the underlying pathways 
affected could be similar. This was partially observed in our staining, where we saw E-
cadherin expression in the absence of ΔNp63 was reduced in the skin but unaffected in the 
mammary tissue. In the future, it would be interesting to compare the pathways affected in 
the keratinocytes and the pathways affected in the mammary epithelial cells further to see if 
there are any commonalities despite different genes being regulated. 
We also developed a 3D culture system that appears to partially recapitulate the 
observed in vivo phenotype and, after further optimization, could be used to screen 
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validated targets from the sequencing data to better understand the mechanisms involved. 
This system could also be used to test some of the genes and microRNAs affected in the 
skin to explore whether there is a link between the phenotypes observed in these different 
tissues despite the sequencing results. The complete analysis and understanding of these 
sequencing results was beyond the scope of this project but this was an important first step. 
Further work is already underway to validate more targets and correlate our findings with 
human disease. With the information and understanding we obtain from these analyses, we 
will potentially be able to identify new targets and develop new therapies to treat cancer.  
Finally we attempted to develop a new breast cancer mouse model using our 
conditional knockout mice and the intraductal injection process. Although our system 
appeared to work and recombination was successful, none of the mice developed tumors. 
This could suggest that ΔNp63 might not be able to promote tumor development by itself. 
The phenotypes observed in the ΔNp63+/- mice could be due to ΔNp63’s role as a modulator 
of tumor development, rather than a role a tumor initiator itself. To test this we would need to 
develop a new tumor study where we could cross ΔNp63 conditional knockout mice with a 
known breast cancer mouse model with high penetrance and assess how the absence of 
ΔNp63 modulates the development of tumors in terms of latency, aggressiveness and 
metastasis. Development of these models could be instrumental to test new therapeutic 
alternatives to treat cancer. 
6.2 Final Thoughts 	  
Finally, I wish to comment on the state of cancer research. Cancer remains one the 
main healthcare challenges of our lifetime. Despite considerable advances in cancer 
research, considerable hurdles remain to cure or even treat many tumor types. One of the 
main problems with cancer research is lack of communication between the research and 
clinical worlds. This leads to promising basic research that never moves beyond the bench 
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and drug development that does not take into account the nuances of the pathways that are 
being targeted. The end result is drugs that have a temporary benefit at best, or do not work 
as expected as worst. We cannot lose track that the reason we are doing this work is to help 
patients that are very sick. We owe it to them to make sure that we communicate better with 
one another, focus on projects with the potential to help patients, and that we properly 
research the mechanisms and pathways that we wish to target to allow the development of 
better drugs. Working together we will be able to make a difference and improve the way of 
life of millions of patients that depend on us. 
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Appendices 	  
Appendix Table 1. Full list of significant differentially expressed genes from ΔNp63 
mammary epithelial cell sequencing. 
 
Gene	  ID	   Biotype	   Gene	  Name	   Fold	  Change	   p-­‐value	  
ENSMUSG00000028188	   protein_coding	   Spata1	   0.472455825	   0.041877971	  
ENSMUSG00000069833	   protein_coding	   Ahnak	   0.605783484	   0.021056628	  
ENSMUSG00000028232	   protein_coding	   Tmem68	   0.634606614	   0.040179051	  
ENSMUSG00000087579	  
processed_	  
transcript	   1500017E21Rik	   0.29553544	   0.006544033	  
ENSMUSG00000021583	   protein_coding	   Erap1	   0.518710693	   0.002234346	  
ENSMUSG00000006179	   protein_coding	   Prss16	   2.202511234	   0.025198551	  
ENSMUSG00000017723	   protein_coding	   Wfdc2	   1.738558092	   0.043126708	  
ENSMUSG00000025261	   protein_coding	   Huwe1	   0.624111383	   0.015531721	  
ENSMUSG00000031007	   protein_coding	   Atp6ap2	   0.603174767	   0.000303827	  
ENSMUSG00000034981	   protein_coding	   Parm1	   0.576371239	   0.004920375	  
ENSMUSG00000021635	   protein_coding	   Rad17	   0.577321858	   0.041677894	  
ENSMUSG00000087299	   antisense	   Gm12953	   1.753327953	   0.010372194	  
ENSMUSG00000044098	   protein_coding	   Rsbn1	   0.436976541	   0.018532493	  
ENSMUSG00000024943	   protein_coding	   Smc5	   0.500974202	   0.049479922	  
ENSMUSG00000051726	   protein_coding	   Kcnf1	   119.1649248	   0.002734457	  
ENSMUSG00000005610	   protein_coding	   Eif4g2	   0.631982918	   0.007883431	  
ENSMUSG00000081382	   pseudogene	   Rpl18-­‐ps1	   1.594876517	   0.00793618	  
ENSMUSG00000022016	   protein_coding	   Akap11	   0.600856307	   0.042616279	  
ENSMUSG00000022018	   protein_coding	   Rgcc	   2.318630937	   0.049511908	  
ENSMUSG00000013646	   protein_coding	   Sh3bp5l	   1.542964965	   0.000445407	  
ENSMUSG00000052395	   protein_coding	   Rft1	   1.828739046	   0.002142806	  
ENSMUSG00000021733	   protein_coding	   Slc4a7	   0.538404911	   0.01364106	  
ENSMUSG00000039826	   protein_coding	   Trub2	   2.003370131	   0.035002903	  
ENSMUSG00000020063	   protein_coding	   Sirt1	   0.552006525	   0.047009325	  
ENSMUSG00000023004	   protein_coding	   Tuba1b	   1.591759209	   0.008350581	  
ENSMUSG00000026037	   protein_coding	   Orc2	   0.592943004	   0.046452867	  
ENSMUSG00000022358	   protein_coding	   Fbxo32	   0.471599166	   0.006052285	  
ENSMUSG00000034863	   protein_coding	   Ano8	   1.649437359	   0.01581636	  
ENSMUSG00000032420	   protein_coding	   Nt5e	   0.618070253	   0.026981946	  
ENSMUSG00000032423	   protein_coding	   Syncrip	   0.586870077	   0.019169812	  
ENSMUSG00000084824	   antisense	   Gm16344	   0.499211937	   0.023499996	  
ENSMUSG00000032301	   protein_coding	   Psma4	   0.583369	   0.043621786	  
ENSMUSG00000057454	   protein_coding	   Lypd3	   1.681614233	   0.039381724	  
ENSMUSG00000055320	   protein_coding	   Tead1	   0.611123102	   0.024296811	  
ENSMUSG00000036138	   protein_coding	   Acaa1a	   1.715144911	   0.012419495	  
ENSMUSG00000097327	   pseudogene	   E030030I06Rik	   3.188553648	   0.032721832	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ENSMUSG00000029675	   protein_coding	   Eln	   2.416634196	   0.001085099	  
ENSMUSG00000038146	   protein_coding	   Notch3	   2.425236741	   0.000162539	  
ENSMUSG00000052214	   protein_coding	   Opa3	   1.590558472	   0.015832973	  
ENSMUSG00000071303	   pseudogene	   Rps8-­‐ps1	   1.558377855	   0.022651824	  
ENSMUSG00000018286	   protein_coding	   Psmb6	   1.551019769	   0.041936645	  
ENSMUSG00000040928	   protein_coding	   S100pbp	   0.564723107	   0.028777518	  
ENSMUSG00000034121	   protein_coding	   Mks1	   1.63901773	   0.006355588	  
ENSMUSG00000034126	   protein_coding	   Pomt2	   1.663827573	   0.009721017	  
ENSMUSG00000035299	   protein_coding	   Mid1	   0.560906396	   0.033314475	  
ENSMUSG00000035293	   protein_coding	   G2e3	   0.530503306	   0.035584166	  
ENSMUSG00000078898	   protein_coding	   Gm4723	   0.585575653	   0.013833798	  
ENSMUSG00000074269	   protein_coding	   2410076I21Rik	   0.082959346	   0.000964462	  
ENSMUSG00000002944	   protein_coding	   Cd36	   5.799925095	   0.028715181	  
ENSMUSG00000066705	   protein_coding	   Fxyd6	   0.284057768	   0.001216221	  
ENSMUSG00000095463	   protein_coding	   Entpd4	   1.86992647	   0.016055019	  
ENSMUSG00000018040	   protein_coding	   Rrp7a	   1.686064613	   0.027236159	  
ENSMUSG00000053411	   protein_coding	   Cbx7	   0.305713468	   0.01061678	  
ENSMUSG00000040774	   protein_coding	   Cept1	   0.483439484	   0.040340229	  
ENSMUSG00000020921	   protein_coding	   Tmem101	   1.891424096	   0.019458113	  
ENSMUSG00000020928	   protein_coding	   Higd1b	   5.874945774	   0.034821525	  
ENSMUSG00000022788	   protein_coding	   Fgd4	   0.534045811	   0.030901835	  
ENSMUSG00000035505	   protein_coding	   Cox18	   1.678836033	   0.003616389	  
ENSMUSG00000020496	   protein_coding	   Rnf187	   1.569657205	   0.022706106	  
ENSMUSG00000059316	   protein_coding	   Slc27a4	   2.832553527	   0.015654845	  
ENSMUSG00000003038	   protein_coding	   Hmgn2	   0.59596679	   0.007289198	  
ENSMUSG00000054648	   protein_coding	   Zfp869	   0.607726426	   0.032456769	  
ENSMUSG00000071072	   protein_coding	   Ptges3	   0.597147513	   0.041639585	  
ENSMUSG00000071076	   protein_coding	   Jund	   1.594640394	   0.008677286	  
ENSMUSG00000023087	   protein_coding	   Ccrn4l	   0.524742733	   0.029995533	  
ENSMUSG00000087298	   pseudogene	   Gm9392	   0.561941963	   0.019289891	  
ENSMUSG00000031785	   protein_coding	   Gpr56	   0.607713274	   0.006566207	  
ENSMUSG00000031781	   protein_coding	   Ciapin1	   2.260305286	   0.007918667	  
ENSMUSG00000034259	   protein_coding	   Exosc4	   1.889073875	   0.014903473	  
ENSMUSG00000030291	   protein_coding	   Med21	   0.598905373	   0.044286093	  
ENSMUSG00000042298	   protein_coding	   Ttc19	   0.603860948	   0.038630241	  
ENSMUSG00000016253	   protein_coding	   Nelfcd	   1.618820153	   0.015305079	  
ENSMUSG00000002718	   protein_coding	   Cse1l	   0.532414904	   0.030982208	  
ENSMUSG00000093470	   lincRNA	   Gm20645	   0.507222015	   0.00024287	  
ENSMUSG00000025466	   protein_coding	   Fuom	   1.889634684	   0.012743902	  
ENSMUSG00000039236	   protein_coding	   Isg20	   1.84282661	   0.027850607	  
ENSMUSG00000096370	   protein_coding	   Gm21992	   1.96053221	   0.039214344	  
ENSMUSG00000074547	   pseudogene	   Gm10712	   1.569945052	   0.00748323	  
ENSMUSG00000046341	   pseudogene	   Gm11223	   1.769934884	   0.040091033	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ENSMUSG00000029287	   protein_coding	   Tgfbr3	   2.447606559	   0.033676054	  
ENSMUSG00000028461	   protein_coding	   Ccdc107	   1.579033726	   0.007541431	  
ENSMUSG00000044258	   protein_coding	   Ctla2a	   0.549759275	   0.025869865	  
ENSMUSG00000057551	   protein_coding	   Zfp317	   0.530981957	   0.006439666	  
ENSMUSG00000055415	   protein_coding	   Atp10b	   0.45325734	   0.034852354	  
ENSMUSG00000007613	   protein_coding	   Tgfbr1	   0.504364491	   0.014690112	  
ENSMUSG00000007617	   protein_coding	   Homer1	   0.518758828	   0.018319242	  
ENSMUSG00000003549	   protein_coding	   Ercc1	   3.320154461	   0.011401933	  
ENSMUSG00000017421	   protein_coding	   Zfp207	   0.661994247	   0.012342569	  
ENSMUSG00000003545	   protein_coding	   Fosb	   1.893676432	   0.023445044	  
ENSMUSG00000031371	   protein_coding	   Haus7	   1.582184715	   0.019957416	  
ENSMUSG00000031373	   protein_coding	   Car5b	   2.640286802	   0.025844549	  
ENSMUSG00000053641	   protein_coding	   Dennd4a	   0.64240839	   0.001012295	  
ENSMUSG00000020413	   protein_coding	   Hus1	   0.356022826	   0.047124709	  
ENSMUSG00000020415	   protein_coding	   Pttg1	   5.527931432	   0.001208261	  
ENSMUSG00000062906	   protein_coding	   Hdac10	   1.82104402	   0.032986587	  
ENSMUSG00000052485	   protein_coding	   Tmem171	   1.745715349	   0.041565185	  
ENSMUSG00000035397	   protein_coding	   Klf16	   1.662621384	   0.027217771	  
ENSMUSG00000058254	   protein_coding	   Tspan7	   1.553022873	   0.017356824	  
ENSMUSG00000001946	   protein_coding	   Esam	   3.312602883	   0.044819171	  
ENSMUSG00000067336	   protein_coding	   Bmpr2	   0.551270724	   0.011446605	  
ENSMUSG00000087439	   antisense	   Gm15788	   0.309619022	   0.033141156	  
ENSMUSG00000038576	   protein_coding	   Susd4	   1.80007631	   0.018610801	  
ENSMUSG00000030704	   protein_coding	   Rab6a	   0.621686665	   0.006471361	  
ENSMUSG00000029073	   protein_coding	   Gltpd1	   1.6354198	   0.007491142	  
ENSMUSG00000022570	   protein_coding	   Tsta3	   1.662621983	   0.037102249	  
ENSMUSG00000020590	   protein_coding	   Snx13	   0.498116186	   0.046758874	  
ENSMUSG00000028032	   protein_coding	   Papss1	   1.664489128	   0.026689271	  
ENSMUSG00000032393	   protein_coding	   Dpp8	   0.656352594	   0.049741888	  
ENSMUSG00000026667	   protein_coding	   Uhmk1	   0.542674605	   0.006682865	  
ENSMUSG00000029635	   protein_coding	   Cdk8	   0.623972342	   0.033703681	  
ENSMUSG00000029633	   pseudogene	   Gm5578	   0.549980501	   0.029034057	  
ENSMUSG00000042408	   protein_coding	   Zmym6	   0.466444526	   0.023679426	  
ENSMUSG00000017697	   protein_coding	   Ada	   1.75016077	   0.043883273	  
ENSMUSG00000041846	   protein_coding	   Smek1	   0.635772088	   0.022791033	  
ENSMUSG00000031843	   protein_coding	   Mphosph6	   0.656715901	   0.013073606	  
ENSMUSG00000056260	   protein_coding	   Lrif1	   0.536706484	   0.019044787	  
ENSMUSG00000083833	   pseudogene	   Gm13841	   3.043333404	   0.000848782	  
ENSMUSG00000076609	   IG_C_gene	   Igkc	   0	   0.012069204	  
ENSMUSG00000092541	   protein_coding	   Gm20537	   0.109145703	   0.003265004	  
ENSMUSG00000037857	   protein_coding	   Nufip2	   0.625077653	   0.027930941	  
ENSMUSG00000037580	   protein_coding	   Gch1	   1.536817969	   0.004678558	  
ENSMUSG00000091775	   protein_coding	   Gm16494	   Inf	   0.038817118	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ENSMUSG00000020810	   protein_coding	   Cygb	   3.211574037	   0.04224035	  
ENSMUSG00000031861	   protein_coding	   Lpar2	   1.61130149	   0.003543204	  
ENSMUSG00000039470	   protein_coding	   Zdhhc2	   0.553419493	   0.00368451	  
ENSMUSG00000048490	   protein_coding	   Nrip1	   0.44016962	   0.042622078	  
ENSMUSG00000042647	   protein_coding	   Acad12	   2.546329803	   0.025684514	  
ENSMUSG00000024121	   protein_coding	   Atp6v0c	   1.597492898	   0.044636953	  
ENSMUSG00000081911	   pseudogene	   Mrps36-­‐ps2	   1.96583267	   0.0244778	  
ENSMUSG00000024870	   protein_coding	   Rab1b	   1.642416738	   0.034948983	  
ENSMUSG00000041939	   protein_coding	   Mvk	   1.642357685	   0.003113777	  
ENSMUSG00000026434	   protein_coding	   Nucks1	   0.601634926	   0.010765334	  
ENSMUSG00000094622	   protein_coding	   Gm3055	   0.321052124	   0.044943295	  
ENSMUSG00000026127	   protein_coding	   Imp4	   1.556651483	   0.004179514	  
ENSMUSG00000043252	   protein_coding	   Tmem64	   0.646949871	   0.01140988	  
ENSMUSG00000025255	   protein_coding	   Zfhx4	   0.437326188	   0.014317485	  
ENSMUSG00000019039	   protein_coding	   Dalrd3	   1.682832793	   0.005086043	  
ENSMUSG00000033671	   protein_coding	   Cep350	   0.516968513	   0.028241129	  
ENSMUSG00000003528	   protein_coding	   Slc25a1	   1.545702543	   0.034822183	  
ENSMUSG00000003527	   protein_coding	   Dgcr14	   1.540668364	   0.048146673	  
ENSMUSG00000050002	   protein_coding	   Idnk	   1.63964968	   0.038783904	  
ENSMUSG00000098374	   protein_coding	   RNF8	   1.554783342	   0.040731083	  
ENSMUSG00000081355	   pseudogene	   Gm15264	   6.496217328	   0.001576894	  
ENSMUSG00000064339	   Mt_rRNA	   mt-­‐Rnr2	   0.424828347	   0.002065595	  
ENSMUSG00000054065	   protein_coding	   Pkp3	   1.562244527	   0.038213068	  
ENSMUSG00000041354	   protein_coding	   Rgl2	   1.893787392	   0.009598832	  
ENSMUSG00000056579	  
processed_	  
transcript	   Tug1	   0.655246389	   0.04843102	  
ENSMUSG00000022066	   protein_coding	   Gm21685	   1.886095064	   0.015159655	  
ENSMUSG00000032245	   protein_coding	   Cln6	   1.681281243	   0.016336121	  
ENSMUSG00000038250	   protein_coding	   Usp38	   0.584297943	   0.015206379	  
ENSMUSG00000028743	   protein_coding	   Akr7a5	   2.049469888	   0.005544379	  
ENSMUSG00000028744	   protein_coding	   Pqlc2	   1.935435511	   0.000318236	  
ENSMUSG00000087006	   lincRNA	   Gm13889	   4.05997505	   0.013462978	  
ENSMUSG00000039126	   protein_coding	   Prune2	   1.690277817	   0.012820535	  
ENSMUSG00000086755	   lincRNA	   Gm11216	   0.031375848	   0.008308377	  
ENSMUSG00000070394	   protein_coding	   Tmem256	   1.500423581	   0.015324512	  
ENSMUSG00000033192	   protein_coding	   Lpcat2	   0.569708261	   0.006305498	  
ENSMUSG00000000253	   protein_coding	   Gmpr	   2.518285846	   0.008839893	  
ENSMUSG00000027356	   protein_coding	   Fermt1	   0.517331106	   0.015331695	  
ENSMUSG00000027353	   protein_coding	   Mcm8	   0.521522649	   0.014366969	  
ENSMUSG00000048379	   protein_coding	   Socs4	   0.523594742	   0.018142494	  
ENSMUSG00000030423	   protein_coding	   Pop4	   0.651352208	   0.039780501	  
ENSMUSG00000023075	   protein_coding	   Akirin1	   0.661226571	   0.006755183	  
ENSMUSG00000026004	   protein_coding	   Kansl1l	   0.490056267	   0.021226223	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ENSMUSG00000089961	   antisense	   Gm16567	   0.513930448	   0.017783118	  
ENSMUSG00000006215	   protein_coding	   Zbtb17	   1.68275631	   0.040081993	  
ENSMUSG00000024098	   protein_coding	   Twsg1	   0.611453076	   0.020390133	  
ENSMUSG00000030246	   protein_coding	   Ldhb	   2.135588229	   0.009446349	  
ENSMUSG00000024542	   protein_coding	   Cep192	   0.552182542	   0.026569039	  
ENSMUSG00000030243	   protein_coding	   Recql	   0.579936848	   0.02149551	  
ENSMUSG00000001768	   protein_coding	   Rin2	   0.444510978	   0.030682235	  
ENSMUSG00000020898	   protein_coding	   Ctc1	   1.548102901	   0.048507538	  
ENSMUSG00000020893	   protein_coding	   Per1	   1.9274878	   0.008148585	  
ENSMUSG00000096953	   protein_coding	   Gm26571	   2.171228186	   0.048710204	  
ENSMUSG00000023277	   protein_coding	   Twf2	   1.685391626	   0.041363508	  
ENSMUSG00000092243	   protein_coding	   Gm7030	   2.396045374	   0.028464235	  
ENSMUSG00000087639	   antisense	   Gm15512	   2.700840819	   0.029523614	  
ENSMUSG00000040957	   protein_coding	   Cables1	   2.592957318	   0.021057192	  
ENSMUSG00000070565	   protein_coding	   Rasal2	   0.64170823	   0.008175748	  
ENSMUSG00000021109	   protein_coding	   Hif1a	   0.591358879	   0.02870421	  
ENSMUSG00000046442	   protein_coding	   Ppm1e	   0.453751938	   0.025135566	  
ENSMUSG00000042569	   protein_coding	   Dhrs7b	   1.829519151	   0.044580457	  
ENSMUSG00000095308	   protein_coding	   Gm5619	   1.502354646	   0.021137584	  
ENSMUSG00000049047	   protein_coding	   Armcx3	   0.624060341	   0.000835137	  
ENSMUSG00000041143	   protein_coding	   Tmco4	   1.503371087	   0.042836468	  
ENSMUSG00000055360	   protein_coding	   Prl2c5	   0.290821441	   0.024363475	  
ENSMUSG00000057858	   protein_coding	   D19Ertd737e	   0.506872438	   0.048041058	  
ENSMUSG00000095432	   protein_coding	   Zfp748	   0.453745744	   0.002129303	  
ENSMUSG00000036022	   protein_coding	   Fam122b	   0.58955641	   0.046263263	  
ENSMUSG00000061286	   protein_coding	   Exosc5	   2.461440306	   0.031727193	  
ENSMUSG00000043019	   protein_coding	   Edem3	   0.560807953	   0.041096367	  
ENSMUSG00000039531	   protein_coding	   Zufsp	   0.297028988	   0.005385881	  
ENSMUSG00000029186	   protein_coding	   Pi4k2b	   0.662751432	   0.0099982	  
ENSMUSG00000070960	   pseudogene	   Gm10307	   2.130056701	   0.028646626	  
ENSMUSG00000028583	   protein_coding	   Pdpn	   13.13064474	   0.017272484	  
ENSMUSG00000086846	   pseudogene	   Gm13642	   0.589901968	   0.011224696	  
ENSMUSG00000024939	   protein_coding	   Fam89b	   1.562046018	   0.024687747	  
ENSMUSG00000085738	   pseudogene	   Gm12335	   0.475786377	   0.024105868	  
ENSMUSG00000029840	   protein_coding	   Mtpn	   0.641339783	   0.019034084	  
ENSMUSG00000017057	   protein_coding	   Il13ra1	   0.559344483	   0.040017046	  
ENSMUSG00000000605	   protein_coding	   Clcn4-­‐2	   0.658807886	   0.011997355	  
ENSMUSG00000090124	   protein_coding	   Ugt1a7c	   0.379842643	   0.032100616	  
ENSMUSG00000055660	   protein_coding	   Mettl4	   0.429891616	   0.00317559	  
ENSMUSG00000036528	   protein_coding	   Ppfibp2	   0.653667151	   0.043512093	  
ENSMUSG00000038056	   protein_coding	   Kmt2c	   0.560546487	   0.024044108	  
ENSMUSG00000038055	   protein_coding	   Dexi	   1.676980358	   0.006161848	  
ENSMUSG00000042462	   protein_coding	   Dctpp1	   1.729226263	   0.034858594	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ENSMUSG00000042460	   protein_coding	   C1galt1	   0.534340477	   0.033146981	  
ENSMUSG00000035184	   protein_coding	   Fam124a	   0.312229892	   0.041305808	  
ENSMUSG00000035181	   protein_coding	   Heatr5a	   0.483465068	   0.024595294	  
ENSMUSG00000045767	   protein_coding	   B230219D22Rik	   0.58937083	   0.032528607	  
ENSMUSG00000007872	   protein_coding	   Id3	   1.924589251	   0.045400314	  
ENSMUSG00000000884	   protein_coding	   Gnb1l	   2.286614094	   0.022959758	  
ENSMUSG00000082789	   pseudogene	   Gm13284	   0.01636126	   3.64E-­‐05	  
ENSMUSG00000026321	   protein_coding	   Tnfrsf11a	   0.44643151	   0.034633406	  
ENSMUSG00000002107	   protein_coding	   Celf2	   0.539341384	   0.03688282	  
ENSMUSG00000033306	   protein_coding	   Lpp	   0.597660856	   0.013189944	  
ENSMUSG00000062931	   protein_coding	   Zfp938	   0.436758329	   0.049936273	  
ENSMUSG00000054302	   protein_coding	   Eapp	   0.553404521	   0.023795201	  
ENSMUSG00000086480	   antisense	   Gm15287	   0.201720792	   0.024157669	  
ENSMUSG00000096252	   pseudogene	   Tes3-­‐ps	   0.500057136	   0.02760951	  
ENSMUSG00000082280	   pseudogene	   Gm7901	   2.443944047	   0.034844239	  
ENSMUSG00000050373	   protein_coding	   Snx21	   2.004251126	   0.002101766	  
ENSMUSG00000091971	   protein_coding	   Hspa1a	   1.893906685	   0.005716001	  
ENSMUSG00000021553	   protein_coding	   Slc28a3	   0.359169352	   0.008202105	  
ENSMUSG00000060586	   protein_coding	   H2-­‐Eb1	   6.978752804	   0.017213769	  
ENSMUSG00000026123	   protein_coding	   Plekhb2	   1.793793953	   0.006138812	  
ENSMUSG00000026126	   protein_coding	   Ptpn18	   1.738582223	   0.002443326	  
ENSMUSG00000025746	   protein_coding	   Il6	   0.313681396	   0.044160689	  
ENSMUSG00000029346	   protein_coding	   Srrd	   1.57464499	   0.040440244	  
ENSMUSG00000087371	   antisense	   Gm15541	   1.783693271	   0.029258811	  
ENSMUSG00000087370	   protein_coding	   Tmem170b	   0.453982939	   0.019846471	  
ENSMUSG00000081434	   pseudogene	   Gm14165	   0.283676252	   0.023710597	  
ENSMUSG00000005150	   protein_coding	   Wdr83	   1.980759896	   0.001494418	  
ENSMUSG00000058586	   protein_coding	   Serhl	   1.752098058	   0.020945297	  
ENSMUSG00000082423	   pseudogene	   Gm15148	   0	   0.036729895	  
ENSMUSG00000022201	   protein_coding	   Zfr	   0.552534117	   0.022670725	  
ENSMUSG00000036792	   protein_coding	   Mbd5	   0.556609333	   0.046785334	  
ENSMUSG00000025862	   protein_coding	   Stag2	   0.558350372	   0.032142329	  
ENSMUSG00000025137	   protein_coding	   Pcyt2	   1.690949882	   0.000540522	  
ENSMUSG00000032000	   protein_coding	   Birc3	   0.457527479	   0.045185159	  
ENSMUSG00000032006	   protein_coding	   Pdgfd	   0.406929776	   0.043786902	  
ENSMUSG00000023994	   protein_coding	   Nfya	   0.665190787	   0.009541107	  
ENSMUSG00000053702	   protein_coding	   Nebl	   0.238611221	   0.040229187	  
ENSMUSG00000030513	   protein_coding	   Pcsk6	   1.822191685	   0.034647208	  
ENSMUSG00000072640	   protein_coding	   Lyrm9	   1.717409646	   0.033211343	  
ENSMUSG00000083111	   pseudogene	   Gm14421	   0.290502469	   0.047787634	  
ENSMUSG00000019433	   protein_coding	   Gipc1	   1.808713618	   0.007379183	  
ENSMUSG00000001334	   protein_coding	   Fndc5	   2.074308876	   0.02554256	  
ENSMUSG00000051169	   protein_coding	   Rpusd3	   1.849541563	   0.031255822	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ENSMUSG00000059668	   protein_coding	   Krt4	   1.746639562	   0.024552624	  
ENSMUSG00000070583	   protein_coding	   Fv1	   0.333308012	   0.011490331	  
ENSMUSG00000002257	   protein_coding	   Def6	   1.758233689	   0.002685983	  
ENSMUSG00000036613	   protein_coding	   Tssc1	   1.534166465	   0.036412453	  
ENSMUSG00000038508	   protein_coding	   Gdf15	   2.196644166	   0.016025478	  
ENSMUSG00000030753	   protein_coding	   Prkrir	   0.539865958	   0.000492156	  
ENSMUSG00000037253	   protein_coding	   Mex3c	   0.511949606	   0.013919599	  
ENSMUSG00000096795	   protein_coding	   Zfp433	   0.26894548	   0.041043873	  
ENSMUSG00000063320	   protein_coding	   1190007I07Rik	   0.443793363	   0.023247762	  
ENSMUSG00000039361	   protein_coding	   Picalm	   0.583368133	   0.009313534	  
ENSMUSG00000020676	   protein_coding	   Ccl11	   2.930877629	   0.035366477	  
ENSMUSG00000030055	   protein_coding	   Rab43	   1.625962683	   0.010666509	  
ENSMUSG00000042978	   protein_coding	   Sbk1	   1.716827934	   0.01617083	  
ENSMUSG00000004655	   protein_coding	   Aqp1	   3.525975716	   0.014111082	  
ENSMUSG00000082946	   pseudogene	   Gm12177	   0.262780633	   0.010908693	  
ENSMUSG00000079084	   protein_coding	   Ccdc82	   0.432441404	   0.026447207	  
ENSMUSG00000040128	   protein_coding	   Pnrc1	   0.623115429	   0.005769393	  
ENSMUSG00000040123	   protein_coding	   Zmym5	   0.513028674	   0.043967249	  
ENSMUSG00000043131	   protein_coding	   Mob1a	   0.610345109	   0.005041739	  
ENSMUSG00000042742	   protein_coding	   B630005N14Rik	   0.530202532	   0.04437797	  
ENSMUSG00000046441	   protein_coding	   Cmtr2	   0.63073934	   0.028304116	  
ENSMUSG00000005057	   protein_coding	   Sh2b2	   1.894385036	   0.00936593	  
ENSMUSG00000046603	   protein_coding	   Tcaim	   0.531465926	   0.021646222	  
ENSMUSG00000074876	  
processed_	  
transcript	   Spata5l1	   0.515552075	   0.036958289	  
ENSMUSG00000039449	   protein_coding	   Prpf18	   0.648983367	   0.012367334	  
ENSMUSG00000089804	   antisense	   Gm16136	   0.553445179	   0.04599459	  
ENSMUSG00000042694	   protein_coding	   Obfc1	   1.512072158	   0.012585792	  
ENSMUSG00000032717	   protein_coding	   Mdfi	   1.676223026	   0.004569167	  
ENSMUSG00000074890	   protein_coding	   Lcmt2	   1.553789491	   0.015536782	  
ENSMUSG00000087519	  
processed_	  
transcript	   AV039307	   0.255410914	   0.009609801	  
ENSMUSG00000091562	  
processed_	  
transcript	   Gm9581	   0.493021644	   0.030269022	  
ENSMUSG00000031383	   protein_coding	   Dusp9	   1.520733003	   0.033297111	  
ENSMUSG00000041440	   protein_coding	   Gk5	   0.600015447	   0.020230106	  
ENSMUSG00000060152	   protein_coding	   Pop5	   1.949752321	   0.022392121	  
ENSMUSG00000038902	   protein_coding	   Pogz	   0.635732267	   0.032979442	  
ENSMUSG00000019951	   protein_coding	   Uhrf1bp1l	   0.639202939	   0.009512865	  
ENSMUSG00000045165	   protein_coding	   AI467606	   0.131853449	   0.001240041	  
ENSMUSG00000032998	   protein_coding	   Foxj3	   0.532356926	   0.02789832	  
ENSMUSG00000034032	   protein_coding	   Rpap1	   1.776584413	   0.009243439	  
ENSMUSG00000026930	   protein_coding	   Gpsm1	   1.701154048	   0.019456288	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ENSMUSG00000025507	   protein_coding	   Lrdd	   1.752556322	   0.013331686	  
ENSMUSG00000006057	   protein_coding	   Atp5g1	   1.608009486	   0.017442356	  
ENSMUSG00000032527	   protein_coding	   Pccb	   1.636067822	   0.034246556	  
ENSMUSG00000024304	   protein_coding	   Cdh2	   0.662908043	   0.042328941	  
ENSMUSG00000024301	   protein_coding	   Kifc5b	   1.583823437	   0.031137258	  
ENSMUSG00000044033	   protein_coding	   Ccdc141	   0.381950703	   0.041291349	  
ENSMUSG00000059555	   protein_coding	   Tor4a	   1.587657746	   0.013594321	  
ENSMUSG00000050786	   protein_coding	   Ccdc126	   0.618042546	   0.028248167	  
ENSMUSG00000095869	   pseudogene	   Ppp1r2-­‐ps6	   0.39489571	   0.024838673	  
ENSMUSG00000094403	   miRNA	   Mir692-­‐2a	   109527.9132	   0.000464519	  
ENSMUSG00000083788	   pseudogene	   Gm11499	   0.15733781	   0.025981936	  
ENSMUSG00000002031	   protein_coding	   Ift46	   0.55016284	   0.047482003	  
ENSMUSG00000078441	   protein_coding	   Scamp4	   1.518633039	   0.04416554	  
ENSMUSG00000096718	   protein_coding	   Zfp781	   0.317360833	   0.046890746	  
ENSMUSG00000038502	   protein_coding	   Ptov1	   1.672227691	   0.001750895	  
ENSMUSG00000000308	   protein_coding	   Ckmt1	   2.745226296	   0.026547468	  
ENSMUSG00000029022	   protein_coding	   Miip	   1.546875224	   0.013039115	  
ENSMUSG00000028771	   protein_coding	   Ptpn12	   0.610988004	   0.034705957	  
ENSMUSG00000052331	   protein_coding	   Ankrd44	   0.610029847	   0.002895737	  
ENSMUSG00000037940	   protein_coding	   Inpp4b	   0.391552929	   0.034490497	  
ENSMUSG00000086784	   protein_coding	   Isoc2a	   2.007065916	   0.037309566	  
ENSMUSG00000074994	   protein_coding	   Qser1	   0.637385674	   0.043933501	  
ENSMUSG00000027324	   protein_coding	   Rpusd2	   1.823756365	   0.046071907	  
ENSMUSG00000027327	   protein_coding	   1700037H04Rik	   1.824716269	   0.029849264	  
ENSMUSG00000078897	   protein_coding	   Gm4724	   0.534646801	   0.042107855	  
ENSMUSG00000083011	   pseudogene	   Gm12816	   2.71254239	   0.011660565	  
ENSMUSG00000083013	   pseudogene	   Gm12978	   0.009700559	   0.000294424	  
ENSMUSG00000096472	   protein_coding	   Cdkn2d	   1.596452184	   0.042337316	  
ENSMUSG00000085334	  
processed_	  
transcript	   Gm12940	   0.455700683	   0.002203986	  
ENSMUSG00000029710	   protein_coding	   Ephb4	   1.588965514	   0.028420689	  
ENSMUSG00000021803	   protein_coding	   Cdhr1	   20.55814452	   0.000485121	  
ENSMUSG00000076431	   protein_coding	   Sox4	   0.598221944	   0.026205497	  
ENSMUSG00000096699	   pseudogene	   Rps19-­‐ps4	   2.254298912	   0.031668579	  
ENSMUSG00000011831	   protein_coding	   Evi5	   0.554630757	   0.045675853	  
ENSMUSG00000020738	   protein_coding	   Sumo2	   0.662681701	   0.047947539	  
ENSMUSG00000087598	   protein_coding	   Zfp111	   0.630123887	   0.020992185	  
ENSMUSG00000049511	   protein_coding	   Htr1b	   0.414574567	   0.034483944	  
ENSMUSG00000027288	   protein_coding	   Zfp106	   0.369184889	   0.001587085	  
ENSMUSG00000027287	   protein_coding	   Snap23	   0.490215215	   0.000693647	  
ENSMUSG00000024889	   protein_coding	   Rce1	   1.5823102	   0.021044105	  
ENSMUSG00000024885	   protein_coding	   Aldh3b1	   1.750035844	   0.004412469	  
ENSMUSG00000026484	   protein_coding	   Rnf2	   0.53853128	   0.02727312	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ENSMUSG00000003808	   protein_coding	   Farsa	   1.857734909	   0.01052692	  
ENSMUSG00000040795	   protein_coding	   Iqcc	   1.800693684	   0.036236699	  
ENSMUSG00000053253	   protein_coding	   Ndfip2	   0.585203624	   0.001242445	  
ENSMUSG00000001604	   protein_coding	   Tcea3	   0.471751461	   0.023098759	  
ENSMUSG00000080950	   pseudogene	   Gm7278	   33.43135683	   0.018978525	  
ENSMUSG00000031391	   protein_coding	   L1cam	   1.812041923	   0.001984365	  
ENSMUSG00000031399	   protein_coding	   Fam3a	   1.734755028	   0.006955007	  
ENSMUSG00000029409	   protein_coding	   U90926	   0.106372938	   0.003407241	  
ENSMUSG00000007908	   protein_coding	   Hmgcll1	   0.59436741	   0.007684991	  
ENSMUSG00000024383	   protein_coding	   Map3k2	   0.460815406	   0.023691552	  
ENSMUSG00000075268	   pseudogene	   Gm10819	   1.620609272	   0.012984021	  
ENSMUSG00000002343	   protein_coding	   Armc6	   2.422763981	   0.024044154	  
ENSMUSG00000040550	   protein_coding	   Otud6b	   0.56615291	   0.038516707	  
ENSMUSG00000006651	   protein_coding	   Aplp1	   2.228061928	   0.033327094	  
ENSMUSG00000097445	   lincRNA	   Gm26631	   0.632454188	   0.047969487	  
ENSMUSG00000041324	   protein_coding	   Inhba	   0.603390588	   0.030629725	  
ENSMUSG00000067608	   protein_coding	   Pcna-­‐ps2	   2.08944811	   0.038438293	  
ENSMUSG00000021711	   protein_coding	   Trappc13	   0.653478988	   0.013422922	  
ENSMUSG00000032890	   protein_coding	   Rims3	   2.301198339	   0.03831195	  
ENSMUSG00000039841	   protein_coding	   Zfp800	   0.465183372	   0.017904793	  
ENSMUSG00000037443	   protein_coding	   Cep85	   0.238009157	   0.03743226	  
ENSMUSG00000030498	   protein_coding	   Gas2	   0.620998162	   0.04721987	  
ENSMUSG00000030232	   protein_coding	   Aebp2	   0.475432843	   0.021424197	  
ENSMUSG00000006262	   protein_coding	   Mob1b	   0.501188099	   0.045866341	  
ENSMUSG00000079559	   protein_coding	   Gm684	   0.225310375	   0.042248346	  
ENSMUSG00000027598	   protein_coding	   Itch	   0.590096175	   0.018913868	  
ENSMUSG00000098117	   lincRNA	   Gm26958	   0.137529698	   0.004809897	  
ENSMUSG00000017677	   protein_coding	   Wsb1	   0.654717342	   0.020672017	  
ENSMUSG00000047084	   protein_coding	   Ngrn	   0.508208419	   0.020711815	  
ENSMUSG00000015749	   protein_coding	   Anp32e	   0.526343883	   0.021634835	  
ENSMUSG00000022177	   protein_coding	   Haus4	   1.680886329	   0.014964766	  
ENSMUSG00000038127	   protein_coding	   Ccdc50	   0.580551264	   0.012011417	  
ENSMUSG00000035992	   protein_coding	   Fnip1	   0.539716422	   0.027884681	  
ENSMUSG00000069892	   protein_coding	  
9930111J21Rik
2	   0.418653259	   0.034593337	  
ENSMUSG00000069893	   protein_coding	  
9930111J21Rik
1	   0.404536108	   0.01790283	  
ENSMUSG00000032171	   protein_coding	   Pin1	   1.556323422	   0.023731741	  
ENSMUSG00000097415	   lincRNA	   AU020206	   0.426762705	   0.022276609	  
ENSMUSG00000022952	   protein_coding	   Runx1	   0.654105054	   0.036141833	  
ENSMUSG00000032235	   protein_coding	   Narg2	   0.374348529	   0.020836912	  
ENSMUSG00000040242	   protein_coding	   Fgfr1op2	   0.516876429	   0.011760408	  
ENSMUSG00000056665	   protein_coding	   Them6	   2.601974128	   0.003352479	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ENSMUSG00000081467	   pseudogene	   Gm13337	   108.9311319	   0.000936578	  
ENSMUSG00000020948	   protein_coding	   Klhl28	   0.395981181	   0.00593541	  
ENSMUSG00000069237	   protein_coding	   C78339	   0.511028426	   0.010262974	  
ENSMUSG00000066357	   protein_coding	   Wdr6	   1.66814587	   0.009363024	  
ENSMUSG00000063802	   protein_coding	   Hspbp1	   1.541079843	   0.047867896	  
ENSMUSG00000066553	   pseudogene	   Gm6969	   22.03590255	   4.30E-­‐08	  
ENSMUSG00000066554	   pseudogene	   Gm10167	   0.036755795	   5.67E-­‐05	  
ENSMUSG00000031591	   protein_coding	   Asah1	   0.538553032	   0.026160244	  
ENSMUSG00000038085	   protein_coding	   Cnbd2	   0.29914734	   0.035024787	  
ENSMUSG00000032487	   protein_coding	   Ptgs2	   0.547692242	   0.017391348	  
ENSMUSG00000027510	   protein_coding	   Rbm38	   1.959572102	   0.008416916	  
ENSMUSG00000074925	   protein_coding	   Ptar1	   0.639562719	   0.017372349	  
ENSMUSG00000098975	   antisense	   RP23-­‐103I12.3	   2.119282395	   0.016501254	  
ENSMUSG00000040616	   protein_coding	   Tmem51	   1.528157623	   0.028573307	  
ENSMUSG00000026393	   protein_coding	   Nek7	   0.661721878	   0.039092085	  
ENSMUSG00000026390	   protein_coding	   Marco	   0.117536602	   0.021662937	  
ENSMUSG00000085622	   antisense	   3110056K07Rik	   0.493085729	   0.009302643	  
ENSMUSG00000098196	   lincRNA	   Gm26964	   0.372023061	   0.003305174	  
ENSMUSG00000083669	   pseudogene	   Gm10169	   1.560254117	   0.0272904	  
ENSMUSG00000053801	   protein_coding	   Grwd1	   1.691079196	   0.012022654	  
ENSMUSG00000052812	   protein_coding	   Atad2b	   0.431891749	   0.045323245	  
ENSMUSG00000020253	   protein_coding	   Ppm1m	   1.680237971	   0.033064219	  
ENSMUSG00000070003	   protein_coding	   Ssbp4	   1.955547828	   0.037309489	  
ENSMUSG00000020877	   protein_coding	   Scrn2	   1.91849139	   0.042952118	  
ENSMUSG00000072082	   protein_coding	   Ccnf	   1.504347771	   0.023149616	  
ENSMUSG00000030177	   protein_coding	   Ccdc77	   0.595234836	   0.000396543	  
ENSMUSG00000031807	   protein_coding	   Pgls	   1.752534117	   0.034019262	  
ENSMUSG00000031805	   protein_coding	   Jak3	   1.917352794	   0.009298532	  
ENSMUSG00000038766	   protein_coding	   Gabpb2	   0.540479199	   0.048131323	  
ENSMUSG00000035278	   protein_coding	   Plekhj1	   1.600777722	   0.005208514	  
ENSMUSG00000024143	   protein_coding	   Rhoq	   0.612825111	   0.023096127	  
ENSMUSG00000079610	   protein_coding	   Ankrd39	   1.533323427	   0.016272917	  
ENSMUSG00000040423	   protein_coding	   Rc3h1	   0.574901508	   0.03775095	  
ENSMUSG00000089715	   protein_coding	   Cbx6	   0.511597608	   0.012819981	  
ENSMUSG00000061273	   protein_coding	   Mmgt1	   0.609826782	   0.013271966	  
ENSMUSG00000045886	   protein_coding	   Gm9803	   1.695806544	   0.031993079	  
ENSMUSG00000037722	   protein_coding	   Gnpnat1	   0.625930671	   0.01258129	  
ENSMUSG00000037096	   pseudogene	   Gm9762	   0.588251254	   0.006193787	  
ENSMUSG00000038371	   protein_coding	   Sbf2	   0.615266113	   0.009175873	  
ENSMUSG00000052137	   protein_coding	   Rbm12b2	   0.464737026	   0.042586819	  
ENSMUSG00000038957	   protein_coding	   Edc3	   1.505809055	   0.022208005	  
ENSMUSG00000025188	   protein_coding	   Hps1	   1.607658352	   0.02033568	  
ENSMUSG00000019988	   protein_coding	   Nedd1	   0.610937162	   0.028784594	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ENSMUSG00000018585	   protein_coding	   Atox1	   1.823316011	   0.02465084	  
ENSMUSG00000053774	   protein_coding	   Ubxn7	   0.560518865	   0.049522672	  
ENSMUSG00000063767	   protein_coding	   S100a7a	   5.119740905	   0.001330727	  
ENSMUSG00000083166	   pseudogene	   Gm8648	   0.425548051	   0.006783951	  
ENSMUSG00000004837	   protein_coding	   Grap	   0.524439574	   0.027583597	  
ENSMUSG00000087262	   pseudogene	   Gm15250	   0.605288118	   0.021357232	  
ENSMUSG00000040323	   pseudogene	   Gm15429	   1.663397562	   0.04354089	  
ENSMUSG00000040322	   protein_coding	   Slc25a24	   0.627170843	   0.043418769	  
ENSMUSG00000040321	   protein_coding	   Zfp770	   0.452932199	   0.027316115	  
ENSMUSG00000024339	   protein_coding	   Tap2	   1.575016057	   0.037313843	  
ENSMUSG00000040584	   protein_coding	   Abcb1a	   0.590904171	   0.017349115	  
ENSMUSG00000038552	   protein_coding	   Fndc4	   2.263538954	   0.031518836	  
ENSMUSG00000037119	   protein_coding	   D15Ertd621e	   0.59949196	   0.026598809	  
ENSMUSG00000001588	   protein_coding	   Acap1	   7.069779859	   0.048810922	  
ENSMUSG00000021265	   protein_coding	   Slc25a29	   2.370957536	   0.020109407	  
ENSMUSG00000093030	   miRNA	   Gm23632	   10.80647877	   0.049123738	  
ENSMUSG00000025026	   protein_coding	   Add3	   0.588786574	   0.036725093	  
ENSMUSG00000072955	   protein_coding	   Tmsb15l	   0.325408509	   0.049244181	  
ENSMUSG00000037938	   protein_coding	   Chchd5	   1.782279255	   0.012102135	  
ENSMUSG00000024640	   protein_coding	   Psat1	   0.608874666	   0.047826645	  
ENSMUSG00000040875	   protein_coding	   Osbpl10	   2.193422593	   0.003398753	  
ENSMUSG00000034216	   protein_coding	   Vps18	   1.624386988	   0.023662545	  
ENSMUSG00000074634	   protein_coding	   Gm7120	   0.424434318	   0.015994748	  
ENSMUSG00000091639	   pseudogene	   Gm3756	   0.183582383	   0.007533816	  
ENSMUSG00000068699	   protein_coding	   Flnc	   1.50948869	   0.046673342	  
ENSMUSG00000082935	   pseudogene	   Gm7658	   6.234993608	   0.001369039	  
ENSMUSG00000086949	   antisense	   Gm13066	   2.522429924	   0.00122581	  
ENSMUSG00000082062	   pseudogene	   Ftl2	   1.644226275	   0.042843197	  
ENSMUSG00000098702	   antisense	   RP24-­‐390G17.1	   23.85238469	   0.004737752	  
ENSMUSG00000066613	   protein_coding	   Zfp932	   0.405424249	   0.027145483	  
ENSMUSG00000021831	   protein_coding	   Ero1l	   0.617332382	   0.014960295	  
ENSMUSG00000013833	   protein_coding	   Med16	   1.614656031	   0.028558976	  
ENSMUSG00000033488	   protein_coding	   BC026585	   2.49799187	   0.012666533	  
ENSMUSG00000033487	   protein_coding	   Fndc3a	   0.585537189	   0.01172785	  
ENSMUSG00000072772	   protein_coding	   Grcc10	   1.573030816	   0.012158994	  
ENSMUSG00000048701	   protein_coding	   Ccdc6	   0.546019833	   0.026724007	  
ENSMUSG00000039199	   protein_coding	   Zdhhc1	   2.421318988	   0.013509191	  
ENSMUSG00000036944	   protein_coding	   Tmem71	   0.59265673	   0.015006955	  
ENSMUSG00000028228	   protein_coding	   Cpne3	   0.600196955	   0.024431197	  
ENSMUSG00000018217	   protein_coding	   Pmp22	   0.589151678	   0.029710916	  
ENSMUSG00000024856	   protein_coding	   Cdk2ap2	   1.658862001	   0.002603952	  
ENSMUSG00000024851	   protein_coding	   Pitpnm1	   2.012406677	   0.007147619	  
ENSMUSG00000004788	   protein_coding	   Eif2b2	   1.515346291	   0.012918407	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ENSMUSG00000025666	   protein_coding	   Tmem47	   0.55787648	   0.039587415	  
ENSMUSG00000006143	   protein_coding	   Upk3bl	   2.494742976	   0.008367456	  
ENSMUSG00000078867	   protein_coding	   Gm14418	   0.402544626	   0.00595818	  
ENSMUSG00000015468	   protein_coding	   Notch4	   1.687545852	   0.016021203	  
ENSMUSG00000078864	   protein_coding	   Gm14322	   0.367771292	   0.003648135	  
ENSMUSG00000040297	   protein_coding	   Suco	   0.559978829	   0.027013401	  
ENSMUSG00000047213	   protein_coding	   Ythdf3	   0.575314846	   0.025975526	  
ENSMUSG00000066798	   protein_coding	   Zbtb6	   0.569705156	   0.04631645	  
ENSMUSG00000036036	   protein_coding	   Zfp57	   2.381994172	   0.018827867	  
ENSMUSG00000026219	   protein_coding	   Trip12	   0.635494101	   0.023795254	  
ENSMUSG00000026211	   protein_coding	   Obsl1	   2.296905536	   0.024789131	  
ENSMUSG00000038646	   protein_coding	   Fam103a1	   0.652743194	   0.014952152	  
ENSMUSG00000031697	   protein_coding	   Orc6	   0.540789445	   0.024799821	  
ENSMUSG00000026960	   protein_coding	   Arl6ip6	   0.605161316	   0.032548889	  
ENSMUSG00000025730	   protein_coding	   Rab40c	   1.890872833	   0.028928967	  
ENSMUSG00000025732	   protein_coding	   Fam195a	   1.766001647	   0.049410968	  
ENSMUSG00000044080	   protein_coding	   S100a1	   2.134233789	   0.001357455	  
ENSMUSG00000024958	   protein_coding	   Gpr137	   1.784598827	   0.047717793	  
ENSMUSG00000082536	   pseudogene	   Gm13456	   0.370070275	   0.005394736	  
ENSMUSG00000002043	   protein_coding	   Trappc6a	   1.766360565	   0.034774206	  
ENSMUSG00000081378	   pseudogene	   Rps13-­‐ps4	   0.552519022	   0.005630097	  
ENSMUSG00000079297	   pseudogene	   Gm2223	   0.623940712	   0.00644037	  
ENSMUSG00000028636	   protein_coding	   Ppcs	   1.768855398	   0.020643799	  
ENSMUSG00000041378	   protein_coding	   Cldn5	   5.63718825	   0.017110426	  
ENSMUSG00000057604	   protein_coding	   Lmcd1	   1.999902111	   0.045230014	  
ENSMUSG00000052384	   protein_coding	   Nrros	   2.689206368	   0.002201829	  
ENSMUSG00000023845	   protein_coding	   Lnpep	   0.523767045	   0.011379734	  
ENSMUSG00000035868	   protein_coding	  
3110052M02Ri
k	   0.34796894	   0.001045491	  
ENSMUSG00000018604	   protein_coding	   Tbx3	   0.476587344	   0.006233764	  
ENSMUSG00000020092	   protein_coding	   Pald1	   1.653826194	   0.030796993	  
ENSMUSG00000037410	   protein_coding	   Tbc1d2b	   1.728630407	   0.036307938	  
ENSMUSG00000027957	   protein_coding	   Slc35a3	   0.602810798	   0.010931225	  
ENSMUSG00000079509	   protein_coding	   Zfx	   0.551187866	   0.04042717	  
ENSMUSG00000041570	   protein_coding	   Camsap2	   0.61025551	   0.020904107	  
ENSMUSG00000024563	   protein_coding	   Smad2	   0.658189451	   0.042512907	  
ENSMUSG00000081232	   pseudogene	   Gm14373	   0.422986647	   0.028811071	  
ENSMUSG00000064023	   protein_coding	   Klk8	   2.600634541	   0.019594924	  
ENSMUSG00000083563	   pseudogene	   Gm13340	   0.52373412	   0.023071733	  
ENSMUSG00000019428	   protein_coding	   Fkbp8	   1.531400074	   0.044859606	  
ENSMUSG00000067058	   pseudogene	   Rps15a-­‐ps5	   0.190141732	   0.001181036	  
ENSMUSG00000038175	   protein_coding	   Mylip	   0.572448018	   0.037060523	  
ENSMUSG00000026721	   protein_coding	   Rabgap1l	   0.577741323	   0.047799704	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ENSMUSG00000026180	   protein_coding	   Cxcr2	   2.144033679	   0.019928542	  
ENSMUSG00000026185	   protein_coding	   Igfbp5	   2.454006564	   0.002363209	  
ENSMUSG00000074064	   protein_coding	   Mlycd	   2.460151505	   0.02649814	  
ENSMUSG00000074063	   protein_coding	   Osgin1	   1.553494557	   0.009026394	  
ENSMUSG00000034480	   protein_coding	   Diap2	   0.616986862	   0.030485718	  
ENSMUSG00000083360	   pseudogene	   Gm13105	   0.402290263	   0.042383536	  
ENSMUSG00000042508	   protein_coding	   Dmtf1	   0.502177721	   0.005967863	  
ENSMUSG00000002416	   protein_coding	   Ndufb2	   1.922825125	   0.010510371	  
ENSMUSG00000035754	   protein_coding	   Wdr18	   1.621405435	   0.039648685	  
ENSMUSG00000050192	   protein_coding	   Eif5a2	   0.454175382	   0.003814343	  
ENSMUSG00000024241	   protein_coding	   Sos1	   0.555009532	   0.046975207	  
ENSMUSG00000050440	   protein_coding	   Hamp	   26.60458793	   0.043977087	  
ENSMUSG00000051319	   lincRNA	   1500011K16Rik	   1.616757594	   0.002581542	  
ENSMUSG00000029221	   protein_coding	   Slc30a9	   0.639326001	   0.036389041	  
ENSMUSG00000020937	   protein_coding	   Plcd3	   1.967587976	   0.021348457	  
ENSMUSG00000031070	   protein_coding	   Mrgprf	   4.872164936	   0.019769659	  
ENSMUSG00000022420	   protein_coding	   Dnal4	   1.904669973	   0.001312389	  
ENSMUSG00000036860	   protein_coding	   Mrpl55	   0.626023915	   0.028775025	  
ENSMUSG00000036863	   protein_coding	   Syde2	   0.413550231	   0.010684988	  
ENSMUSG00000020153	   protein_coding	   Ndufs7	   1.588462456	   0.036136851	  
ENSMUSG00000048807	   protein_coding	   Slc35e4	   1.685561722	   0.017723695	  
ENSMUSG00000080873	   pseudogene	   Rpl30-­‐ps3	   0.459039951	   0.004827473	  
ENSMUSG00000029823	   protein_coding	   Luc7l2	   0.64343085	   0.02516138	  
ENSMUSG00000084403	   pseudogene	   Rps15a-­‐ps8	   0.003613855	   0.004147457	  
ENSMUSG00000074746	   protein_coding	   Pdzd8	   0.640342491	   0.045109135	  
ENSMUSG00000046096	   protein_coding	   BC030336	   0.615612078	   0.011179904	  
ENSMUSG00000036199	   protein_coding	   Ndufa13	   1.516045544	   0.016234552	  
ENSMUSG00000041046	   protein_coding	   Ramp3	   3.445091761	   0.003472542	  
ENSMUSG00000040026	   protein_coding	   Saa3	   0.230487981	   0.047762837	  
ENSMUSG00000025533	   protein_coding	   Asl	   1.718695911	   0.030634088	  
ENSMUSG00000020019	   protein_coding	   Ntn4	   0.184878858	   0.007025107	  
ENSMUSG00000071064	   protein_coding	   Zfp827	   0.613105925	   0.043898869	  
ENSMUSG00000001918	   protein_coding	   Slc1a5	   0.169131584	   0.014626492	  
ENSMUSG00000038072	   protein_coding	   Galnt11	   2.491781136	   0.015242846	  
ENSMUSG00000032846	   protein_coding	   Zswim6	   0.66203639	   0.024670393	  
ENSMUSG00000031791	   protein_coding	   Tmem38a	   1.772410682	   0.027482662	  
ENSMUSG00000024072	   protein_coding	   Yipf4	   0.525857538	   0.04732503	  
ENSMUSG00000058793	   protein_coding	   Cds2	   1.814505757	   0.034839924	  
ENSMUSG00000058799	   protein_coding	   Nap1l1	   0.621832182	   0.037361578	  
ENSMUSG00000080932	   pseudogene	   Gm10224	   1.514284559	   0.026637011	  
ENSMUSG00000025348	   protein_coding	   Itga7	   1.781308593	   0.025162249	  
ENSMUSG00000026343	   protein_coding	   Gpr39	   2.139499836	   0.014457375	  
ENSMUSG00000017607	   protein_coding	   Tns4	   3.763402828	   0.040886593	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ENSMUSG00000097517	   lincRNA	   Gm26695	   3.784526803	   0.047957228	  
ENSMUSG00000050359	   protein_coding	   Sprr1a	   11.70003154	   0.000353093	  
ENSMUSG00000066362	   pseudogene	   Rps13-­‐ps1	   0.225167759	   0.000954158	  
ENSMUSG00000033454	   protein_coding	   Zbtb1	   0.462217615	   0.038113713	  
ENSMUSG00000026103	   protein_coding	   Gls	   0.554418044	   0.021274978	  
ENSMUSG00000026107	   protein_coding	   Nabp1	   0.57618357	   0.008506457	  
ENSMUSG00000034158	   protein_coding	   Lrrc58	   0.611278583	   0.001597601	  
ENSMUSG00000046352	   protein_coding	   Gjb2	   0.557117126	   0.026310494	  
ENSMUSG00000035206	   protein_coding	   Sppl2b	   1.82516413	   0.005808559	  
ENSMUSG00000028414	   protein_coding	   Fktn	   0.66258497	   0.048621703	  
ENSMUSG00000044864	   protein_coding	   Ankrd50	   0.594761972	   0.004743906	  
ENSMUSG00000032263	   protein_coding	   Bckdhb	   2.601726488	   0.018362498	  
ENSMUSG00000047749	   protein_coding	   Zc3hav1l	   0.555848866	   0.030060568	  
ENSMUSG00000027778	   protein_coding	   Ift80	   0.567034714	   0.02454636	  
ENSMUSG00000009575	   protein_coding	   Cbx5	   0.415540109	   0.018128189	  
ENSMUSG00000083449	   pseudogene	   Gm13487	   0.330127246	   0.019524932	  
ENSMUSG00000017418	   protein_coding	   Arl5b	   0.536484548	   0.035421966	  
ENSMUSG00000001627	   protein_coding	   Ifrd1	   0.545357533	   0.040568343	  
ENSMUSG00000001622	   protein_coding	   Csn3	   2.197619552	   0.032630839	  
ENSMUSG00000040936	   protein_coding	   Ulk4	   0.660925211	   0.015073817	  
ENSMUSG00000038347	   protein_coding	   Tcte2	   0.397652076	   0.019450131	  
ENSMUSG00000025153	   protein_coding	   Fasn	   1.562243346	   0.020443691	  
ENSMUSG00000028382	   protein_coding	   Ptbp3	   0.548878756	   0.021117074	  
ENSMUSG00000028381	   protein_coding	   Ugcg	   0.660169253	   0.025436994	  
ENSMUSG00000032060	   protein_coding	   Cryab	   1.921432695	   0.043961191	  
ENSMUSG00000032932	   protein_coding	   Hspa13	   0.632934389	   0.016700038	  
ENSMUSG00000027170	   protein_coding	   Eif3m	   0.540826118	   0.004082667	  
ENSMUSG00000020380	   protein_coding	   Rad50	   0.589717492	   0.026822773	  
ENSMUSG00000027177	   protein_coding	   Hipk3	   0.560928037	   0.030676817	  
ENSMUSG00000075470	   protein_coding	   Alg10b	   0.521367265	   0.011369406	  
ENSMUSG00000045095	   protein_coding	   Magi1	   0.452073444	   0.018833045	  
ENSMUSG00000024360	   protein_coding	   Etf1	   0.639378183	   0.03210856	  
ENSMUSG00000032293	   protein_coding	   Ireb2	   0.585830587	   0.04123814	  
ENSMUSG00000041954	   protein_coding	   Tnfrsf18	   2.578586599	   0.045586529	  
ENSMUSG00000050105	   protein_coding	   Grrp1	   2.843356343	   0.026716115	  
ENSMUSG00000053522	   protein_coding	   Lgals7	   0.1788679	   0.00748083	  
ENSMUSG00000036639	   protein_coding	   Nudt1	   1.560365836	   0.028119741	  
ENSMUSG00000014158	   protein_coding	   Trpv4	   1.525617579	   0.000886373	  
ENSMUSG00000059900	   protein_coding	   Tmem40	   1.895600558	   0.01560518	  
ENSMUSG00000001018	   protein_coding	   Snapin	   0.567553108	   0.000938649	  
ENSMUSG00000048142	   protein_coding	   Nat8l	   2.097245572	   0.013384303	  
ENSMUSG00000048149	   pseudogene	   Gm12663	   2.855430274	   0.007648168	  
ENSMUSG00000035757	   protein_coding	   Selo	   1.532606527	   0.034972686	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ENSMUSG00000070372	   protein_coding	   Capza1	   0.452063813	   0.001636534	  
ENSMUSG00000037242	   protein_coding	   Clic4	   0.599951543	   0.01138256	  
ENSMUSG00000033166	   protein_coding	   Dis3	   0.65146902	   0.033516246	  
ENSMUSG00000058873	   pseudogene	   Gm5582	   0.509768654	   0.029282419	  
ENSMUSG00000063317	   protein_coding	   Usp31	   0.606305694	   0.006597809	  
ENSMUSG00000031168	   protein_coding	   Ebp	   1.750396619	   0.047211739	  
ENSMUSG00000040102	   protein_coding	   Klhl42	   0.614804533	   0.01967469	  
ENSMUSG00000032320	   protein_coding	   Rcn2	   0.640028745	   0.004439556	  
ENSMUSG00000053935	   protein_coding	   Atf7ip	   0.618701275	   0.006545699	  
ENSMUSG00000099083	   protein_coding	   ATF7	   0.664798443	   0.008642771	  
ENSMUSG00000033364	   protein_coding	   Usp37	   0.650130912	   0.032235673	  
ENSMUSG00000021867	   protein_coding	   Tmem254b	   2.463116548	   0.000932675	  
ENSMUSG00000021866	   protein_coding	   Anxa11	   1.516008351	   0.047368472	  
ENSMUSG00000038481	   protein_coding	   Cdk19	   0.628348274	   0.016575832	  
ENSMUSG00000038736	   protein_coding	   Nudcd1	   0.648551273	   0.038495341	  
ENSMUSG00000049421	   protein_coding	   Zfp260	   0.657289933	   0.018258304	  
ENSMUSG00000034731	   protein_coding	   Dgkh	   0.613011228	   0.005195604	  
ENSMUSG00000029545	   protein_coding	   Acads	   1.649076516	   0.042923008	  
ENSMUSG00000044573	   protein_coding	   Acp1	   0.492291915	   0.041665596	  
ENSMUSG00000024790	   protein_coding	   Sac3d1	   1.590120912	   0.03955599	  
ENSMUSG00000026798	   protein_coding	   Coq4	   2.113637724	   0.005665277	  
ENSMUSG00000040472	   protein_coding	   Rabggta	   1.558977863	   0.041070517	  
ENSMUSG00000026420	   protein_coding	   Il24	   2.023176924	   0.049953766	  
ENSMUSG00000047126	   protein_coding	   Cltc	   0.657652115	   0.009448229	  
ENSMUSG00000040280	   protein_coding	   Ndufa4l2	   10.86606157	   0.02239018	  
ENSMUSG00000040738	   protein_coding	   Ints8	   0.603875594	   0.024750937	  
ENSMUSG00000023973	   protein_coding	   Cnpy3	   1.686785508	   0.042880822	  
ENSMUSG00000019978	   protein_coding	   Epb4.1l2	   0.625429917	   0.031484301	  
ENSMUSG00000020300	   protein_coding	   Cpeb4	   0.541888288	   0.018902855	  
ENSMUSG00000060279	   protein_coding	   Ap2a1	   1.539820889	   0.038730129	  
ENSMUSG00000073422	   protein_coding	   H2-­‐Ke6	   1.57626821	   0.017783389	  
ENSMUSG00000035365	   protein_coding	   Parpbp	   0.605043475	   0.021836914	  
ENSMUSG00000042046	   protein_coding	   Dstyk	   0.599981717	   0.03251959	  
ENSMUSG00000004885	   protein_coding	   Crabp2	   3.103088998	   0.009723583	  
ENSMUSG00000034947	   protein_coding	   Tmem106a	   1.525295312	   0.007040652	  
ENSMUSG00000086563	   lincRNA	   Gm14136	   Inf	   0.00941344	  
ENSMUSG00000042446	   protein_coding	   Zmym4	   0.608787514	   0.009631223	  
ENSMUSG00000046027	   protein_coding	   Stard5	   1.567273225	   0.001971542	  
ENSMUSG00000064264	   protein_coding	   Zfp428	   1.640952873	   0.00880763	  
ENSMUSG00000079733	   protein_coding	   Tmem181b-­‐ps	   1.749382791	   0.004745081	  
ENSMUSG00000032554	   protein_coding	   Trf	   2.010036909	   0.040613458	  
ENSMUSG00000041346	   protein_coding	   Wrap53	   1.657074404	   0.011802092	  
ENSMUSG00000029134	   protein_coding	   Plb1	   0.375739168	   0.048017021	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ENSMUSG00000062078	   protein_coding	   Qk	   0.561327129	   0.027727813	  
ENSMUSG00000062075	   protein_coding	   Lmnb2	   1.566428562	   0.027466604	  
ENSMUSG00000037965	   protein_coding	   Zc3h7a	   0.610066654	   0.022517579	  
ENSMUSG00000092843	   miRNA	   Gm24332	   6.755100677	   0.02763102	  
ENSMUSG00000038880	   protein_coding	   Mrps34	   1.578400573	   0.000122236	  
ENSMUSG00000038886	   protein_coding	   Man2a2	   1.708450786	   0.002079582	  
ENSMUSG00000039130	   protein_coding	   Zc3hc1	   1.790104735	   0.035528689	  
ENSMUSG00000021775	   protein_coding	   Nr1d2	   0.643862139	   0.0276718	  
ENSMUSG00000027341	   protein_coding	   Tmem230	   1.60661557	   0.014369784	  
ENSMUSG00000027962	   protein_coding	   Vcam1	   0.575857695	   0.047009155	  
ENSMUSG00000027966	   protein_coding	   Col11a1	   0.511616696	   0.000688923	  
ENSMUSG00000006782	   protein_coding	   Cnp	   1.697691941	   0.043312977	  
ENSMUSG00000024084	   protein_coding	   Qpct	   0.586769104	   0.002071726	  
ENSMUSG00000024085	   protein_coding	   Man2a1	   0.608487579	   0.041604083	  
ENSMUSG00000040187	   protein_coding	   Arntl2	   0.453052285	   0.001199534	  
ENSMUSG00000091903	   protein_coding	   Gm6460	   0.309340117	   0.00636746	  
ENSMUSG00000071713	   protein_coding	   Csf2rb	   1.55805555	   0.014071302	  
ENSMUSG00000002222	   protein_coding	   Rmnd5a	   0.544440738	   0.014277838	  
ENSMUSG00000042632	   protein_coding	   Pla2g6	   1.649447975	   0.036332138	  
ENSMUSG00000032116	   protein_coding	   Stt3a	   0.631305306	   0.01763453	  
ENSMUSG00000006423	   protein_coding	   C330007P06Rik	   0.633623218	   0.043530701	  
ENSMUSG00000003824	   protein_coding	   Syce2	   0.574644788	   0.007276386	  
ENSMUSG00000062758	   protein_coding	   Gm16477	   1.51138572	   0.022934373	  
ENSMUSG00000036707	   protein_coding	   Cab39	   0.621938474	   0.045774122	  
ENSMUSG00000034674	   protein_coding	   Tdg	   0.565344405	   0.019480229	  
ENSMUSG00000012640	   protein_coding	   Zfp715	   0.569664662	   0.016588167	  
ENSMUSG00000020102	   protein_coding	   Slc16a7	   0.627445217	   0.043770776	  
ENSMUSG00000044328	   protein_coding	   Trp53i13	   2.019302933	   0.027203362	  
ENSMUSG00000096035	   protein_coding	   Gm1045	   20.30932724	   0.018323196	  
ENSMUSG00000001542	   protein_coding	   Ell2	   0.579223248	   0.049483972	  
ENSMUSG00000097340	   lincRNA	   Gm26617	   0.522090502	   0.047778542	  
ENSMUSG00000093378	  
processed_	  
transcript	   Gm20663	   0.234892267	   0.049241013	  
ENSMUSG00000052688	   protein_coding	   5430435G22Rik	   0.4267864	   0.001541776	  
ENSMUSG00000052681	   protein_coding	   Rap1b	   0.602991461	   0.044148063	  
ENSMUSG00000020023	   protein_coding	   Tmcc3	   0.665988518	   0.04162493	  
ENSMUSG00000096474	   pseudogene	   Gm5561	   9.959146487	   0.033524	  
ENSMUSG00000026070	   protein_coding	   Il18r1	   0.49534495	   0.01884274	  
ENSMUSG00000069633	   protein_coding	   Pex11g	   1.603759511	   0.00708513	  
ENSMUSG00000038024	   protein_coding	   Dennd4c	   0.571513454	   0.032383302	  
ENSMUSG00000046229	   protein_coding	   Scand1	   1.70857322	   0.047963871	  
ENSMUSG00000043618	   pseudogene	   Eif5al3-­‐ps	   8.610470981	   0.001302018	  
ENSMUSG00000071856	   protein_coding	   Mcc	   0.594416317	   0.041096591	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ENSMUSG00000027068	   protein_coding	   Dhrs9	   3.076354279	   0.013643543	  
ENSMUSG00000093954	   protein_coding	   Gm21464	   2.131742596	   0.02032976	  
ENSMUSG00000081262	   pseudogene	   Gm12261	   0.393437798	   0.049719669	  
ENSMUSG00000029638	   protein_coding	   Glcci1	   0.560604526	   0.036339921	  
ENSMUSG00000037622	   protein_coding	   Wdtc1	   1.740732654	   0.036625759	  
ENSMUSG00000022159	   protein_coding	   Rab2b	   0.327779534	   0.002255357	  
ENSMUSG00000097616	   lincRNA	   1110019D14Rik	   0.272607682	   0.002515544	  
ENSMUSG00000036990	   protein_coding	   Otud4	   0.567061898	   0.035075035	  
ENSMUSG00000057751	   protein_coding	   Megf6	   2.5606622	   0.047094981	  
ENSMUSG00000020794	   protein_coding	   Ube2g1	   0.617855984	   0.035715476	  
ENSMUSG00000095918	   protein_coding	   Gm5861	   0.232086096	   0.000665245	  
ENSMUSG00000022948	   protein_coding	   Setd4	   2.827430583	   0.004062675	  
ENSMUSG00000021549	   protein_coding	   Rasa1	   0.494831183	   0.024269809	  
ENSMUSG00000068744	   protein_coding	   Psrc1	   2.109906934	   0.009881815	  
ENSMUSG00000042447	   protein_coding	   Mios	   0.552123085	   0.025027283	  
ENSMUSG00000071649	   protein_coding	   B3gat3	   1.636908049	   0.011683071	  
ENSMUSG00000046380	   protein_coding	   Jrk	   3.035724282	   0.008282536	  
ENSMUSG00000029376	   protein_coding	   Mthfd2l	   0.607562666	   0.021100699	  
ENSMUSG00000035781	   protein_coding	   R3hdm4	   1.553029116	   0.017532594	  
ENSMUSG00000000085	   protein_coding	   Scmh1	   1.696400118	   0.03408686	  
ENSMUSG00000027428	   protein_coding	   Rbbp9	   0.52514201	   0.017917635	  
ENSMUSG00000027420	   protein_coding	   Bfsp1	   2.444156418	   0.03507797	  
ENSMUSG00000079671	   protein_coding	   2610203C22Rik	   3.269099494	   0.02911373	  
ENSMUSG00000032252	   protein_coding	   Glce	   0.61572884	   0.028562998	  
ENSMUSG00000016487	   protein_coding	   Ppfibp1	   0.521654985	   0.002216466	  
ENSMUSG00000074811	   protein_coding	   Hps6	   1.975722459	   0.011954522	  
ENSMUSG00000048772	   protein_coding	   Tmem53	   1.703490957	   0.047724561	  
ENSMUSG00000020962	   protein_coding	   Gtf2a1	   0.574634846	   0.012474706	  
ENSMUSG00000031333	   protein_coding	   Abcb7	   0.553401492	   0.029505749	  
ENSMUSG00000029176	   protein_coding	   Anapc4	   0.599563299	   0.027980969	  
ENSMUSG00000020189	   protein_coding	   Osbpl8	   0.467358373	   0.029875836	  
ENSMUSG00000049811	   protein_coding	   Fam161a	   1.978484138	   0.02363679	  
ENSMUSG00000003500	   protein_coding	   Impdh1	   1.5176624	   0.030805085	  
ENSMUSG00000008167	   protein_coding	   Fbxw9	   2.750124757	   0.007462882	  
ENSMUSG00000058126	   protein_coding	   Tpm3-­‐rs7	   3.912056151	   0.005518293	  
ENSMUSG00000050730	   protein_coding	   Arhgap42	   0.55327596	   0.035280538	  
ENSMUSG00000041966	   protein_coding	   Dcaf17	   0.541437944	   0.002592881	  
ENSMUSG00000056380	   protein_coding	   Gpr50	   0.524514787	   0.004071757	  
ENSMUSG00000020015	   protein_coding	   Cdk17	   0.580506301	   0.018682438	  
ENSMUSG00000033216	   protein_coding	   Eefsec	   1.584093906	   0.015013896	  
ENSMUSG00000033213	   protein_coding	   AA467197	   0.032359702	   0.000840947	  
ENSMUSG00000021282	   protein_coding	   Eif5	   0.611251402	   0.044089134	  
ENSMUSG00000022533	   protein_coding	   Atp13a3	   0.4413868	   0.025007185	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ENSMUSG00000029703	   protein_coding	   Lrwd1	   1.671008693	   0.008080527	  
ENSMUSG00000033792	   protein_coding	   Atp7a	   0.358580393	   0.040082221	  
ENSMUSG00000026623	   protein_coding	   Lpgat1	   0.586494996	   0.008659463	  
ENSMUSG00000008822	   protein_coding	   Acyp1	   0.431262133	   0.008463602	  
ENSMUSG00000059842	   protein_coding	   Zfp341	   1.862726159	   0.041963553	  
ENSMUSG00000000489	   protein_coding	   Pdgfb	   0.407684733	   0.034093697	  
ENSMUSG00000025429	   protein_coding	   Pstpip2	   0.48730891	   0.006567473	  
ENSMUSG00000020594	   protein_coding	   Pum2	   0.624706591	   0.000917313	  
ENSMUSG00000019843	   protein_coding	   Fyn	   0.64374936	   0.019141257	  
ENSMUSG00000021893	   protein_coding	   Capn7	   0.472603393	   0.039442637	  
ENSMUSG00000020859	   protein_coding	   Spag9	   0.617471641	   0.016707864	  
ENSMUSG00000097062	   lincRNA	   Gm17586	   1.818298325	   0.036976209	  
ENSMUSG00000037235	   protein_coding	   Mxd4	   1.982317457	   0.008191117	  
ENSMUSG00000042688	   protein_coding	   Mapk6	   0.602251908	   0.033523648	  
ENSMUSG00000025986	   protein_coding	   Slc39a10	   0.544516876	   0.010260615	  
ENSMUSG00000021070	   protein_coding	   Bdkrb2	   0.588549209	   0.045336497	  
ENSMUSG00000042357	   protein_coding	   Gjb5	   1.912324908	   0.035470397	  
ENSMUSG00000024298	   protein_coding	   Zfp871	   0.433221401	   0.017477192	  
ENSMUSG00000040447	   protein_coding	   Spns2	   1.717687082	   0.033774103	  
ENSMUSG00000023066	   protein_coding	   Rttn	   0.630762816	   0.032798906	  
ENSMUSG00000092626	  
processed_	  
transcript	   9130230N09Rik	   0.102819546	   0.028051926	  
ENSMUSG00000097667	   lincRNA	   Gm26764	   1.931931948	   0.032436814	  
ENSMUSG00000041459	   protein_coding	   Tardbp	   0.644454845	   0.007502981	  
ENSMUSG00000022749	   protein_coding	   Tbc1d23	   0.629498849	   0.031690386	  
ENSMUSG00000022748	   protein_coding	   Cmss1	   1.635826652	   0.021428721	  
ENSMUSG00000039046	   protein_coding	   Usp6nl	   0.595720931	   0.022966067	  
ENSMUSG00000023909	   protein_coding	   Paqr4	   1.808379059	   0.036167379	  
ENSMUSG00000068394	   protein_coding	   Cep152	   0.595367511	   0.04674816	  
ENSMUSG00000027104	   protein_coding	   Atf2	   0.534011746	   0.02961546	  
ENSMUSG00000054226	   protein_coding	   Tprkb	   0.641924242	   0.005042828	  
ENSMUSG00000031982	   protein_coding	   Arv1	   1.739995734	   0.00702993	  
ENSMUSG00000071451	   protein_coding	   Psmg4	   1.521449329	   0.00358729	  
ENSMUSG00000046791	   protein_coding	   2410016O06Rik	   1.604034131	   0.040484919	  
ENSMUSG00000032519	   protein_coding	   Slc25a38	   2.078530622	   0.02896989	  
ENSMUSG00000032513	   protein_coding	   Gorasp1	   1.501634385	   0.002273309	  
ENSMUSG00000024319	   protein_coding	   Vps52	   1.77700724	   0.030300397	  
ENSMUSG00000027660	   protein_coding	   Skil	   0.562991626	   0.019816422	  
ENSMUSG00000027665	   protein_coding	   Pik3ca	   0.556006033	   0.046725679	  
ENSMUSG00000080893	   pseudogene	   Gm15920	   3.329451872	   0.001866435	  
ENSMUSG00000066026	   protein_coding	   Dhrs3	   0.42126141	   0.006707634	  
ENSMUSG00000067869	   pseudogene	   Tcea1-­‐ps1	   0.61188929	   0.003990117	  
ENSMUSG00000055041	   protein_coding	   Commd5	   1.994958702	   0.021541837	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ENSMUSG00000056537	   protein_coding	   Rlim	   0.566267673	   0.03513402	  
ENSMUSG00000056536	   protein_coding	   Pign	   0.465969951	   0.007792368	  
ENSMUSG00000028788	   protein_coding	   Ptp4a2	   0.522140265	   0.00942461	  
ENSMUSG00000029787	   protein_coding	   Avl9	   0.54422798	   0.045814995	  
ENSMUSG00000038217	   protein_coding	   Tlcd2	   2.195785124	   0.006056916	  
ENSMUSG00000038212	   protein_coding	   Hiatl1	   0.565379038	   0.010671249	  
ENSMUSG00000059013	   protein_coding	   Sh2d3c	   2.26021758	   0.046617112	  
ENSMUSG00000021469	   protein_coding	   Msx2	   1.704818785	   0.025767489	  
ENSMUSG00000040818	   protein_coding	   Dennd6a	   0.621424201	   0.044725047	  
ENSMUSG00000024576	   protein_coding	   Csnk1a1	   0.592128904	   0.016343516	  
ENSMUSG00000038618	   protein_coding	   Rassf7	   1.698539804	   0.009202144	  
ENSMUSG00000083022	   pseudogene	   Rps15a-­‐ps6	   1.905567442	   0.006512515	  
ENSMUSG00000035142	   protein_coding	   Nubpl	   0.508419128	   0.03107837	  
ENSMUSG00000041801	   protein_coding	   Phlda3	   1.769092523	   0.039076464	  
ENSMUSG00000092586	   protein_coding	   Ly6g6c	   4.931792699	   0.031405244	  
ENSMUSG00000014852	   protein_coding	   Adamts13	   0.479416241	   0.028574611	  
ENSMUSG00000013858	   protein_coding	   Tmem259	   1.544762194	   0.042700736	  
ENSMUSG00000096112	   miRNA	   Gm26269	   0.194496943	   0.017627162	  
ENSMUSG00000033319	   protein_coding	   Fem1c	   0.561337042	   0.03478019	  
ENSMUSG00000002279	   protein_coding	   Lmf1	   2.5518365	   0.005493752	  
ENSMUSG00000039789	   protein_coding	   Zfp597	   0.412966457	   0.045581786	  
ENSMUSG00000096910	   protein_coding	   Zfp955b	   0.574874811	   0.042850721	  
ENSMUSG00000069355	   protein_coding	   Gm5152	   0.199457596	   0.040522425	  
ENSMUSG00000029598	   protein_coding	   Plbd2	   1.563149543	   0.009421308	  
ENSMUSG00000020747	   protein_coding	   2310067B10Rik	   1.506404986	   0.022189048	  
ENSMUSG00000028248	   protein_coding	   Sfrs18	   0.623953781	   0.024051284	  
ENSMUSG00000028249	   protein_coding	   Sdcbp	   0.602909423	   0.046473142	  
ENSMUSG00000028860	   protein_coding	   Sytl1	   3.307043619	   0.005175533	  
ENSMUSG00000005410	   protein_coding	   Mcm5	   1.5297627	   0.037344354	  
ENSMUSG00000085525	   lincRNA	   Gm13166	   0.210586702	   0.048361702	  
ENSMUSG00000049130	   protein_coding	   C5ar1	   0.400038727	   0.013466643	  
ENSMUSG00000040767	   protein_coding	   Snrnp25	   1.611005433	   0.010778404	  
ENSMUSG00000049606	   protein_coding	   Zfp644	   0.466232415	   0.041225018	  
ENSMUSG00000054733	   protein_coding	   Msra	   1.855622598	   0.009046315	  
ENSMUSG00000071722	   protein_coding	   Spin4	   0.587047842	   0.028245829	  
ENSMUSG00000049686	   protein_coding	   Orai1	   1.595570166	   0.005297773	  
ENSMUSG00000026941	   protein_coding	   Mamdc4	   0.077538712	   0.00462729	  
ENSMUSG00000070923	   protein_coding	   Klhl9	   0.519563046	   0.00647932	  
ENSMUSG00000048087	   protein_coding	   Gm4737	   2.841606308	   0.003094814	  
ENSMUSG00000034997	   protein_coding	   Htr2a	   0.303893821	   0.02697941	  
ENSMUSG00000032598	   protein_coding	   Nckipsd	   1.552735389	   0.022431858	  
ENSMUSG00000005609	   protein_coding	   Ctr9	   0.610224257	   0.038562232	  
ENSMUSG00000040564	   protein_coding	   Apoc1	   31.91678282	   0.032235077	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ENSMUSG00000001774	   protein_coding	   Chordc1	   0.543084801	   0.028861652	  
ENSMUSG00000026535	   protein_coding	   Ifi202b	   0.182144664	   0.040710162	  
ENSMUSG00000008730	   protein_coding	   Hipk1	   0.614960221	   0.036928296	  
ENSMUSG00000095362	   protein_coding	   Gm14325	   0.423249692	   0.005261555	  
ENSMUSG00000023262	   protein_coding	   Acy1	   1.875925947	   0.036007075	  
ENSMUSG00000017548	   protein_coding	   Suz12	   0.439325915	   0.017685216	  
ENSMUSG00000032372	   protein_coding	   Plscr2	   0.465437962	   0.003728918	  
ENSMUSG00000094800	   pseudogene	   Gm9780	   3.868203132	   0.04534847	  
ENSMUSG00000060032	   protein_coding	   H2afj	   1.824065191	   0.016463544	  
ENSMUSG00000020072	   protein_coding	   Pbld1	   1.756117846	   0.017563027	  
ENSMUSG00000027931	   protein_coding	   Npr1	   2.244509675	   0.045923479	  
ENSMUSG00000003444	   protein_coding	   Med29	   1.643206221	   0.000445627	  
ENSMUSG00000041889	   protein_coding	   Shisa4	   1.836188215	   0.02200698	  
ENSMUSG00000016534	   protein_coding	   Lamp2	   0.632999734	   0.039799243	  
ENSMUSG00000015750	   protein_coding	   Aph1a	   1.724461169	   0.023318924	  
ENSMUSG00000067071	   protein_coding	   Hes6	   1.618374351	   0.032215261	  
ENSMUSG00000054836	   protein_coding	   Elp6	   1.781488848	   0.009491016	  
ENSMUSG00000050335	   protein_coding	   Lgals3	   1.693794927	   0.032049679	  
ENSMUSG00000028134	   protein_coding	   Ptbp2	   0.629997435	   0.009940437	  
ENSMUSG00000039285	   protein_coding	   Azi2	   0.660203708	   0.015208211	  
ENSMUSG00000071337	   protein_coding	   Tia1	   0.538103901	   0.001576022	  
ENSMUSG00000087679	   lincRNA	   C330006A16Rik	   1.535142511	   0.042499297	  
ENSMUSG00000060096	   pseudogene	   Amd-­‐ps3	   0.497749548	   0.020186751	  
ENSMUSG00000062300	   protein_coding	   Pvrl2	   1.653978188	   0.005183557	  
ENSMUSG00000073802	   protein_coding	   Cdkn2b	   1.743520244	   0.044923735	  
ENSMUSG00000078881	   protein_coding	   Gm14434	   0.447025974	   0.047385363	  
ENSMUSG00000000296	   protein_coding	   Tpd52l1	   1.852580096	   0.000360929	  
ENSMUSG00000044562	   protein_coding	   Rasip1	   2.793545545	   0.003504755	  
ENSMUSG00000091549	   pseudogene	   Gm6548	   0.32132922	   0.006116913	  
ENSMUSG00000020956	   protein_coding	   Dtd2	   0.250081588	   0.003896093	  
ENSMUSG00000072568	   protein_coding	   Fam84b	   0.595704775	   0.019342032	  
ENSMUSG00000037007	   protein_coding	   Zfp113	   0.499323957	   0.045815923	  
ENSMUSG00000029142	   protein_coding	   Mrpl33	   0.582602332	   0.047262289	  
ENSMUSG00000025790	   protein_coding	   Slco3a1	   0.563146785	   0.005572137	  
ENSMUSG00000027479	   protein_coding	   Mapre1	   0.652418749	   0.02736103	  
ENSMUSG00000018570	   protein_coding	   2810408A11Rik	   2.788337863	   0.009628796	  
ENSMUSG00000033068	   protein_coding	   Entpd6	   1.602319699	   0.038939433	  
ENSMUSG00000033065	   protein_coding	   Pfkm	   1.608433687	   0.038348577	  
ENSMUSG00000005686	   protein_coding	   Ampd3	   1.586980187	   0.033718263	  
ENSMUSG00000079492	   protein_coding	   Gm11127	   1.852767729	   0.031375007	  
ENSMUSG00000081883	   pseudogene	   Gm15574	   0.468311428	   0.036787234	  
ENSMUSG00000041935	   protein_coding	   AW549877	   0.465816508	   0.018309843	  
ENSMUSG00000017831	   protein_coding	   Rab5a	   0.567434449	   0.015220874	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ENSMUSG00000019139	   protein_coding	   Isyna1	   1.612100214	   0.005203616	  
ENSMUSG00000094627	   pseudogene	   Gm10182	   2.598121447	   0.001100664	  
ENSMUSG00000030793	   protein_coding	   Pycard	   2.651036582	   0.021337393	  
ENSMUSG00000039323	   protein_coding	   Igfbp2	   0.581965732	   0.038193534	  
ENSMUSG00000032496	   protein_coding	   Ltf	   3.144732106	   0.034571338	  
ENSMUSG00000042115	   protein_coding	   Klhdc8a	   1.60492632	   0.036966268	  
ENSMUSG00000024050	   protein_coding	   Wiz	   0.618594836	   0.038985125	  
ENSMUSG00000043333	   protein_coding	   Rhbdl2	   0.662194309	   0.011525936	  
ENSMUSG00000026361	   protein_coding	   Cdc73	   0.64991766	   0.01075973	  
ENSMUSG00000085636	  
processed_	  
transcript	   Gm11769	   1.563748913	   0.015129021	  
ENSMUSG00000098183	   lincRNA	   Gm27010	   2.197818944	   0.013952069	  
ENSMUSG00000046133	   protein_coding	   C130073F10Rik	   5.163510434	   0.025935525	  
ENSMUSG00000053870	   protein_coding	   Fpgt	   0.648090956	   0.048965677	  
ENSMUSG00000022105	   protein_coding	   Rb1	   0.527900605	   0.045347757	  
ENSMUSG00000051469	   protein_coding	   Zfp191	   0.521468138	   0.003998962	  
ENSMUSG00000039201	   protein_coding	   Tbc1d25	   1.551942441	   0.038045066	  
ENSMUSG00000068264	   protein_coding	   Ap5s1	   1.749299622	   0.030778389	  
ENSMUSG00000019813	   protein_coding	   Cep57l1	   0.59770529	   0.022350113	  
ENSMUSG00000074553	   pseudogene	   Gm10713	   0.350502898	   0.00080409	  
ENSMUSG00000003271	   protein_coding	   Sult2b1	   0.325743572	   0.030789165	  
ENSMUSG00000026832	   protein_coding	   Cytip	   0.352764449	   0.016493262	  
ENSMUSG00000011254	   protein_coding	   Thg1l	   1.532014079	   0.008241575	  
ENSMUSG00000029385	   protein_coding	   Ccng2	   0.624910968	   0.025406896	  
ENSMUSG00000029386	   protein_coding	   Tctn2	   1.591020073	   0.001223878	  
ENSMUSG00000048799	   protein_coding	   Cep120	   0.647877083	   0.011499377	  
ENSMUSG00000028470	   protein_coding	   Hint2	   1.549855326	   0.010076254	  
ENSMUSG00000006356	   protein_coding	   Crip2	   1.788287615	   0.004755242	  
ENSMUSG00000031722	   protein_coding	   Hp	   0.285739086	   0.030595236	  
ENSMUSG00000059412	   protein_coding	   Fxyd2	   0.263166152	   0.023468476	  
ENSMUSG00000082399	   pseudogene	   Gm14036	   2.421009801	   0.020452543	  
ENSMUSG00000080700	   pseudogene	   Gm15981	   2.05606493	   0.035910832	  
ENSMUSG00000028671	   protein_coding	   Gale	   1.652211323	   0.014801419	  
ENSMUSG00000053291	   protein_coding	   Rab4b	   1.576067519	   0.049552101	  
ENSMUSG00000032952	   protein_coding	   Ap4b1	   0.457986175	   0.006323345	  
ENSMUSG00000072680	   protein_coding	   Tmem254c	   2.360950718	   0.001267783	  
ENSMUSG00000073158	   protein_coding	   9030624G23Rik	   0.579047284	   0.016930962	  
ENSMUSG00000034926	   protein_coding	   Dhcr24	   1.679114266	   0.019712591	  
ENSMUSG00000006095	   protein_coding	   Tbcb	   1.585585018	   0.037573639	  
ENSMUSG00000040339	   protein_coding	   Fam102b	   0.652505564	   0.025587021	  
ENSMUSG00000079418	   protein_coding	   Atg4a	   0.634520413	   0.02649739	  
ENSMUSG00000040596	   protein_coding	   Pogk	   0.612823318	   0.03194595	  
ENSMUSG00000051034	   protein_coding	   Zfp11	   0.414151402	   0.023715455	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ENSMUSG00000047648	   protein_coding	   Fbxo30	   0.555158772	   0.020697807	  
ENSMUSG00000008384	   protein_coding	   Sertad1	   1.853086453	   0.048443888	  
ENSMUSG00000014956	   protein_coding	   Ppp1cb	   0.527161623	   0.007339326	  
ENSMUSG00000067855	   protein_coding	   Speer3	   0.381767611	   0.033265963	  
ENSMUSG00000018846	   protein_coding	   Pank3	   0.536333584	   0.007263979	  
ENSMUSG00000001039	   protein_coding	   B9d1	   3.101518152	   0.001555207	  
ENSMUSG00000039630	   protein_coding	   Hnrnpu	   0.62664303	   0.048761419	  
ENSMUSG00000023348	   protein_coding	   Trip6	   1.563730196	   0.015623765	  
ENSMUSG00000037295	   protein_coding	   Ldlrap1	   1.668791832	   0.02370703	  
ENSMUSG00000021185	   protein_coding	   9030617O03Rik	   1.585598639	   0.00964419	  
ENSMUSG00000020634	   protein_coding	   Ubxn2a	   0.574291967	   0.013112298	  
ENSMUSG00000039195	   protein_coding	   1110008P14Rik	   1.868338645	   0.032828431	  
ENSMUSG00000030452	   protein_coding	   Nipa2	   0.617582265	   0.021180787	  
ENSMUSG00000026094	   protein_coding	   Stk17b	   0.603057808	   0.029764061	  
ENSMUSG00000003346	   protein_coding	   Abhd17a	   1.731779929	   0.048384248	  
ENSMUSG00000074649	  
processed_	  
transcript	   BC029722	   1.668129535	   0.024639041	  
ENSMUSG00000028945	   protein_coding	   Rheb	   0.624983506	   0.018303443	  
ENSMUSG00000042410	   protein_coding	   Agps	   0.611201927	   0.011975019	  
ENSMUSG00000002767	   protein_coding	   Mrpl2	   1.837266507	   0.032881762	  
ENSMUSG00000002769	   protein_coding	   Gnmt	   4.554205096	   0.002605721	  
ENSMUSG00000044712	   protein_coding	   Slc38a6	   0.537518547	   0.029358257	  
ENSMUSG00000038650	   protein_coding	   Rnh1	   1.570247118	   0.038871754	  
ENSMUSG00000097815	   lincRNA	   Gm26809	   0.386813463	   0.03557972	  
ENSMUSG00000097811	   lincRNA	  
2810425M01Ri
k	   1.696189626	   0.023046173	  
ENSMUSG00000060216	   protein_coding	   Arrb2	   1.974383358	   0.019837214	  
ENSMUSG00000013822	   protein_coding	   Elof1	   1.587147607	   0.004538205	  
ENSMUSG00000048930	   protein_coding	   Tada3	   1.612175973	   0.002898239	  
ENSMUSG00000089847	   protein_coding	   Timm10b	   1.763751396	   0.020031725	  
ENSMUSG00000021027	   protein_coding	   Ralgapa1	   0.563662089	   0.043777203	  
ENSMUSG00000021020	   protein_coding	   Srp54c	   0.58807848	   0.043668216	  
ENSMUSG00000029569	   protein_coding	   Tmem168	   0.593256163	   0.013938104	  
ENSMUSG00000027463	   protein_coding	   Slc52a3	   0.196533655	   0.001473219	  
ENSMUSG00000027466	   protein_coding	   Rbck1	   1.66745494	   0.00431521	  
ENSMUSG00000024845	  
processed_	  
transcript	   Tmem134	   1.630402809	   0.006064439	  
ENSMUSG00000097554	   lincRNA	   Gm26825	   0.043691414	   0.013185276	  
ENSMUSG00000047141	   protein_coding	   Zfp654	   0.549597516	   0.015590252	  
ENSMUSG00000017707	   protein_coding	   Serinc3	   0.607329063	   0.04228069	  
ENSMUSG00000078872	   protein_coding	   Gm14401	   0.176067652	   0.034239938	  
ENSMUSG00000041483	   protein_coding	   Zfp281	   0.617145015	   0.027395363	  
ENSMUSG00000041482	   protein_coding	   Piezo2	   0.53588872	   0.015956128	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ENSMUSG00000051502	   protein_coding	   Ufsp1	   1.93305344	   0.009088212	  
ENSMUSG00000023953	   protein_coding	   Polh	   0.560271628	   0.022097628	  
ENSMUSG00000023951	   protein_coding	   Vegfa	   0.328724622	   0.032836391	  
ENSMUSG00000091105	   pseudogene	   Gm5633	   0.26900409	   0.029307959	  
ENSMUSG00000019261	   protein_coding	   Map1s	   1.672212661	   0.029085932	  
ENSMUSG00000066415	   protein_coding	   Msl2	   0.630513733	   0.017507099	  
ENSMUSG00000020362	   protein_coding	   Cnot6	   0.522764342	   0.017669428	  
ENSMUSG00000064127	   protein_coding	   Med14	   0.578076244	   0.017768419	  
ENSMUSG00000030088	   protein_coding	   Aldh1l1	   2.729800361	   0.037375434	  
ENSMUSG00000073405	   pseudogene	   C920025E04Rik	   1.893071857	   0.017209276	  
ENSMUSG00000039737	   protein_coding	   Prkrip1	   1.521302451	   0.026308508	  
ENSMUSG00000045039	   protein_coding	   Megf8	   1.876089766	   0.01340271	  
ENSMUSG00000025723	   protein_coding	   Nmb	   2.217008685	   0.015469058	  
ENSMUSG00000086503	   lincRNA	   Xist	   0.560918575	   0.015728824	  
ENSMUSG00000027610	   protein_coding	   Gss	   1.811032701	   0.013279965	  
ENSMUSG00000027612	   protein_coding	   Mmp24	   2.477574305	   0.017117707	  
ENSMUSG00000086320	   lincRNA	   Gm12840	   0.406054233	   0.04091855	  
ENSMUSG00000040511	   protein_coding	   Pvr	   0.65871058	   0.022092243	  
ENSMUSG00000061527	   protein_coding	   Krt5	   0.205620679	   0.014177178	  
ENSMUSG00000047166	   pseudogene	   Tigd5	   1.687267933	   0.004920095	  
ENSMUSG00000031292	   protein_coding	   Cdkl5	   0.454968409	   0.041648597	  
ENSMUSG00000066235	   protein_coding	   Pomgnt2	   1.783462979	   0.035283338	  
ENSMUSG00000013663	   protein_coding	   Pten	   0.600416421	   0.048258865	  
ENSMUSG00000063659	   protein_coding	   Zbtb18	   0.596290674	   0.032603639	  
ENSMUSG00000027363	   protein_coding	   Usp8	   0.612179797	   0.024455176	  
ENSMUSG00000027940	   protein_coding	   Tpm3	   0.454015667	   0.002644191	  
ENSMUSG00000031765	   protein_coding	   Mt1	   7.809953605	   0.02223719	  
ENSMUSG00000023067	   protein_coding	   Cdkn1a	   1.850254253	   0.00125138	  
ENSMUSG00000023064	   protein_coding	   Sncg	   3.812064493	   0.015175913	  
ENSMUSG00000032549	   protein_coding	   Rab6b	   20.54612313	   0.040240608	  
ENSMUSG00000042496	   protein_coding	   Prdm10	   0.479444289	   0.020831944	  
ENSMUSG00000059895	   protein_coding	   Ptp4a3	   1.7617956	   0.001266217	  
ENSMUSG00000032449	   protein_coding	   Slc25a36	   0.567108255	   0.029880569	  
ENSMUSG00000027002	   protein_coding	   Nckap1	   0.405758753	   0.013074163	  
ENSMUSG00000000811	   protein_coding	   Txnrd3	   1.639138485	   0.02057612	  
ENSMUSG00000051285	   protein_coding	   Pcmtd1	   0.573215094	   0.026672899	  
ENSMUSG00000053626	   protein_coding	   Tll1	   0.413717368	   0.017215891	  
ENSMUSG00000036114	   protein_coding	   Rpp25l	   1.823658391	   0.047599114	  
ENSMUSG00000061517	   protein_coding	   Sox21	   0.330191454	   0.01663781	  
ENSMUSG00000030613	   protein_coding	   Ccdc90b	   0.664625912	   0.000195356	  
ENSMUSG00000039481	   protein_coding	   Nrtn	   1.63133367	   0.028647582	  
ENSMUSG00000093106	   miRNA	   Gm25534	   Inf	   0.005749115	  
ENSMUSG00000022602	   protein_coding	   Arc	   3.259089843	   0.012706523	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ENSMUSG00000071362	   protein_coding	   Gm10330	   0.283943211	   0.004375132	  
ENSMUSG00000005447	   protein_coding	   Pafah1b3	   1.528617212	   0.009010685	  
ENSMUSG00000020290	   protein_coding	   Xpo1	   0.538304665	   0.034975053	  
ENSMUSG00000026197	   protein_coding	   Zfand2b	   1.949078948	   0.014616655	  
ENSMUSG00000083392	   pseudogene	   Gm6335	   0.475573456	   0.028602722	  
ENSMUSG00000042510	   protein_coding	   AA986860	   1.614400395	   0.02490333	  
ENSMUSG00000036093	   protein_coding	   Arl5a	   0.397099313	   0.009913208	  
ENSMUSG00000037058	   protein_coding	   Paip2	   0.576636317	   0.025968238	  
ENSMUSG00000020905	   protein_coding	   Usp43	   1.879753103	   0.038382427	  
ENSMUSG00000092171	   lincRNA	   4833427F10Rik	   0.265145399	   0.049949581	  
ENSMUSG00000092178	  
processed_	  
transcript	   Gm3912	   0.077207769	   0.006624867	  
ENSMUSG00000021690	   protein_coding	   Jmy	   0.635508217	   0.038771513	  
ENSMUSG00000029447	   protein_coding	   Cct6a	   0.552320618	   0.030956834	  
ENSMUSG00000035521	   protein_coding	   Gnptg	   1.730644637	   0.011737275	  
ENSMUSG00000094114	   protein_coding	   Gm21967	   0.426248878	   0.049928266	  
ENSMUSG00000095648	   protein_coding	   Gm2004	   0.129555049	   0.019864824	  
ENSMUSG00000094843	   pseudogene	   Ppp1r2-­‐ps1	   0.333933483	   0.01846604	  
ENSMUSG00000041058	   protein_coding	   Wwp1	   0.653107369	   0.019071356	  
ENSMUSG00000060380	   lincRNA	   C030014I23Rik	   2.79346844	   0.010819733	  
ENSMUSG00000018387	   protein_coding	   Shroom1	   1.862621214	   0.048792427	  
ENSMUSG00000022899	   protein_coding	   Slc15a2	   1.638353832	   0.019295388	  
ENSMUSG00000036686	   protein_coding	   Cc2d1a	   1.74829115	   0.026589778	  
ENSMUSG00000039886	   protein_coding	   Tmem120a	   1.677274618	   0.017324074	  
ENSMUSG00000073563	   protein_coding	   Csnk1g3	   0.548449373	   0.005283863	  
ENSMUSG00000029761	   protein_coding	   Cald1	   0.57647206	   0.038410177	  
ENSMUSG00000029767	   protein_coding	   Calu	   0.64117141	   0.003153042	  
ENSMUSG00000039385	   protein_coding	   Cdh6	   0.437351372	   0.041493165	  
ENSMUSG00000042275	   protein_coding	   Pelo	   1.808187688	   0.015494618	  
ENSMUSG00000040653	   protein_coding	   Ppp1r14c	   1.971962715	   0.027989518	  
ENSMUSG00000027087	   protein_coding	   Itgav	   0.568198287	   0.005786716	  
ENSMUSG00000029016	   protein_coding	   Clcn6	   0.491937619	   0.027396023	  
ENSMUSG00000026358	   protein_coding	   Rgs1	   0.283573942	   0.029000812	  
ENSMUSG00000026356	   protein_coding	   Dars	   0.58285015	   0.03657611	  
ENSMUSG00000037487	   protein_coding	   Ubr5	   0.643020737	   0.040869698	  
ENSMUSG00000046169	   protein_coding	   Adamts6	   0.421649824	   0.001088982	  
ENSMUSG00000081249	   pseudogene	   Gm11517	   0.026336932	   0.004385111	  
ENSMUSG00000002799	   protein_coding	   Jag2	   2.71307953	   0.036315477	  
ENSMUSG00000000420	   protein_coding	   Galnt1	   0.639011409	   0.024373685	  
ENSMUSG00000035958	   protein_coding	   Tdp2	   0.61648261	   0.042860094	  
ENSMUSG00000035954	   protein_coding	   Dock4	   0.532052727	   0.02616129	  
ENSMUSG00000022914	   protein_coding	   Brwd1	   0.584139388	   0.043430363	  
ENSMUSG00000018199	   protein_coding	   Trove2	   0.559794241	   0.038549925	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ENSMUSG00000019820	   protein_coding	   Utrn	   0.600802769	   0.042168737	  
ENSMUSG00000020219	   protein_coding	   Timm13	   1.680833753	   0.041464671	  
ENSMUSG00000037568	   protein_coding	   Vash2	   0.615568818	   0.017915792	  
ENSMUSG00000003228	   protein_coding	   Grk5	   1.620807191	   0.00015314	  
ENSMUSG00000028403	   protein_coding	   Zdhhc21	   0.547307442	   0.028617049	  
ENSMUSG00000030752	   protein_coding	   Kdm8	   1.928514841	   0.049120586	  
ENSMUSG00000079659	   protein_coding	   Tmem243	   0.589837775	   0.013501231	  
ENSMUSG00000028737	   protein_coding	   Aldh4a1	   1.750711014	   0.019550816	  
ENSMUSG00000043192	   protein_coding	   Gm1840	   1.98095656	   0.03166322	  
ENSMUSG00000058594	   protein_coding	   Fbxo18	   1.532357752	   0.025850375	  
ENSMUSG00000084104	   pseudogene	   Gm13578	   0.583639719	   0.001758668	  
ENSMUSG00000016756	   protein_coding	   Cmah	   0.251508735	   0.024801332	  
ENSMUSG00000053470	   protein_coding	   Kdm3a	   0.631560581	   0.015760971	  
ENSMUSG00000017400	   protein_coding	   Stac2	   4.551533794	   0.004578225	  
ENSMUSG00000001630	   protein_coding	   Stk38l	   0.492032643	   0.005922575	  
ENSMUSG00000074489	   protein_coding	   Bglap3	   0.467384877	   0.033869858	  
ENSMUSG00000074482	   pseudogene	   Gm16589	   0.618567522	   0.012103981	  
ENSMUSG00000069274	   protein_coding	   Hist1h4f	   0.276548516	   0.018071471	  
ENSMUSG00000045316	   protein_coding	   Fahd1	   0.43097975	   0.015124601	  
ENSMUSG00000001348	   protein_coding	   Acp5	   1.545333061	   0.039181206	  
ENSMUSG00000040097	   protein_coding	   Flywch1	   1.764119086	   0.03514826	  
ENSMUSG00000002083	   protein_coding	   Bbc3	   1.796509586	   0.022910554	  
ENSMUSG00000017307	   protein_coding	   Acot8	   1.528539902	   0.021747406	  
ENSMUSG00000061062	   protein_coding	   Gm10093	   2.042305497	   0.009150115	  
ENSMUSG00000038517	   protein_coding	   Tbkbp1	   1.931043897	   0.023468961	  
ENSMUSG00000097230	   lincRNA	   Gm26853	   0.395886545	   0.003503577	  
ENSMUSG00000072476	   protein_coding	   Gm9008	   0.404676695	   0.009580745	  
ENSMUSG00000058709	   protein_coding	   Egln2	   1.522389552	   0.027641391	  
ENSMUSG00000033170	   protein_coding	   Card10	   1.740540203	   0.00665837	  
ENSMUSG00000026603	   protein_coding	   Smyd2	   1.544885283	   0.006305327	  
ENSMUSG00000085666	   pseudogene	   Gm9855	   2.799184558	   0.020561662	  
ENSMUSG00000024548	   protein_coding	   Setbp1	   0.468125553	   0.029657292	  
ENSMUSG00000045427	   protein_coding	   Hnrnph2	   0.638493583	   0.012907176	  
ENSMUSG00000042428	   protein_coding	   Mgat3	   0.443384425	   0.041041431	  
ENSMUSG00000078949	   protein_coding	   R3hdml	   15.36390745	   0.037273373	  
ENSMUSG00000028988	   protein_coding	   Ctnnbip1	   1.707325626	   0.003578325	  
ENSMUSG00000036775	   protein_coding	   Decr2	   2.084985121	   0.015550277	  
ENSMUSG00000078954	   protein_coding	   Arhgap8	   1.940868576	   0.048787625	  
ENSMUSG00000075600	   protein_coding	   Zc3h3	   1.655506309	   0.019149933	  
ENSMUSG00000097006	   lincRNA	   9530082P21Rik	   1.988957145	   0.027608364	  
ENSMUSG00000027828	   protein_coding	   Ssr3	   0.559812716	   0.03262528	  
ENSMUSG00000031841	   protein_coding	   Cdh13	   2.623839479	   0.016535559	  
ENSMUSG00000039450	   protein_coding	   Dcxr	   2.613737899	   0.003379623	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ENSMUSG00000034729	   protein_coding	   Mrps10	   1.521301461	   0.009407525	  
ENSMUSG00000034724	   protein_coding	   Cnot6l	   0.594119798	   0.019072615	  
ENSMUSG00000031010	   protein_coding	   Usp9x	   0.525897108	   0.018950496	  
ENSMUSG00000029535	   protein_coding	   Triap1	   1.518138473	   0.024025892	  
ENSMUSG00000045636	   protein_coding	   Mtus1	   0.562199357	   0.042441836	  
ENSMUSG00000032030	   protein_coding	   Cul5	   0.498466575	   0.036480449	  
ENSMUSG00000024811	   protein_coding	   Tnks2	   0.596813122	   0.049979691	  
ENSMUSG00000026411	   protein_coding	   Tmem9	   1.761232284	   0.002919916	  
ENSMUSG00000064254	   protein_coding	   Ethe1	   1.973672	   0.005227515	  
ENSMUSG00000032590	   protein_coding	   Apeh	   1.578306506	   0.028216007	  
ENSMUSG00000041471	   protein_coding	   Fam35a	   0.542985057	   0.028537035	  
ENSMUSG00000022761	   protein_coding	   Lztr1	   1.524369153	   0.019948986	  
ENSMUSG00000025235	   protein_coding	   Bbs4	   0.6479654	   0.020806967	  
ENSMUSG00000052794	   protein_coding	   1700030K09Rik	   1.579993724	   0.041762061	  
ENSMUSG00000023150	   protein_coding	   Ivns1abp	   0.565446751	   0.047913153	  
ENSMUSG00000026921	   protein_coding	   Egfl7	   2.139297605	   0.004922047	  
ENSMUSG00000026922	   protein_coding	   Agpat2	   1.659315314	   0.040900656	  
ENSMUSG00000034686	   protein_coding	   Prr7	   2.607776356	   0.020441657	  
ENSMUSG00000028568	   protein_coding	   Btf3l4	   0.614017098	   0.04809021	  
ENSMUSG00000028550	   protein_coding	   Atg4c	   0.477633421	   0.029731708	  
ENSMUSG00000044950	   protein_coding	   Pwwp2a	   0.574682242	   0.041070251	  
ENSMUSG00000045394	   protein_coding	   Epcam	   0.571735063	   0.041406516	  
ENSMUSG00000030264	   protein_coding	   Thumpd3	   0.644950072	   0.034286419	  
ENSMUSG00000027641	   protein_coding	   Rbl1	   0.625519056	   0.025174162	  
ENSMUSG00000004319	   protein_coding	   Clcn3	   0.640285183	   0.034890364	  
ENSMUSG00000004317	   protein_coding	   Clcn5	   0.603364099	   0.048951699	  
ENSMUSG00000057329	   protein_coding	   Bcl2	   0.602976154	   0.047719079	  
ENSMUSG00000061576	   protein_coding	   Dpp6	   0.008092109	   0.002704636	  
ENSMUSG00000003873	   protein_coding	   Bax	   1.562348006	   0.009209187	  
ENSMUSG00000021222	   protein_coding	   Dcaf4	   1.697952875	   0.001116249	  
ENSMUSG00000029019	   protein_coding	   Nppb	   7.123407204	   0.013880181	  
ENSMUSG00000025064	   protein_coding	   Col17a1	   0.26793373	   0.004624325	  
ENSMUSG00000092853	   miRNA	   Gm25959	   7.858725482	   0.044683948	  
ENSMUSG00000032333	   protein_coding	   Stoml1	   1.657403004	   0.005676848	  
ENSMUSG00000071256	   protein_coding	   Zfp213	   2.876163828	   0.0058256	  
ENSMUSG00000046185	   protein_coding	   Zfp84	   0.651244665	   0.006943714	  
ENSMUSG00000021767	   protein_coding	   Kat6b	   0.438783557	   0.032117413	  
ENSMUSG00000022867	   protein_coding	   Usp25	   0.561589282	   0.040469053	  
ENSMUSG00000040836	   protein_coding	   Gpr161	   0.631745519	   0.04937103	  
ENSMUSG00000047037	   protein_coding	   Nipa1	   0.575376924	   0.008914411	  
ENSMUSG00000073664	   protein_coding	   Nbeal1	   0.436996246	   0.03723263	  
ENSMUSG00000009640	   protein_coding	   Dmap1	   1.618594377	   0.035471946	  
ENSMUSG00000094497	   pseudogene	   Gm8210	   1.77028596	   0.002014653	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ENSMUSG00000035125	   protein_coding	   Gcfc2	   0.34047822	   0.002687169	  
ENSMUSG00000004931	   protein_coding	   Apba3	   1.620589147	   0.046104134	  
ENSMUSG00000055228	   protein_coding	   Zfp935	   0.547562457	   0.047981192	  
ENSMUSG00000091243	   protein_coding	   Vgll3	   0.655253573	   0.046862174	  
ENSMUSG00000037349	   protein_coding	   Nudt22	   2.103233075	   0.010641194	  
ENSMUSG00000096979	   lincRNA	   Gm26880	   0.269738513	   0.008332728	  
ENSMUSG00000063894	   protein_coding	   Zkscan8	   0.467006613	   0.035372498	  
ENSMUSG00000025921	   protein_coding	   Rdh10	   0.551226552	   0.003066761	  
ENSMUSG00000063253	   protein_coding	   Scoc	   0.57468781	   0.019582502	  
ENSMUSG00000032109	   protein_coding	   Nlrx1	   2.035014421	   0.00907513	  
ENSMUSG00000043991	   protein_coding	   Pura	   0.622773063	   0.021306615	  
ENSMUSG00000074800	   pseudogene	   Gm4149	   1.836979137	   0.00716657	  
ENSMUSG00000026491	   protein_coding	   Ahctf1	   0.613658405	   0.036582566	  
ENSMUSG00000026490	   protein_coding	   Cdc42bpa	   0.572253283	   0.010039558	  
ENSMUSG00000081619	   pseudogene	   Gm13351	   0.292181717	   0.01182391	  
ENSMUSG00000003299	   protein_coding	   Mrpl4	   1.516753869	   0.049009427	  
ENSMUSG00000002459	   protein_coding	   Rgs20	   0.607884341	   0.012320372	  
ENSMUSG00000017776	   protein_coding	   Crk	   0.661084024	   0.01052634	  
ENSMUSG00000002985	   protein_coding	   Apoe	   0.379074798	   0.010035223	  
ENSMUSG00000078821	   lincRNA	   Gm17414	   0.049486826	   0.000197494	  
ENSMUSG00000058388	   protein_coding	   Phtf1	   0.608940943	   0.02396119	  
ENSMUSG00000016918	   protein_coding	   Sulf1	   0.542395304	   0.028959191	  
ENSMUSG00000056124	   protein_coding	   B4galt6	   0.506144391	   0.017488736	  
ENSMUSG00000061118	   protein_coding	   Dnajc30	   1.747237975	   0.024983991	  
ENSMUSG00000071748	   protein_coding	   Gm14698	   0.456730454	   0.014406508	  
ENSMUSG00000033526	   protein_coding	   Ppip5k1	   1.816087365	   0.033047918	  
ENSMUSG00000037060	   protein_coding	   Prkcdbp	   1.658414918	   0.038587011	  
ENSMUSG00000002580	   protein_coding	   Mien1	   1.538701111	   0.01664508	  
ENSMUSG00000022280	   protein_coding	   Rnf19a	   0.644924084	   0.039831005	  
ENSMUSG00000086869	   pseudogene	   Gm7809	   4.960487418	   0.000583134	  
ENSMUSG00000020115	   protein_coding	   Tbk1	   0.615149641	   0.04882086	  
ENSMUSG00000033955	   protein_coding	   Tnks1bp1	   1.597371055	   0.022164285	  
ENSMUSG00000024911	   protein_coding	   Fibp	   1.771700679	   0.039318958	  
ENSMUSG00000004393	   protein_coding	   Ddx56	   1.691762235	   0.043159935	  
ENSMUSG00000045103	   protein_coding	   Dmd	   0.573632867	   0.008422676	  
ENSMUSG00000003623	   protein_coding	   Crot	   0.567576108	   0.017373089	  
ENSMUSG00000064358	   protein_coding	   mt-­‐Co3	   0.542445116	   0.041807312	  
ENSMUSG00000046056	   protein_coding	   Sbsn	   2.521675578	   0.002058536	  
ENSMUSG00000083716	   pseudogene	   Gm13436	   1.566684446	   0.010745051	  
ENSMUSG00000045503	   protein_coding	   Sys1	   2.03438643	   0.002503947	  
ENSMUSG00000015542	   protein_coding	   Nat9	   1.710516342	   0.017675017	  
ENSMUSG00000081824	   pseudogene	   BC002163	   2.436936491	   0.042770147	  
ENSMUSG00000035828	   protein_coding	   Pim3	   1.677331606	   0.020241111	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ENSMUSG00000054693	   protein_coding	   Adam10	   0.528088749	   0.022528567	  
ENSMUSG00000019158	   protein_coding	   Tmem160	   2.019262707	   0.017336311	  
ENSMUSG00000033752	   protein_coding	   Mnd1	   0.576917483	   0.047705285	  
ENSMUSG00000036504	   protein_coding	   Phpt1	   1.865156461	   0.007380722	  
ENSMUSG00000027913	   protein_coding	   Crct1	   0.381762374	   0.006080593	  
ENSMUSG00000027919	   protein_coding	   Lce1g	   2.067120763	   0.024796821	  
ENSMUSG00000003423	   protein_coding	   Pih1d1	   1.89077127	   0.013967157	  
ENSMUSG00000022360	   protein_coding	   Atad2	   0.516166355	   0.047061194	  
ENSMUSG00000089906	   pseudogene	   Gm6428	   0.310791261	   0.000920662	  
ENSMUSG00000071847	   protein_coding	   Apcdd1	   2.94022336	   0.040458064	  
ENSMUSG00000084349	   pseudogene	   Rpl3-­‐ps1	   2.295211169	   0.00215209	  
ENSMUSG00000083693	   pseudogene	   Gm11971	   0	   0.009057883	  
ENSMUSG00000050310	   protein_coding	   Rictor	   0.580767847	   0.041797131	  
ENSMUSG00000036986	   protein_coding	   Pml	   1.725378578	   0.042214831	  
ENSMUSG00000013483	   protein_coding	   Card14	   5.93931509	   0.025586349	  
ENSMUSG00000053137	   protein_coding	   Mapk11	   1.814876364	   0.001156896	  
ENSMUSG00000071671	   pseudogene	   Gm10343	   0.463770127	   0.049479965	  
ENSMUSG00000034112	   protein_coding	   Atp2c2	   3.897580949	   0.049636188	  
ENSMUSG00000021111	   protein_coding	   Papola	   0.55166473	   0.034483292	  
ENSMUSG00000075376	   protein_coding	   Rc3h2	   0.515125506	   0.013760957	  
ENSMUSG00000078532	   protein_coding	   Nkain1	   1.606796332	   0.016060272	  
ENSMUSG00000024205	   pseudogene	   Rpl36-­‐ps2	   2.233103518	   0.048795351	  
ENSMUSG00000024201	   protein_coding	   Kdm4b	   1.550891383	   0.035166033	  
ENSMUSG00000051355	   protein_coding	   Commd1	   1.527294392	   0.030815184	  
ENSMUSG00000084131	   pseudogene	   Rpl3-­‐ps2	   3.115192572	   0.000425883	  
ENSMUSG00000020646	   protein_coding	   Mboat2	   1.685465021	   0.012047287	  
ENSMUSG00000062729	   protein_coding	   Ppox	   1.589616763	   0.043847979	  
ENSMUSG00000036046	   protein_coding	   5031439G07Rik	   1.539592942	   0.016504527	  
ENSMUSG00000031309	   protein_coding	   Rps6ka3	   0.615630174	   0.037298992	  
ENSMUSG00000036820	   protein_coding	   Amdhd2	   2.724640067	   0.032384479	  
ENSMUSG00000035559	   protein_coding	   Mpv17l2	   1.870133745	   0.003109812	  
ENSMUSG00000028344	   protein_coding	   Invs	   1.570105467	   0.008480728	  
ENSMUSG00000087153	   protein_coding	   Gm6483	   0.526447267	   0.025921561	  
ENSMUSG00000026594	   protein_coding	   Ralgps2	   0.476612433	   0.040861447	  
ENSMUSG00000059363	   protein_coding	   Fxn	   1.525995068	   0.001151467	  
ENSMUSG00000058979	   protein_coding	   Cecr5	   1.842565442	   0.000297831	  
ENSMUSG00000032419	   protein_coding	   Tbx18	   0.582283966	   0.03736789	  
ENSMUSG00000078700	  
processed_	  
transcript	   D030028A08Rik	   0.66604986	   0.025329078	  
ENSMUSG00000040356	   protein_coding	   Skiv2l	   1.85364927	   0.028927653	  
ENSMUSG00000015134	   protein_coding	   Aldh1a3	   0.489670225	   0.012303698	  
ENSMUSG00000059647	   protein_coding	   Gm10068	   0.545540493	   0.042263	  
ENSMUSG00000002763	   protein_coding	   Pex6	   2.011553439	   0.047632297	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ENSMUSG00000054612	   protein_coding	   Mgmt	   2.726530816	   0.007911592	  
ENSMUSG00000054619	   protein_coding	   Mettl7a1	   2.197793868	   0.021393489	  
ENSMUSG00000021908	   protein_coding	   Gm6768	   0.630203201	   0.014594438	  
ENSMUSG00000096111	   antisense	   Gm21917	   11.30215077	   0.008973939	  
ENSMUSG00000002504	   protein_coding	   Slc9a3r2	   1.602555742	   0.018585621	  
ENSMUSG00000097799	   lincRNA	   Gm26899	   0.48278542	   0.017962358	  
ENSMUSG00000048186	   protein_coding	   Bend7	   0.327901148	   0.032694006	  
ENSMUSG00000070867	   protein_coding	   Trabd2b	   4.151481304	   0.019421865	  
ENSMUSG00000027562	   protein_coding	   Car2	   1.542097413	   0.037503657	  
ENSMUSG00000058756	   protein_coding	   Thra	   1.544876737	   0.035455638	  
ENSMUSG00000026389	   protein_coding	   Steap3	   4.472553157	   0.030488637	  
ENSMUSG00000045464	  
processed_	  
transcript	   2810002D19Rik	   0.386991556	   0.002149833	  
ENSMUSG00000050395	   protein_coding	   Tnfsf15	   0.54898252	   0.043693556	  
ENSMUSG00000066324	   protein_coding	   Impad1	   0.543717128	   0.005016898	  
ENSMUSG00000040146	   protein_coding	   Rgl3	   1.678414517	   0.040715547	  
ENSMUSG00000025383	   protein_coding	   Il23a	   0.551504887	   0.014221498	  
ENSMUSG00000065007	   snRNA	   Gm26324	   0.238446536	   0.013364667	  
ENSMUSG00000068205	   protein_coding	   Macrod2	   2.237467439	   0.003597434	  
ENSMUSG00000036282	   protein_coding	   Naa30	   0.577829005	   0.008986332	  
ENSMUSG00000019877	   protein_coding	   Serinc1	   0.636764678	   0.018113228	  
ENSMUSG00000033411	   protein_coding	   Ctdspl2	   0.505556125	   0.043359307	  
ENSMUSG00000029455	   protein_coding	   Aldh2	   1.925473483	   0.003243171	  
ENSMUSG00000020841	   protein_coding	   Cpd	   0.528535741	   0.011092889	  
ENSMUSG00000031813	   protein_coding	   Mvb12a	   1.639903313	   0.02276326	  
ENSMUSG00000038776	   protein_coding	   Ephx1	   2.068691631	   0.001522857	  
ENSMUSG00000037103	   protein_coding	   Dcaf15	   1.643004667	   0.037124744	  
ENSMUSG00000026854	   protein_coding	   Usp20	   2.331723262	   0.019483425	  
ENSMUSG00000026857	   protein_coding	   Ntmt1	   1.682175926	   0.008261139	  
ENSMUSG00000028458	   protein_coding	   Tesk1	   1.818426583	   0.002538414	  
ENSMUSG00000024177	   protein_coding	   Nme4	   2.989725021	   0.018994918	  
ENSMUSG00000024283	   protein_coding	   Wac	   0.517212884	   0.04609735	  
ENSMUSG00000037347	   protein_coding	   Chst7	   2.183886616	   0.001658215	  
ENSMUSG00000079889	   pseudogene	   Gm11951	   1.815044583	   0.033483976	  
ENSMUSG00000030800	   protein_coding	   Prss8	   1.63908558	   0.001447105	  
ENSMUSG00000046876	   protein_coding	   Atxn1	   0.538652437	   0.012274478	  
ENSMUSG00000089728	   pseudogene	   Clec2f	   0.033706317	   0.021012635	  
ENSMUSG00000080268	   protein_coding	   Brms1	   1.765578846	   0.004336203	  
ENSMUSG00000054178	   protein_coding	   Gm9938	   0.513216404	   0.01933479	  
ENSMUSG00000041426	   protein_coding	   Hibch	   0.585693817	   0.023554865	  
ENSMUSG00000044221	   protein_coding	   Grsf1	   0.655334396	   0.034561099	  
ENSMUSG00000057886	   pseudogene	   Gm6984	   0.617337493	   0.014058381	  
ENSMUSG00000020441	   protein_coding	   2310033P09Rik	   1.944344499	   0.011967008	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ENSMUSG00000072676	   protein_coding	   Tmem254a	   2.461426564	   0.000923034	  
ENSMUSG00000025199	   protein_coding	   Chuk	   0.57429642	   0.003193736	  
ENSMUSG00000040152	   protein_coding	   Thbs1	   0.512699917	   0.0119707	  
ENSMUSG00000027132	   protein_coding	   Katnbl1	   0.526026733	   0.021084073	  
ENSMUSG00000031996	   protein_coding	   Aplp2	   0.629781241	   0.049422184	  
ENSMUSG00000074476	   protein_coding	   Spc24	   1.528700184	   0.031072191	  
ENSMUSG00000096990	   lincRNA	   Gm26790	   0.665161004	   0.049656286	  
ENSMUSG00000050063	   protein_coding	   Klk6	   9.12322023	   0.036512392	  
ENSMUSG00000028556	   protein_coding	   Dock7	   0.552743654	   0.044418442	  
ENSMUSG00000028557	   protein_coding	   Rnf11	   0.644850279	   0.01343588	  
ENSMUSG00000044903	   protein_coding	   Psg22	   0.02499172	   0.004715722	  
ENSMUSG00000021824	   protein_coding	   Ap3m1	   0.65891095	   0.001976924	  
ENSMUSG00000031536	   protein_coding	   Polb	   0.589940901	   0.009795764	  
ENSMUSG00000041992	   protein_coding	   Rapgef5	   0.446020896	   0.04261956	  
ENSMUSG00000002379	   protein_coding	   Ndufa11	   1.91593878	   0.034565813	  
ENSMUSG00000009470	   protein_coding	   Tnpo1	   0.635088713	   0.008989953	  
ENSMUSG00000079478	   protein_coding	   Sssca1	   1.633498172	   0.013918415	  
ENSMUSG00000036676	   protein_coding	   Tmtc3	   0.559425305	   0.041991738	  
ENSMUSG00000066839	   protein_coding	   Ecsit	   1.735985348	   0.035442878	  
ENSMUSG00000039617	   pseudogene	   Gm7488	   1.508918498	   0.036329087	  
ENSMUSG00000073371	   protein_coding	   Gm6594	   Inf	   0.005970766	  
ENSMUSG00000022096	   protein_coding	   Hr	   1.672874715	   0.045429004	  
ENSMUSG00000035615	   protein_coding	   Frmpd1	   3.314162469	   0.025385086	  
ENSMUSG00000038225	   protein_coding	   Ccdc111	   0.457447925	   0.001253138	  
ENSMUSG00000025016	   protein_coding	   Tm9sf3	   0.640281438	   0.003152915	  
ENSMUSG00000069972	   pseudogene	   Rps13-­‐ps2	   1.651121538	   0.010855534	  
ENSMUSG00000032344	   protein_coding	   Mb21d1	   0.640716582	   0.03559247	  
ENSMUSG00000025326	   protein_coding	   Ube3a	   0.547450583	   0.042483166	  
ENSMUSG00000036333	   protein_coding	   Kidins220	   0.536100826	   0.021236955	  
ENSMUSG00000025321	   protein_coding	   Itgb8	   0.361039369	   0.042292357	  
ENSMUSG00000030471	   protein_coding	   Zdhhc13	   0.656372381	   0.037662702	  
ENSMUSG00000058835	   protein_coding	   Abi1	   0.577207469	   0.017875298	  
ENSMUSG00000058833	   protein_coding	   2810428I15Rik	   1.809916671	   0.011767505	  
ENSMUSG00000095710	   protein_coding	   Gm8871	   0.241006001	   0.004872404	  
ENSMUSG00000074625	   protein_coding	   Arhgap40	   2.334272343	   0.027567813	  
ENSMUSG00000035150	   protein_coding	   Eif2s3x	   0.646540372	   0.029968824	  
ENSMUSG00000042474	   protein_coding	   Faim3	   2.902236599	   0.044848416	  
ENSMUSG00000042473	   protein_coding	   Tbc1d8b	   0.582300706	   0.03380968	  
ENSMUSG00000033400	   protein_coding	   Agl	   0.613117776	   0.010644586	  
ENSMUSG00000041815	   protein_coding	   Poldip3	   1.520244881	   0.022856749	  
ENSMUSG00000051223	   protein_coding	   Bzw1	   0.585272261	   0.048840942	  
ENSMUSG00000037808	   protein_coding	   Fam76b	   0.530448892	   0.035618295	  
ENSMUSG00000005043	   protein_coding	   Sgsh	   1.617234264	   0.045359134	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ENSMUSG00000056018	   protein_coding	   1700008F21Rik	   0.145923421	   0.046485597	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Appendix Table 2. Full list of differentially expressed microRNAs from ΔNp63 knockout 
mammary epithelial cell sequencing 
 
microRNA	  ID	   Fold	  Change	   p-­‐value	  
mmu-­‐let-­‐7g-­‐3p	   1.70273553	   0.047364148	  
mmu-­‐mir-­‐10b-­‐5p	   1.596353876	   0.030040532	  
mmu-­‐mir-­‐139-­‐5p	   1.855381713	   0.001236052	  
mmu-­‐mir-­‐146b-­‐5p	   1.626768239	   0.049534176	  
mmu-­‐mir-­‐147-­‐3p	   0.047710952	   0.002332487	  
mmu-­‐mir-­‐147-­‐5p	   0.345098365	   0.000641297	  
mmu-­‐mir-­‐150-­‐5p	   2.935659555	   0.006295063	  
mmu-­‐mir-­‐155-­‐3p	   0.50809615	   0.022448719	  
mmu-­‐mir-­‐193b-­‐5p	   0.338982469	   0.043209234	  
mmu-­‐mir-­‐195a-­‐3p	   1.849994583	   0.020074576	  
mmu-­‐mir-­‐1964-­‐3p	   0.14643117	   0.006620285	  
mmu-­‐mir-­‐205-­‐3p	   0.285544892	   0.003235674	  
mmu-­‐mir-­‐3084-­‐3p	   0.279531617	   0.040482324	  
mmu-­‐mir-­‐33-­‐3p	   2.204620123	   0.034053163	  
mmu-­‐mir-­‐3473b	   2.142942477	   0.00992017	  
mmu-­‐mir-­‐3473d	   0.601101691	   0.049275803	  
mmu-­‐mir-­‐3473e	   3.370262119	   0.015960721	  
mmu-­‐mir-­‐34c-­‐3p	   1.560740508	   0.040299379	  
mmu-­‐mir-­‐451a	   4.071961653	   0.038340711	  
mmu-­‐mir-­‐466a-­‐3p	   2.681149719	   0.038634707	  
mmu-­‐mir-­‐466b-­‐3p	   2.546483484	   0.039292175	  
mmu-­‐mir-­‐466c-­‐3p	   2.546483484	   0.039292175	  
mmu-­‐mir-­‐466e-­‐3p	   2.681149719	   0.038634707	  
mmu-­‐mir-­‐466p-­‐3p	   2.546483484	   0.039292175	  
mmu-­‐mir-­‐592-­‐5p	   5.125489635	   0.00458933	  
mmu-­‐mir-­‐6390	   0.494557626	   0.016550889	  
mmu-­‐mir-­‐6406	   2.407306678	   0.004896486	  
mmu-­‐mir-­‐6414	   2.172543327	   0.041848263	  
mmu-­‐mir-­‐668-­‐3p	   3.19129028	   0.008358401	  
mmu-­‐mir-­‐672-­‐5p	   2.41882197	   0.007673931	  
mmu-­‐mir-­‐7047-­‐5p	   2.142989094	   0.038206719	  
mmu-­‐mir-­‐7086-­‐5p	   0.606363359	   0.004926464	  
mmu-­‐mir-­‐712-­‐5p	   0.625737496	   0.037626281	  
mmu-­‐mir-­‐879-­‐5p	   0.411254017	   0.004801053	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Appendix Table 3. Functional Pair Analysis results for ΔNp63 mammary epithelial cell 
sequencing 
 
microRNA up, gene down: 
 
microRNA	   Gene	   p-­‐value	  
mmu-­‐let-­‐7g-­‐3p	   EDEM3	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   SMAD2	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CPEB4	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CLCN5	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   DMD	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   LPGAT1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CEP120	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   SULF1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CNOT6L	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   FBXO32	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   BRWD1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CPD	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   ARL5A	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   COL11A1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   SYNCRIP	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   UTRN	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   FNIP1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   NIPA1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   FAM84B	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   RPS6KA3	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CALU	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   TGFBR1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   NAP1L1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   PTP4A2	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   EIF4G2	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   ATF7	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   ERO1L	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   PARM1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   IL6	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   POGZ	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   NAA30	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   ATAD2B	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   MGAT3	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CRCT1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   THBS1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   SNAP23	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   ITGB8	   2.32E-­‐23	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mmu-­‐let-­‐7g-­‐3p	   USP38	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   LAMP2	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   MTPN	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   ARL6IP6	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   PDGFB	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   YTHDF3	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   RICTOR	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   SOCS4	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CCDC141	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   MTUS1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   MAPK6	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   SLC4A7	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   GALNT1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   FAM103A1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CBX5	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   SLC25A24	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   TMTC3	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   AHCTF1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   RDH10	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   CHUK	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   MAP3K2	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   BZW1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   VGLL3	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   RB1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   GK5	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   VASH2	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   C1GALT1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   PTAR1	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   BTF3L4	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   FNDC3A	   2.32E-­‐23	  
mmu-­‐let-­‐7g-­‐3p	   TIA1	   2.32E-­‐23	  
mmu-­‐miR-­‐10b-­‐5p	   SMAD2	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   CLCN5	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   RLIM	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   NUFIP2	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   FBXO30	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   BRWD1	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   CRK	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   PIK3CA	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   PTP4A2	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   UBXN7	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   CNOT6	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   ITGB8	   4.54E-­‐10	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mmu-­‐miR-­‐10b-­‐5p	   ZDHHC21	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   TMEM170B	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   GALNT1	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   CBX5	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   CELF2	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   MAP3K2	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   USP25	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   MAPRE1	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   SPAG9	   4.54E-­‐10	  
mmu-­‐miR-­‐10b-­‐5p	   CEP350	   4.54E-­‐10	  
mmu-­‐miR-­‐150-­‐5p	   NR1D2	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   CPD	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   RC3H1	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   TM9SF3	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   CALU	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   ETF1	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   HNRNPU	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   TEAD1	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   LRRC58	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   AEBP2	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   TPM3	   0.00132779	  
mmu-­‐miR-­‐150-­‐5p	   PTBP2	   0.00132779	  
mmu-­‐miR-­‐195a-­‐3p	   DENND4A	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CLCN5	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SLC39A10	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   EVI5	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   RLIM	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CDK17	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CNOT6L	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   EIF5A2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   NUFIP2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   ATP13A3	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   ATP7A	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CCDC6	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CHORDC1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   BCL2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   HTR2A	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SFRS18	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CPD	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   ARL5B	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   DMTF1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   USP9X	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   WSB1	   2.84E-­‐18	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mmu-­‐miR-­‐195a-­‐3p	   RPS6KA3	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CALU	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   FAM122B	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SKIL	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   RSBN1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   EIF4G2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CAB39	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   PARM1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   WWP1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   PI4K2B	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   USP31	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   PURA	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SCOC	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CCDC126	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   LAMP2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SYDE2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   TEAD1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   RICTOR	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   PPM1E	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   LRRC58	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   GLCE	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   AEBP2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   TNPO1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   POP4	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SLC4A7	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   TMEM170B	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   LPP	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   GALNT1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   ZFHX4	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   CBX5	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SUZ12	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SNX13	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   G2E3	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   NEBL	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   ELL2	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   SOS1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   STK38L	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   VEGFA	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   OTUD4	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   AKAP11	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   USP25	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   MAPRE1	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   TLL1	   2.84E-­‐18	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mmu-­‐miR-­‐195a-­‐3p	   CEP350	   2.84E-­‐18	  
mmu-­‐miR-­‐195a-­‐3p	   UHMK1	   2.84E-­‐18	  
mmu-­‐miR-­‐33-­‐3p	   SMAD2	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   RLIM	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   CDK19	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   HIPK1	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   NUFIP2	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   TM9SF3	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   AGPS	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   NIPA1	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   TGFBR1	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   CDK8	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   NAA30	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   CROT	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   SYDE2	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   PDGFD	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   YTHDF3	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   RMND5A	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   UBR5	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   NRIP1	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   CDC42BPA	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   TPM3	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   SPIN4	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   ZFHX4	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   CELF2	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   ELL2	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   CDH6	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   GLCCI1	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   MAPRE1	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   ANKRD44	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   PANK3	   4.64E-­‐12	  
mmu-­‐miR-­‐33-­‐3p	   CEP350	   4.64E-­‐12	  
mmu-­‐miR-­‐451a	   CAB39	   0.004330218	  
mmu-­‐miR-­‐451a	   MEX3C	   0.004330218	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microRNA down, gene up: 
 
MicroRNA	   Gene	   p-­‐value	  
mmu-­‐miR-­‐155-­‐3p	   CSF2RB	   0.781083842	  
mmu-­‐miR-­‐155-­‐3p	   ARRB2	   0.781083842	  
mmu-­‐miR-­‐155-­‐3p	   VPS18	   0.781083842	  
mmu-­‐miR-­‐155-­‐3p	   USP43	   0.781083842	  
mmu-­‐miR-­‐193b-­‐5p	   IGFBP5	   0.25893452	  
mmu-­‐miR-­‐193b-­‐5p	   TGFBR3	   0.25893452	  
mmu-­‐miR-­‐193b-­‐5p	   RFT1	   0.25893452	  
mmu-­‐miR-­‐205-­‐3p	   DHCR24	   0.57570751	  
mmu-­‐miR-­‐205-­‐3p	   WDTC1	   0.57570751	  
mmu-­‐miR-­‐205-­‐3p	   SCMH1	   0.57570751	  
mmu-­‐miR-­‐205-­‐3p	   CNP	   0.57570751	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Appendix Table 4. List of Intraductally Injected Mice. The list includes additional genotypes 
that were injected from other projects in our lab. 	  
Mouse 
number Genotype DOB 
Weight 
(g) Surgery Date Right Left Comments 
G503 
ΔNp63 fl/fl, 
Rosa M/M 10/21/13 18 12/4/13 Empty Cre   
G504 
ΔNp63 fl/fl, 
Rosa M/M 10/21/13 20 12/4/13 Empty Cre   
G521 
ΔNp63 fl/fl, 











































Rosa M/M 12/26/13 23 2/18/14 Cre Empty   
N481 
Dicer fl/fl, 
Rosa M/M 12/26/13 19 2/18/14 Cre Empty   
N484 
Dicer fl/fl, 
Rosa M/M 12/26/13 23 2/18/14 Cre Empty   
N485 
Dicer fl/fl, 
Rosa M/M 12/26/13 20 2/18/14 Cre Empty   
N491 
Dicer fl/fl, 
Rosa M/M 12/26/13 21 2/18/14 
Cre (fat 
pad) Cre   
W208 
TAp63 fl/fl, 
Rosa M/M 2/24/14 23.1 4/22/14 
Cre (fat 
pad) Cre   
W209 
TAp63 fl/fl, 
Rosa M/M 2/24/14 21.9 4/22/14 Cre Empty   
W210 
TAp63 fl/fl, 
Rosa M/M 2/24/14 21.4 4/22/14 Cre Empty   
W211 
TAp63 fl/fl, 
Rosa M/M 2/24/14 18.7 4/22/14 Cre Empty   
W212 
TAp63 fl/fl, 
Rosa M/M 2/24/14 20.2 4/22/14 Cre Empty 
Found dead 
on 6/30/14. No 
tumors found 
on necropsy 
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W213 
TAp63 fl/fl, 







Rosa M/M 2/25/14 19.7 4/22/14 Cre Empty   
W223 
TAp63 fl/fl, 
Rosa M/M 2/25/14 21.5 4/22/14 Cre Empty   
N728 
BRCA1 fl/fl, 
Rosa M/M 8/7/14 21.5 10/2/14 Cre Empty   
N730 
BRCA1 fl/fl, 
Rosa M/M 8/7/14 19.7 10/2/14 Cre Empty 
Found dead 

















Rosa M/M 8/20/14 14.55 10/2/14     
too small - 






Rosa M/M 8/7/14 21.5 10/3/14 Cre Empty   
N732 
BRCA1 fl/fl, 
Rosa M/M 8/7/14 19.8 10/3/14 Cre Empty   
N733 
BRCA1 fl/fl, 




Rosa M/M 8/22/14 24.13 10/7/14 Cre Empty 






Rosa M/M 8/22/14 20.79 10/7/14 
Cre (fat 
pad) Cre 






Rosa M/M 8/22/14 21.54 10/7/14 Cre Empty 














Rosa M/M 8/24/14 18.73 10/7/14     
too small - 










into nipple but 
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Rosa M/M 8/24/14 21.68 10/13/14 Cre Empty   
G1024 
ΔNp63 fl/fl, 
Rosa M/M 9/1/14 21.24 10/13/14 Cre Empty   
G1025 
ΔNp63 fl/fl, 
Rosa M/M 9/1/14 21.12 10/13/14 Cre Empty   
no tag 
ΔNp63 fl/fl, 
Rosa M/M 9/1/14 19.19 10/13/14     
too small - 






Rosa M/M 9/1/14 20.29 10/13/14     






Rosa M/M 9/1/14 19.52 10/13/14     






Rosa M/M 8/12/14 21.57 10/14/14 
Cre (fat 
pad) Cre   
N742 
Dicer fl/fl, 
Rosa M/M 8/12/14 19.76 10/14/14 Cre Empty 













Rosa M/M 8/12/14 20.48 10/14/14 Cre Empty   
G1026 
ΔNp63 fl/fl, 
Rosa M/M 9/1/14 21.84 10/23/14 Cre Empty   
G1027 
ΔNp63 fl/fl, 
Rosa M/M 9/1/14 20.13 10/23/14     











Rosa M/M 9/9/14 20.6 10/23/14 Cre Empty 







Rosa M/M 9/15/14 22.78 10/28/14 Cre Empty 






Rosa M/M 9/15/14 22.84 10/28/14 Cre Empty 





Rosa M/M 9/1/14 20.09 10/28/14     
Died 
immediately 














Rosa M/M 9/1/14 19.5 10/28/14 Cre Empty 





Rosa M/M 9/1/14 16.78 10/28/14 
Cre (fat 




















Rosa M/M 9/4/14 19.33 10/31/14 Cre Empty   
N762 
Dicer fl/fl, 
Rosa M/M 9/4/14 21.3 10/31/14 Cre Empty   
N763 
Dicer fl/fl, 
Rosa M/M 9/4/14 18.68 10/31/14 Cre Empty   
N758 
Dicer fl/fl, 
Rosa M/M 9/4/14 20.43 10/31/14 Cre Empty   
N759 
Dicer fl/fl, 
Rosa M/M 9/4/14 19.7 10/31/14 
Cre (fat 








Rosa M/M 9/2/14 18.43 10/31/14 Cre 
Empty 
(fat 




Rosa M/M 9/2/14 17.17 10/31/14 
Cre (fat 




Rosa M/M 9/2/14 20.49 10/31/14 
Cre (fat 




Rosa M/M 9/2/14 18.6 10/31/14 
Cre (fat 








Rosa M/M 9/9/14 20.28 10/31/14 
Cre (fat 
pad) Cre 






Rosa M/M 9/9/14 19.3 10/31/14     
too small - 
could not get 
needle into 
ducts - 





Rosa M/M 9/17/14 20.35 11/3/14 
Cre (fat 




Rosa M/M 9/17/14 18.68 11/3/14     









Rosa M/M 9/17/14 18.17 11/3/14     
too small - 







Rosa M/M 9/21/14 18.78 11/7/14 
Cre (fat 




Rosa M/M 9/21/14 20.03 11/7/14 Cre Empty   
G1053 
ΔNp63 fl/fl, 
Rosa M/M 9/13/14 18.93 11/7/14 Cre Empty   
G1054 
ΔNp63 fl/fl, 
Rosa M/M 9/13/14 17.19 11/7/14 
Cre (fat 
pad) Cre   
no tag 
ΔNp63 fl/fl, 
Rosa M/M 9/13/14 16.11 11/7/14     
too small - 






Rosa M/M 9/19/14 18.4 11/11/14 Cre 
Cre 
(fat 
pad)   
G1056 
ΔNp63 fl/fl, 
Rosa M/M 9/19/14 18.1 11/11/14     
too small - 






Rosa M/M 9/19/14 17.1 11/11/14 Cre 
Cre 
(fat 




Rosa M/M 9/21/14 16.8 11/11/14 
Cre (fat 














too small - 






BRCA1 fl/fl, 9/17/14 18.4 11/17/14 Cre Empty 
Had to inject 
additional 
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too small - 












too small - 






Rosa M/M 9/26/14 19.9 11/17/14 Cre 
Cre 
(fat 
pad)   
no tag 
TAp63 fl/fl, 






too small - 






Rosa M/M 10/3/14 20.6 11/17/14 Cre Empty   
G1064 
TAp63 fl/fl, 
Rosa M/M 10/2/14 18.9 11/17/14 Cre Empty   
G1065 
TAp63 fl/fl, 
Rosa M/M 10/2/14 20.1 11/21/14 Cre Empty   
no tag 
TAp63 fl/fl, 






too small - 






Rosa M/M 10/2/14 20.2 11/21/14 Cre  
Empty 
(fat 
pad)   
N843 
Dicer fl/fl, 
Rosa M/M 9/30/14 22.1 12/3/14 Cre Empty 





Rosa M/M 9/30/14 20.95 12/3/14 Cre Empty 









Rosa M/M 10/5/14 24.86 12/3/14 Cre Empty 






Rosa M/M 10/5/14 21.39 12/3/14 Cre Empty 










Rosa M/M 10/5/14 23.98 12/3/14 Cre Empty 
Did not wake 
up from 
anesthesia 
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no tag 
TAp63 fl/fl, 
Rosa M/M 10/18/14 19.43 12/3/14     






Rosa M/M 10/1/14 21.7 12/5/14 Cre  Empty   
N847 
BRCA1 fl/fl, 
Rosa M/M 10/1/14 19 12/5/14 Empty Cre   
N785 
BRCA1 fl/fl, 
Rosa M/M 10/5/14 24 12/5/14 Cre  Empty   
N787 
BRCA1 fl/fl, 
Rosa M/M 10/5/14 26.2 12/5/14 Cre  Empty   
N788 
BRCA1 fl/fl, 
Rosa M/M 10/5/14 22.2 12/5/14 Cre  Empty   
N789 
BRCA1 fl/fl, 









Rosa M/M 10/5/14 21 12/5/14 Cre  Empty   
N791 
BRCA1 fl/fl, 
Rosa M/M 10/5/14 22.4 12/5/14 Cre  Empty   
N792 
BRCA1 fl/fl, 
Rosa M/M 10/5/14 23 12/5/14 Cre  Empty   
G1071 
TAp63 fl/fl, 
Rosa M/M 10/18/14 20 12/17/14 Cre Empty   
G1072 
TAp63 fl/fl, 
Rosa M/M 10/18/14 19.5 12/17/14 Cre 
Cre 
(fat 
pad)   
N804 
BRCA1 fl/fl, 
Rosa M/M 10/13/14 25 12/17/14 Cre Empty   
N809 
Dicer fl/fl, 
Rosa M/M 10/18/14 20.8 12/17/14 Cre Empty   
N810 
Dicer fl/fl, 
Rosa M/M 10/18/14 20.5 12/17/14 Cre Empty 











Rosa M/M 10/20/14 16.4 12/17/14 
Cre (fat 
pad) Cre   
G1073 
ΔNp63 fl/fl, 
Rosa M/M 10/24/14 19 12/17/14 Cre Empty   
G1074 
ΔNp63 fl/fl, 








Rosa M/M 10/26/14 23.1 12/17/14 Cre Empty   
G1077 ΔNp63 fl/fl, 10/31/14 21.7 12/17/14 Cre Empty   






Rosa M/M 10/31/14 20 12/17/14 
Cre (fat 




Rosa M/M 10/31/14 19.6 12/17/14 Cre Empty   
N842 
BRCA1 fl/fl, 
Rosa fl/fl 11/11/14 21.6 1/13/15 Cre Empty 






Rosa M/M 11/13/14 20.3 1/13/15 Cre Empty 






Rosa M/M 11/13/14 19 1/13/15 Cre Empty 






Rosa M/M 11/13/14 19.6 1/13/15     








Rosa M/M 11/13/14 20.2 1/13/15 Cre Empty   
G1083 
ΔNp63 fl/fl, 
Rosa M/M 11/13/14 18.3 1/13/15 Cre Empty   
G1084 
ΔNp63 fl/fl, 












Rosa M/M 11/14/14 18.9 1/13/15 
Cre (fat 
















Rosa M/M 11/17/14 17.5 1/13/15 Cre Empty   
N903 
TAp73 fl/fl 
TdT 11/17/14 22.5 1/21/15 Cre Empty   
D324 TAp73 fl/fl 11/24/14 16.7 1/21/15 Cre Empty   








Rosa M/M 11/18/14 23.6 1/21/15 Cre Empty 






Rosa M/M 11/18/14 20.9 1/21/15 Cre Empty 





Rosa M/M 11/19/14 21.6 1/21/15 Cre Empty   
W1379 
p53 LSL/+, 
Rosa M/M 11/19/14 18.9 1/21/15 Cre Empty   
W1380 
p53 LSL/+, 
Rosa M/M 11/19/14 23.5 1/21/15 Cre Empty   
W1381 
p53 LSL/+, 
Rosa M/M 11/19/14 20.1 1/21/15 Cre Empty 





Rosa M/M 11/19/14 17.1 1/21/15 Cre Empty 





TdT 12/7/14 22.5 2/3/15 Cre Empty   
D347 
TAp73 fl/fl 
TdT 12/7/14 16.7 2/3/15 Cre Empty   
D348 
TAp73 fl/fl 
TdT 12/7/14 18.2 2/3/15 Cre Empty   
D359 
TAp73 fl/fl 




Rosa M/M 12/23/14 22.1 2/6/15 Cre Empty 






Rosa M/M 12/27/14 19.3 2/6/15 Cre Empty   
N879 
Dicer fl/+, 
Rosa M/M 12/27/14 26.2 3/3/15 Cre  Empty   
N880 
Dicer fl/+, 






















Rosa M/M 12/27/14 22.8 3/3/15 Cre Empty   
D398 
TAp73 fl/fl 
TdT 1/5/15 20.5 3/3/15 Cre Empty   
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D399 
TAp73 fl/fl 
TdT 1/5/15 17.1 3/3/15 Cre Empty   
D400 
TAp73 fl/fl 
TdT 1/5/15 13.6 3/3/15     
too small - 






TdT 1/14/15 18 3/3/15 Cre Empty   
D407 
TAp73 fl/fl 
TdT 1/14/15 18.7 3/3/15 Cre Empty   
W1615 
p53 LSL/+, 
Rosa M/M 2/2/15 20 4/1/15 Cre  Empty 





Rosa M/M 2/2/15 20.2 4/1/15 Cre  Empty 





Rosa M/M 2/5/15 21.5 4/1/15 Cre Empty 





Rosa M/M 2/5/15 23.3 4/1/15 Cre Empty 





Rosa M/M 2/5/15 20 4/1/15 Cre Empty   
N960 
Dicer fl/+, 
Rosa M/M 2/5/15 16.9 4/1/15 Cre Empty   
N961 
Dicer fl/+, 












Rosa M/M 2/6/15 21 4/1/15 Cre 
Empty 
(fat 
pad)   
N962 
TAp63 fl/fl, 









Rosa M/M 2/6/15 21.7 4/1/15 Cre Empty 





Rosa M/M 2/24/15 20.9 4/28/15 Cre Empty   
W1695 
p53 LSL/+, 
Rosa M/M 2/24/15 16.3 4/28/15 Cre Empty   
W1696 
p53 LSL/+, 
Rosa M/M 2/24/15 22.4 4/28/15 Cre Empty   
N952 Dicer fl/+, 3/2/15 17.8 4/28/15 Cre Empty   




Rosa M/M 3/2/15 20.1 4/28/15 Cre Empty   
N951 
Dicer fl/+, 
Rosa M/M 3/2/15 19.4 4/28/15 Cre 
Empty 
(fat 
pad)   
N954 
Dicer fl/+, 
Rosa M/M 3/2/15 19.4 4/28/15 Cre Empty   
N956 
Dicer fl/+, 
Rosa M/M 3/2/15 21.5 4/28/15 Cre Empty   
N957 
Dicer fl/+, 
Rosa M/M 3/2/15 21.2 4/28/15 Cre Empty   
D493 
TAp73 fl/fl 
TdT 3/4/15 18.7 4/28/15 Cre Empty 





TdT 3/4/15 18.9 4/28/15 Cre Empty 





TdT 3/4/15 18.2 4/28/15 Cre Empty 






Rosa M/M 3/4/15 22.1 4/28/15 Cre  Empty 






Rosa M/M 3/4/15 22.7 4/28/15 Cre  Empty 






Rosa M/M 3/4/15 23.2 4/28/15 Cre  Empty 






Rosa M/M 3/10/15 25.1 5/5/15 Cre Empty 










Rosa M/M 3/10/15 18.4 5/5/15 Cre Empty   
N964 
Dicer fl/+, 
Rosa M/M 3/16/15 18.7 5/5/15 Cre Empty   
N965 
Dicer fl/+, 
Rosa M/M 3/16/15 18.2 5/5/15 Cre Empty   
N969 
Dicer fl/+, 












Rosa M/M 3/25/15 20.1 5/27/15 Cre Empty   
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N994 
Dicer fl/+, 
Rosa M/M 4/18/15 22.9 6/19/15 Cre Empty   
N1009 
p53 LSL/+, 
Rosa M/M 4/23/15 21.8 6/19/15 Cre Empty   
W1868 
p53 LSL/+, 
Rosa M/M 4/21/15 17.9 6/19/15 Cre Empty   
W1869 
p53 LSL/+, 
Rosa M/M 4/21/15 16.8 6/19/15 Cre Empty   
W1870 
p53 LSL/+, 
Rosa M/M 4/21/15 17.6 6/19/15 Cre Empty   
W1871 
p53 LSL/+, 












































Rosa M/M 5/20/15 20.7 7/14/15 Cre Empty   
D581 
TAp73 fl/fl 
TdT 5/26/15 20.1 7/14/15 Cre Empty   
F8623 
TAp73 fl/fl 
TdT 5/26/15 18.7 7/14/15 Cre Empty   
D583 
TAp73 fl/fl 
TdT 5/26/15 19.4 7/14/15 Cre Empty   
D584 
TAp73 fl/fl 
TdT 5/26/15 20.4 7/14/15 Cre Empty   
N1093 p53 LSL/+, 6/24/15 19.9 8/11/15 Cre Empty   


















Rosa M/M 6/26/15 19.2 8/11/15 
Cre (fat 
















Rosa M/M 6/28/15 19.2 8/27/15 Cre  
Empty 
(fat 
























Rosa M/M 6/8/15   8/5/15 Cre Empty   	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